Bibliography

Reference List

  1. Vandenbroucke JP. Is the randomized controlled trial the real paradigm in epidemiology? J Chronic Dis 1986;39:572-574.
  2. Nube M, Kok FJ, Vandenbroucke JP, Heide-Wessel C, van der Heide RM. Scoring of prudent dietary habits and its relation to 25-year survival. J Am Diet Assoc 1987;87:171-175.
  3. van Saase J, Vandenbroucke J, Valkenburg H, Boersma J, Cats A, Festen J, Hartman A, Huber-Bruning O, Rasker J, Weber J. Changing pattern of drug use in relation to disease duration of rheumatoid arthritis. J Rheumatol 1987;14:476-478.
  4. Vandenbroucke JP. The 1665-1666 plague epidemic at Eyam: two paradigms, one verdict. Int J Epidemiol 1987;16:623-624.
  5. Vandenbroucke JP. [Breast cancer and alcohol consumption in perspective]. Ned Tijdschr Geneeskd 1987;131:2007-2009.
  6. Vandenbroucke JP, Kaaks R, Valkenburg HA, Boersma JW, Cats A, Festen JJ, Hartman AP, Huber-Bruning O, Rasker JJ, Weber J. Frequency of infections among rheumatoid arthritis patients, before and after disease onset. Arthritis Rheum 1987;30:810-813.
  7. Vandenbroucke JP. Should we abandon statistical modeling altogether? Am J Epidemiol 1987;126:10-13.
  8. Vandenbroucke JP. Historical interpretations of the decline of tuberculosis mortality. Am J Epidemiol 1987;125:750.
  9. Vandenbroucke JP. A check-list for observational research? J Chronic Dis 1987;40:1067-1070.
  10. Vandenbroucke JP. A short note on the history of the randomized controlled trial. J Chronic Dis 1987;40:985-987.
  11. Westgeest AA, Boerbooms AM, Jongmans M, Vandenbroucke JP, Vierwinden G, van de Putte LB. Antiperinuclear factor: indicator of more severe disease in seronegative rheumatoid arthritis. J Rheumatol 1987;14:893-897.
  12. Albada-Kuipers GA, Linthorst J, Peeters EA, Breedveld FC, Dijkmans BA, Hermans J, Vandenbroucke JP, Cats A. Frequency of infection among patients with rheumatoid arthritis versus patients with osteoarthritis or soft tissue rheumatism. Arthritis Rheum 1988;31:667-671.
  13. Grobbee DE, van Hemert AM, Vandenbroucke JP, Hofman A, Valkenburg HA. Importance of body weight in determining rise and level of blood pressure in postmenopausal women. J Hypertens Suppl 1988;6:S614-S616.
  14. Muts-Homsma SJ, Vandenbroucke JP, Feuth JD. [Cardiac risk in non-cardiac surgery]. Ned Tijdschr Geneeskd 1988;132:1616-1619.
  15. Offerhaus GJ, Tersmette AC, Huibregtse K, van de Stadt J, Tersmette KW, Stijnen T, Hoedemaeker PJ, Vandenbroucke JP, Tytgat GN. Mortality caused by stomach cancer after remote partial gastrectomy for benign conditions: 40 years of follow up of an Amsterdam cohort of 2633 postgastrectomy patients. Gut 1988;29:1588-1590.
  16. Offerhaus GJ, Tersmette AC, Tersmette KW, Tytgat GN, Hoedemaeker PJ, Vandenbroucke JP. Gastric, pancreatic, and colorectal carcinogenesis following remote peptic ulcer surgery. Review of the literature with the emphasis on risk assessment and underlying mechanism. Mod Pathol 1988;1:352-356.
  17. Offerhaus GJ, Tersmette AC, Huibregtse K, Tersmette KW, Vandenbroucke JP, Tytgat GN. [Mortality from stomach carcinoma following stomach surgery for benign disorders; analysis of an Amsterdam cohort]. Ned Tijdschr Geneeskd 1988;132:628-630.
  18. van den Wall Bake AW, Kroon HM, van der Linden SM, Cats A, Vandenbroucke JP, van Es LA. Association of IgA nephropathy with minor radiological abnormalities of the sacroiliac joints. Clin Nephrol 1988;29:163.
  19. van Saase JL, Vandenbroucke JP, van Romunde LK, Valkenburg HA. Osteoarthritis and obesity in the general population. A relationship calling for an explanation. J Rheumatol 1988;15:1152-1158.
  20. Vandenbroucke JP. Is 'the causes of cancer' a miasma theory for the end of the twentieth century? Int J Epidemiol 1988;17:708-709.
  21. Vandenbroucke JP. [The role of clinical experiments in medicine]. Ned Tijdschr Geneeskd 1988;132:2014-2016.
  22. Vandenbroucke JP. [Does the cultural revolution last longer in The Netherlands than in China?]. Ned Tijdschr Geneeskd 1988;132:1943-1944.
  23. Vandenbroucke JP. [Life expectancy of man in adulthood and old age]. Ned Tijdschr Geneeskd 1988;132:664-667.
  24. Vandenbroucke JP, Vandenbroucke-Grauls CM. A note on the history of the calculation of hospital statistics. Am J Epidemiol 1988;127:699-702.
  25. Vandenbroucke JP. Weighing alternatives. JAMA 1988;259:1500.
  26. Vandenbroucke JP. [Quantitative modernism in medicine: an attempt at arrangement]. Ned Tijdschr Geneeskd 1988;132:337-340.
  27. Vandenbroucke JP. Passive smoking and lung cancer: a publication bias? Br Med J (Clin Res Ed) 1988;296:391-392.
  28. Vandenbroucke JP. Which John Snow should set the example for clinical epidemiology? J Clin Epidemiol 1988;41:1215-1216.
  29. Elsacker-Niele AM, Lichtendahl-Bernards AT, Hermans J, Vandenbroucke JP, Mouton RP. Comparison of the automated Bactec NR-660 with a conventional blood culture system. Eur J Clin Microbiol Infect Dis 1989;8:724-726.
  30. Hazes JM, Dijkmans BA, Hoevers JM, Janson JJ, de Vries RR, Vandenbroucke JP, Cats A. DR4 prevalence related to the age at disease onset in female patients with rheumatoid arthritis. Ann Rheum Dis 1989;48:406-408.
  31. Hazes JM, Silman AJ, Brand R, Spector TD, Walker DJ, Vandenbroucke JP. A case-control study of oral contraceptive use in women with rheumatoid arthritis and their unaffected sisters. Br J Rheumatol 1989;28 Suppl 1:35.
  32. Hazes JM, Dijkmans BA, Vandenbroucke JP, de Vries RR, Cats A. Oral contraceptives and rheumatoid arthritis; further evidence for a protective effect independent of duration of pill use. Br J Rheumatol 1989;28 Suppl 1:34:34-35.
  33. Hazes JM, Dijkmans BA, Vandenbroucke JP, Cats A. Oral contraceptive treatment for rheumatoid arthritis: an open study in 10 female patients. Br J Rheumatol 1989;28 Suppl 1:28-30.
  34. Rosendaal FR, Varekamp I, Smit C, Bröcker-Vriends AH, van Dijck H, Vandenbroucke JP, Hermans J, Suurmeijer TP, Briët E. Mortality and causes of death in Dutch haemophiliacs, 1973-86. Br J Haematol 1989;71:71-76.
  35. Smit C, Rosendaal FR, Varekamp I, Brocker-Vriends A, van Dijck H, Suurmeijer TP, Briët E. Physical condition, longevity, and social performance of Dutch haemophiliacs, 1972-85. BMJ 1989;298:235-238.
  36. van Gelder T, Hoogsteden HC, Versnel MA, van Hezik EJ, Vandenbroucke JP, Planteydt HT. Malignant pleural mesothelioma in the southwestern part of The Netherlands. Eur Respir J 1989;2:981-984.
  37. van Gelder T, Hoogsteden HC, Versnel MA, de Beer PH, Vandenbroucke JP, Planteydt HT. Malignant peritoneal mesothelioma: a series of 19 cases. Digestion 1989;43:222-227.
  38. van Hemert AM, Birkenhager JC, de Jong FH, Vandenbroucke JP, Valkenburg HA. Sex hormone binding globulin in postmenopausal women: a predictor of osteoporosis superior to endogenous oestrogens. Clin Endocrinol (Oxf) 1989;31:499-509.
  39. van Oosterhout EC, Hermans J, Haak HL, Vandenbroucke JP. [Are hematologic reference values applicable to the healthy elderly?]. Ned Tijdschr Geneeskd 1989;133:940-942.
  40. van Saase JL, van Romunde LK, Cats A, Vandenbroucke JP, Valkenburg HA. Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Ann Rheum Dis 1989;48:271-280.
  41. Vandenbroucke JP. [The obstinacy of a profession]. Ned Tijdschr Geneeskd 1989;133:2540-2542.
  42. Vandenbroucke JP. [The Central Bureau for Statistics: the burial place of our causes of death]. Ned Tijdschr Geneeskd 1989;133:2112-2114.
  43. Vandenbroucke JP. Statistical modelling: the old standardisation problem in disguise? J Epidemiol Community Health 1989;43:207-208.
  44. Vandenbroucke JP. Those who were wrong. Am J Epidemiol 1989;130:3-5.
  45. Vandenbroucke JP. Is there a hierarchy of methods in clinical research? Klin Wochenschr 1989;67:515-517.
  46. Vandenbroucke JP. On the new clinical fashion in epidemiology. Epidemiol Infect 1989;102:191-198.
  47. Vandenbroucke JP, Pardoel VP. An autopsy of epidemiologic methods: the case of "poppers" in the early epidemic of the acquired immunodeficiency syndrome (AIDS). Am J Epidemiol 1989;129:455-457.
  48. Vandenbroucke JP. [A prescription for clinico-scientific educational research]. Ned Tijdschr Geneeskd 1989;133:34-38.
  49. Vandenbroucke JP, Hazes JM, Dijkmans BA, Cats A. Oral contraceptives and the risk of rheumatoid arthritis: the great transatlantic divide? Br J Rheumatol 1989;28 Suppl 1:1-3; discussion 18-23.:1-3.
  50. Vandenbroucke JP. Oral contraceptives and the risk of rheumatoid arthritis: the great transatlantic divide? Scand J Rheumatol Suppl 1989;79:31-2.:31-32.
  51. Varekamp I, Rosendaal FR, Smit-van Dijck HC, Bröcker-Vriends A, Suurmeijer TP, Briët E. [Social effects of current hemophilia treatment]. Ned Tijdschr Geneeskd 1989;133:404-408.
  52. Varekamp I, Smit C, Rosendaal FR, Bröcker-Vriends A, Briët E, van Dijck H, Suurmeijer TP. Employment of individuals with haemophilia in The Netherlands. Soc Sci Med 1989;28:261-270.
  53. Zwetsloot-Schonk JH, Snitker P, Vandenbroucke JP, Bakker AR. Using hospital information systems for clinical epidemiological research. Med Inform (Lond) 1989;14:53-62.
  54. Allaart CF, Aronson DC, Ruys T, Rosendaal FR, van Bockel JH, Bertina RM, Briët E. Hereditary protein S deficiency in young adults with arterial occlusive disease. Thromb Haemost 1990;64:206-210.
  55. Bavinck JN, Kootte AM, van der Woude FJ, Vandenbroucke JP, Vermeer BJ, Claas FH. HLA-A11-associated resistance to skin cancer in renal-transplant patients. N Engl J Med 1990;323:1350.
  56. Burger BJ, Burger JD, Bos CF, Obermann WR, Rozing PM, Vandenbroucke JP. Neonatal screening and staggered early treatment for congenital dislocation or dysplasia of the hip. Lancet 1990;336:1549-1553.
  57. Collee G, Dijkmans BA, Vandenbroucke JP, Rozing PM, Cats A. A clinical epidemiological study in low back pain. Description of two clinical syndromes. Br J Rheumatol 1990;29:354-357.
  58. Dekker FW, Mulder Dzn JD, Kramps JA, Kaptein AA, Vandenbroucke JP, Dijkman JH. The Phadiatop in vitro test for allergy in general practice: is it useful? Fam Pract 1990;7:144-148.
  59. Hartevelt MM, Bavinck JN, Kootte AM, Vermeer BJ, Vandenbroucke JP. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 1990;49:506-509.
  60. Hazes JM, Dijkmans BA, Vandenbroucke JP, de Vries RR, Cats A. Lifestyle and the risk of rheumatoid arthritis: cigarette smoking and alcohol consumption. Ann Rheum Dis 1990;49:980-982.
  61. Hazes JM, Dijkmans BA, Vandenbroucke JP, de Vries RR, Cats A. Pregnancy and the risk of developing rheumatoid arthritis. Arthritis Rheum 1990;33:1770-1775.
  62. Hazes JM, Dijkmans BC, Vandenbroucke JP, de Vries RR, Cats A. Reduction of the risk of rheumatoid arthritis among women who take oral contraceptives. Arthritis Rheum 1990;33:173-179.
  63. Hazes JM, Silman AJ, Brand R, Spector TD, Walker DJ, Vandenbroucke JP. Influence of oral contraception on the occurrence of rheumatoid arthritis in female sibs. Scand J Rheumatol 1990;19:306-310.
  64. Kwekkeboom DJ, de Jong FH, van Hemert AM, Vandenbroucke JP, Valkenburg HA, Lamberts SW. Serum gonadotropins and alpha-subunit decline in aging normal postmenopausal women. J Clin Endocrinol Metab 1990;70:944-950.
  65. Rosendaal FR, Smit C, Varekamp I, Bröcker-Vriends AH, van Dijck H, Suurmeijer TP, Vandenbroucke JP, Briët E. Modern haemophilia treatment: medical improvements and quality of life. J Intern Med 1990;228:633-640.
  66. Rosendaal FR, Bröcker-Vriends AH, van Houwelingen JC, Smit C, Varekamp I, van Dijck H, Suurmeijer TP, Vandenbroucke JP, Briët E. Sex ratio of the mutation frequencies in haemophilia A: estimation and meta-analysis. Hum Genet 1990;86:139-146.
  67. Rosendaal FR, Briët E, Stibbe J, van Herpen G, Leuven JA, Hofman A, Vandenbroucke JP. Haemophilia protects against ischaemic heart disease: a study of risk factors. Br J Haematol 1990;75:525-530.
  68. Rosendaal FR, Briët E. The increasing prevalence of haemophilia. Thromb Haemost 1990;63:145.
  69. Tersmette AC, Offerhaus GJ, Giardiello FM, Tersmette KW, Vandenbroucke JP, Tytgat GN. Occurrence of non-gastric cancer in the digestive tract after remote partial gastrectomy: analysis of an Amsterdam cohort. Int J Cancer 1990;46:792-795.
  70. Tersmette AC, Offerhaus GJ, Tersmette KW, Giardiello FM, Moore GW, Tytgat GN, Vandenbroucke JP. Meta-analysis of the risk of gastric stump cancer: detection of high risk patient subsets for stomach cancer after remote partial gastrectomy for benign conditions. Cancer Res 1990;50:6486-6489.
  71. van Hemert AM, Vandenbroucke JP, Birkenhager JC, Valkenburg HA. Prediction of osteoporotic fractures in the general population by a fracture risk score. A 9-year follow-up among middle-aged women. Am J Epidemiol 1990;132:123-135.
  72. van Hemert AM, Vandenbroucke JP, Hofman A, Valkenburg HA. Metacarpal bone loss in middle-aged women: "horse racing" in a 9-year population based follow-up study. J Clin Epidemiol 1990;43:579-588.
  73. van Hemert AM. Prediction of hip fracture in elderly women. BMJ 1990;301:1100.
  74. van Hemert AM. Bone density screening for osteoporosis. Lancet 1990;336:818.
  75. van Hemert AM. [Dietary calcium content and prevention of postmenopausal osteoporosis]. Ned Tijdschr Geneeskd 1990;134:353-354.
  76. van Saase JL, Noteboom WM, Vandenbroucke JP. Longevity of men capable of prolonged vigorous physical exercise: a 32 year follow up of 2259 participants in the Dutch eleven cities ice skating tour. BMJ 1990;301:1409-1411.
  77. van Zeben D, Hazes JM, Vandenbroucke JP, Dijkmans BA, Cats A. Diminished incidence of severe rheumatoid arthritis associated with oral contraceptive use. Arthritis Rheum 1990;33:1462-1465.
  78. Vandenbroucke JP. [The prospective course of the AIDS epidemic in The Netherlands according to Farr's Law]. Ned Tijdschr Geneeskd 1990;134:2479-2482.
  79. Vandenbroucke JP. Tracking AIDS epidemic in libraries. Lancet 1990;336:318.
  80. Vandenbroucke JP, Rosendaal FR. [Should nearly finished medical students be able to interpret the entire professional literature?]. Ned Tijdschr Geneeskd 1990;134:843-844.
  81. Vandenbroucke JP. Epidemiology in transition: a historical hypothesis. Epidemiology 1990;1:164-167.
  82. Vandenbroucke JP. [The Central Bureau for Statistics, breeding place for cause of death statistics]. Ned Tijdschr Geneeskd 1990;134:139.
  83. Vandenbroucke JP. [Medical ethics and health legislation; obstacles for further increase in knowledge in medicine?]. Ned Tijdschr Geneeskd 1990;134:5-6.
  84. Vandenbroucke JP. Hierarchy of methods. J Clin Epidemiol 1990;43:627-628.
  85. Vandenbroucke JP. How trustworthy is epidemiologic research? Epidemiology 1990;1:83-84.
  86. Varekamp I, Suurmeijer TP, Bröcker-Vriends AH, van Dijck H, Smit C, Rosendaal FR, Briët E. Carrier testing and prenatal diagnosis for hemophilia: experiences and attitudes of 549 potential and obligate carriers. Am J Med Genet 1990;37:147-154.
  87. Bouwes Bavinck JN, Vermeer BJ, van der Woude FJ, Vandenbroucke JP, Schreuder GM, Thorogood J, Persijn GG, Claas FH. Relation between skin cancer and HLA antigens in renal-transplant recipients. N Engl J Med 1991;325:843-848.
  88. Bouwes Bavinck JN, Kootte AM, van der Woude FJ, Vandenbroucke JP, Vermeer BJ, Claas FH. On a possible protective effect of HLA-A11 against skin cancer and keratotic skin lesions in renal transplant recipients. J Invest Dermatol 1991;97:269-272.
  89. Brocker-Vriends AH, Rosendaal FR, van Houwelingen JC, Bakker E, van Ommen GJ, van de Kamp JJ, Briët E. Sex ratio of the mutation frequencies in haemophilia A: coagulation assays and RFLP analysis. J Med Genet 1991;28:672-680.
  90. Collee G, Dijkmans BA, Vandenbroucke JP, Cats A. Iliac crest pain syndrome in low back pain: frequency and features. J Rheumatol 1991;18:1064-1067.
  91. Collee G, Dijkmans BA, Vandenbroucke JP, Cats A. Iliac crest pain syndrome in low back pain. A double blind, randomized study of local injection therapy. J Rheumatol 1991;18:1060-1063.
  92. Collee G, Dijkmans BA, Vandenbroucke JP, Cats A. Greater trochanteric pain syndrome (trochanteric bursitis) in low back pain. Scand J Rheumatol 1991;20:262-266.
  93. Koster T, Rosendaal FR, van der Meer FJ, Briët E, Vandenbroucke JP. More objective diagnoses of venous thromboembolism? Neth J Med 1991;38:246-248.
  94. Meynaar IA, van't Wout JW, Vandenbroucke JP, van Furth R. Use of influenza vaccine in The Netherlands. BMJ 1991;303:508.
  95. Noteboom WM, Rosendaal FR, Vandenbroucke JP. [150 years of life expectancy of Dutch members of parliament; 1848-1989]. Ned Tijdschr Geneeskd 1991;135:2425-2428.
  96. Rosendaal FR, Heijboer H, Briët E, Büller HR, Brandjes DP, de Bruin K, Hommes DW, Vandenbroucke JP. Mortality in hereditary antithrombin-III deficiency--1830 to 1989. Lancet 1991;337:260-262.
  97. Rosendaal FR, Heijboer H. Mortality related to thrombosis in congenital antithrombin III deficiency. Lancet 1991;337:1545.
  98. Rosendaal FR, Smit C, Briët E. Hemophilia treatment in historical perspective: a review of medical and social developments. Ann Hematol 1991;62:5-15.
  99. Schouten EG, Dekker JM, Meppelink P, Kok FJ, Vandenbroucke JP, Pool J. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population. Circulation 1991;84:1516-1523.
  100. Symmons DP, van Hemert AM, Vandenbroucke JP, Valkenburg HA. A longitudinal study of back pain and radiological changes in the lumbar spines of middle aged women. I. Clinical findings. Ann Rheum Dis 1991;50:158-161.
  101. Tersmette AC, Offerhaus GJ, Giardiello FM, Brand R, Tersmette KW, Tytgat GN, Vandenbroucke JP. Long-term prognosis after partial gastrectomy for benign conditions. Survival and smoking-related death of 2633 Amsterdam postgastrectomy patients followed up since surgery between 1931 and 1960. Gastroenterology 1991;101:148-153.
  102. Tersmette AC, Goodman SN, Offerhaus GJ, Tersmette KW, Giardiello FM, Vandenbroucke JP, Tytgat GN. Multivariate analysis of the risk of stomach cancer after ulcer surgery in an Amsterdam cohort of postgastrectomy patients. Am J Epidemiol 1991;134:14-21.
  103. Tersmette AC, Giardiello FM, Offerhaus GJ, Tersmette KW, Ohara K, Vandenbroucke JP, Tytgat GN. Geographical variance in the risk of gastric stump cancer: no increased risk in Japan? Jpn J Cancer Res 1991;82:266-272.
  104. van Gelder T, Hoogsteden HC, Vandenbroucke JP, van der Kwast TH, Planteydt HT. The influence of the diagnostic technique on the histopathological diagnosis in malignant mesothelioma. Virchows Arch A Pathol Anat Histopathol 1991;418:315-317.
  105. van Kregten E, Huber-Bruning O, Vandenbroucke JP, Willers JM. No conclusive evidence of an epidemiological relation between Klebsiella and ankylosing spondylitis. J Rheumatol 1991;18:384-388.
  106. Vandenbroucke-Grauls CM, Vandenbroucke JP. Effect of selective decontamination of the digestive tract on respiratory tract infections and mortality in the intensive care unit. Lancet 1991;338:859-862.
  107. Vandenbroucke JP. [Diseases charted in the Nederlandsch Tijdschrift voor Geneeskunde, 1857-1880]. Ned Tijdschr Geneeskd 1991;135:1819-1826.
  108. Vandenbroucke JP. Postmenopausal oestrogen and cardioprotection. Lancet 1991;337:1482-1483.
  109. Vandenbroucke JP. [An epidemiological thriller; better than the reality?]. Ned Tijdschr Geneeskd 1991;135:1067-1068.
  110. Vandenbroucke JP. [Scientific research and privacy; the importance of careful consideration]. Ned Tijdschr Geneeskd 1991;135:1023-1024.
  111. Vandenbroucke JP, Eelkman Rooda HM, Beukers H. Who made John Snow a hero? Am J Epidemiol 1991;133:967-973.
  112. Vandenbroucke JP. Prospective or retrospective: what's in a name? BMJ 1991;302:249-250.
  113. Vandenbroucke JP. Postmenopausal oestrogen and cardioprotection. Lancet 1991;337:833-834.
  114. Zwetsloot-Schonk JH, van Stiphout WA, Snitker P, van Es LA, Vandenbroucke JP. How to approach a hospital information system as sampling frame. Selection of patients with a percutaneous renal biopsy. Med Inform (Lond) 1991;16:287-298.
  115. Brunekreef B, Groot B, Rijcken B, Hoek G, Steenbekkers A, de Boer A. Reproducibility of childhood respiratory symptom questions. Eur Respir J 1992;5:930-935.
  116. Chandie Shaw PK, van der Meer JT, van der Meer FJ, Thompson J, Vandenbroucke JP, Rosendaal FR. [The thrombosis service as a source of information for studies in patients with heart valve prostheses]. Ned Tijdschr Geneeskd 1992;136:526-530.
  117. Eikenboom JC, Rosendaal FR, Briët E. Value of the patient interview: all but consensus among haemostasis experts. Haemostasis 1992;22:221-223.
  118. Heeren TJ, van Hemert AM, Lagaay AM, Rooymans HG. The general population prevalence of non-organic psychiatric disorders in subjects aged 85 years and over. Psychol Med 1992;22:733-738.
  119. Heeren TJ, van Hemert AM, Rooymans HG. A community-based study of survival in dementia. Acta Psychiatr Scand 1992;85:415-418.
  120. Hofman A, Vandenbroucke JP. Geoffrey Rose's big idea. BMJ 1992;305:1519-1520.
  121. Janssen M, Dijkmans BA, van der Sluys FA, van der Wielen JG, Havenga K, Vandenbroucke JP, Lamers CB, Zwinderman AH, Cats A. Upper gastrointestinal complaints and complications in chronic rheumatic patients in comparison with other chronic diseases. Br J Rheumatol 1992;31:747-752.
  122. Janssen M, Dijkmans BA, Vandenbroucke JP, van Duijn W, Pena AS, Lamers CB. Decreased level of antibodies against Helicobacter pylori in patients with rheumatoid arthritis receiving intramuscular gold. Ann Rheum Dis 1992;51:1036-1038.
  123. Kooiman CG, van Hemert AM, Bolk JH, Hermans J. [Non-urgent patients in a non-traumatology Emergency Service; general aspects and screening for psychiatric disorders]. Ned Tijdschr Geneeskd 1992;136:880-884.
  124. Koster T, Vandenbroucke JP. Helicobacter pylori, musings from the epidemiologic armchair. Epidemiol Infect 1992;109:81-85.
  125. Meynaar IA, 't Wout JW, Vandenbroucke JP, van Furth R. [Implementation of influenza vaccination in 3 hospitals]. Ned Tijdschr Geneeskd 1992;136:180-183.
  126. Meynaar IA, 't Wout JW, Vandenbroucke JP, van Furth R. [Opinions of family physicians and specialists on vaccination against influenza]. Ned Tijdschr Geneeskd 1992;136:176-179.
  127. Meynaar IA, 't Wout JW, Vandenbroucke JP, van Furth R. [Vaccination against influenza; encourage it or adopt a wait and see attitude?]. Ned Tijdschr Geneeskd 1992;136:168-172.
  128. Nurmohamed MT, Rosendaal FR, Büller HR, Dekker E, Hommes DW, Vandenbroucke JP, Briët E. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:152-156.
  129. Offerhaus GJ, Tersmette AC, Giardiello FM, Huibregtse K, Vandenbroucke JP, Tytgat GN. Evaluation of endoscopy for early detection of gastric-stump cancer. Lancet 1992;340:33-35.
  130. Rosendaal FR. Factor VIII and coronary heart disease. Eur J Epidemiol 1992;8 Suppl 1:71-5.:71-75.
  131. Sont JK, van Stiphout WA, Noordijk EM, Molenaar J, Zwetsloot-Schonk JH, Willemze R, Vandenbroucke JP. Increased risk of second cancers in managing Hodgkins disease: the 20-year Leiden experience. Ann Hematol 1992;65:213-218.
  132. Sont JK, Bel EH, Dijkman JH, Sterk PJ. The long-term effect of nedocromil sodium on the maximal degree of airway narrowing to methacholine in atopic asthmatic subjects. Clin Exp Allergy 1992;22:554-560.
  133. Sramek R, Sramek A, Koster T, Briët E, Rosendaal FR. A randomized and blinded comparison of three bleeding time techniques: the Ivy method, and the Simplate II method in two directions. Thromb Haemost 1992;67:514-518.
  134. Sterk PJ, Bel EH, Vandenbroucke JP. [Asthma: theory and practice in the year 1992]. Ned Tijdschr Geneeskd 1992;136:451-455.
  135. van der Meer FJM, Rosendaal FR, Cannegieter SC, Briët E. Oral anticoagulant drugs. N Engl J Med 1992;326:68-69.
  136. van der Meer JT, van Wijk W, Thompson J, Vandenbroucke JP, Valkenburg HA, Michel MF. Efficacy of antibiotic prophylaxis for prevention of native-valve endocarditis. Lancet 1992;339:135-139.
  137. Vandenbroucke JP. [Diseases come and go]. Ned Tijdschr Geneeskd 1992;136:2500-2502.
  138. Vandenbroucke JP. Bungee-jumping and design of experiments. Lancet 1992;340:800.
  139. Vandenbroucke JP. Colon cancer and ulcerative colitis: an epidemiologic exercise revisited. J Clin Epidemiol 1992;45:923-924.
  140. Vandenbroucke JP. Privacy, confidentiality and epidemiology: the Dutch ordeal. Int J Epidemiol 1992;21:825-826.
  141. Varekamp I, Suurmeijer T, Bröcker-Vriends A, Rosendaal FR. Hemophilia and the use of genetic counseling and carrier testing within family networks. Birth Defects Orig Artic Ser 1992;28:139-148.
  142. Allaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briët E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993;341:134-138.
  143. Bavinck JN, de Boer A, Vermeer BJ, Hartevelt MM, van der Woude FJ, Claas FH, Wolterbeek R, Vandenbroucke JP. Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. Br J Dermatol 1993;129:242-249.
  144. Bindels AJ, Vandenbroucke JP. [Do ACE inhibitors help prevent heart failure? Results of 3 clinical trials]. Ned Tijdschr Geneeskd 1993;137:173-176.
  145. Burger BJ, Burger JD, Bos CF, Hermans J, Rozing PM, Vandenbroucke JP. Frejka pillow and Becker device for congenital dislocation of the hip. Prospective 6-year study of 104 late-diagnosed cases. Acta Orthop Scand 1993;64:305-311.
  146. de Melker HE, Rosendaal FR, Vandenbroucke JP. [The importance of publication bias in medical-scientific literature]. Ned Tijdschr Geneeskd 1993;137:2126-2130.
  147. de Melker HE, Rosendaal FR, Vandenbroucke JP. Is publication bias a medical problem? Lancet 1993;342:621.
  148. Geul KW, van Sluisveld IL, Grobbee DE, Docter R, de Bruyn AM, Hooykaas H, van der Merwe JP, van Hemert AM, Krenning EP, Hennemann G, . The importance of thyroid microsomal antibodies in the development of elevated serum TSH in middle-aged women: associations with serum lipids. Clin Endocrinol (Oxf) 1993;39:275-280.
  149. Ierodiakonou K, Vandenbroucke JP. Medicine as a stochastic art. Lancet 1993;341:542-543.
  150. Janssen M, Baak LC, Jansen JB, Dijkmans BA, Vandenbroucke JP, Lamers CB. Effects of indomethacin on intragastric pH and meal-stimulated serum gastrin secretion in rheumatoid arthritis patients. Aliment Pharmacol Ther 1993;7:393-400.
  151. Janssen M, Dijkmans BA, Vandenbroucke JP, Biemond I, Lamers CB. The frequency of extremely low serum pepsinogen, indicative of corpus gastritis with severe atrophy, in rheumatoid arthritis, other chronic rheumatic diseases and non-rheumatic diseases. Br J Rheumatol 1993;32:371-374.
  152. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-1506.
  153. Lansink M, de Boer A, Dijkmans BA, Vandenbroucke JP, Hazes JM. The onset of rheumatoid arthritis in relation to pregnancy and childbirth. Clin Exp Rheumatol 1993;11:171-174.
  154. Peerlinck K, Vermylen J, Rosendaal FR, Briët E. Factor VIII inhibitor. Lancet 1993;342:1110.
  155. Peerlinck K, Rosendaal FR, Vermylen J. Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate. Blood 1993;81:3332-3335.
  156. Rosendaal FR, van Everdingen JJ. [Cumulative meta-analysis as ultimate truth]. Ned Tijdschr Geneeskd 1993;137:1591-1594.
  157. Rosendaal FR, Nieuwenhuis HK, van den Berg HM, Heijboer H, Mauser-Bunschoten EP, van der Meer J., Smit C, Strengers PF, Briët E. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. Blood 1993;81:2180-2186.
  158. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993;69:236-239.
  159. Schlemper RJ, van der Werf SD, Vandenbroucke JP, Biemond I, Lamers CB. Peptic ulcer, non-ulcer dyspepsia and irritable bowel syndrome in The Netherlands and Japan. Scand J Gastroenterol Suppl 1993;200:33-41.:33-41.
  160. Sont JK, Booms P, Bel EH, Vandenbroucke JP, Sterk PJ. The determinants of airway hyperresponsiveness to hypertonic saline in atopic asthma in vivo. Relationship with sub-populations of peripheral blood leucocytes. Clin Exp Allergy 1993;23:678-688.
  161. Sont JK, Vandenbroucke JP. Life expectancy and mitochondrial DNA. Do we inherit longevity from our mother's mitochondria? J Clin Epidemiol 1993;46:199-201.
  162. Speckens AE, Hengeveld MW, Nijeholt GA, van Hemert AM, Hawton KE. Discrimination between psychogenic and organic erectile dysfunction. J Psychosom Res 1993;37:135-145.
  163. van der Eb MM, Leyten EM, Gavarasana S, Vandenbroucke JP, Kahn PM, Cleton FJ. Reverse smoking as a risk factor for palatal cancer: a cross-sectional study in rural Andhra Pradesh, India. Int J Cancer 1993;54:754-758.
  164. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993;153:1557-1562.
  165. van der Meer FJ, Rosendaal FR. [No advantage in the addition of dipyridamole or of oral anticoagulants in comparison to low-dose acetylsalicylic acid (50mg per day) in the prevention of venous transplant occlusion following coronary bypass surgery]. Ned Tijdschr Geneeskd 1993;137:2223-2224.
  166. van der Meer FJ, Rosendaal FR. [The possibility of intestinal hemorrhage in long-term use of acenocoumarol; a cohort study]. Ned Tijdschr Geneeskd 1993;137:1267-1268.
  167. van der Meer JT, Thompson J, Vandenbroucke JP. Prophylaxis for endocarditis. Lancet 1993;341:374-375.
  168. van Hemert AM, Hengeveld MW, Bolk JH, Rooijmans HG, Vandenbroucke JP. Psychiatric disorders in relation to medical illness among patients of a general medical out-patient clinic. Psychol Med 1993;23:167-173.
  169. van Hemert AM, Bakker CH, Vandenbroucke JP, Valkenburg HA. Psychologic distress as a longterm predictor of medical utilisation. Int J Psychiatry Med 1993;23:295-305.
  170. van Hemert AM, Hawton K, Bolk JH, Fagg J. Key symptoms in the detection of affective disorders in medical patients. J Psychosom Res 1993;37:397-404.
  171. van Hemert AM. [Is there a relationship between fatal myocardial infarct and the use of psychotropic drugs in young women?]. Ned Tijdschr Geneeskd 1993;137:580-581.
  172. van Praag MC, Bavinck JN, Bergman W, Rosendaal FR, Mommaas AM, Bruynzeel I, Scheffer E, Vermeer BJ, Bruijn JA. PUVA keratosis. A clinical and histopathologic entity associated with an increased risk of nonmelanoma skin cancer. J Am Acad Dermatol 1993;28:412-417.
  173. van Schaardenburg D, Lagaay AM, Breedveld FC, Hijmans W, Vandenbroucke JP. Rheumatoid arthritis in a population of persons aged 85 years and over. Br J Rheumatol 1993;32:104-109.
  174. van Schaardenburg D, Hazes JM, de Boer A, Zwinderman AH, Meijers KA, Breedveld FC. Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis. J Rheumatol 1993;20:45-52.
  175. van Zeben D, Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC. Factors predicting outcome of rheumatoid arthritis: results of a followup study. J Rheumatol 1993;20:1288-1296.
  176. van Zeben D, Hazes JM, Breedveld FC, Zwinderman AH, Vandenbroucke JP. Which clinical variables contribute to the physician's assessment of medium term outcome in rheumatoid arthritis? J Rheumatol 1993;20:33-39.
  177. Varekamp I, Suurmeijer TP, Rosendaal FR, Bröcker-Vriends AH. The use of preventive health care services: carrier testing for the genetic disorder haemophilia. Soc Sci Med 1993;37:639-648.
  178. Witteman JC, Grobbee DE, Valkenburg HA, van Hemert AM, Stijnen T, Hofman A. Cigarette smoking and the development and progression of aortic atherosclerosis. A 9-year population-based follow-up study in women. Circulation 1993;88:2156-2162.
  179. Azar AJ, Deckers JW, Rosendaal FR, van Bergen PF, van der Meer FJM, Jonker JJ, Briët E. Assessment of therapeutic quality control in a long-term anticoagulant trial in post-myocardial infarction patients. Thromb Haemost 1994;72:347-351.
  180. Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
  181. Briët E, Rosendaal FR, Kreuz W, Rasi V, Peerlinck K, Vermylen J, Ljung R, Rocino A, Addiego J, Lorenzo JI. High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products. Thromb Haemost 1994;72:162-164.
  182. Briët E, van der Meer FJ, Rosendaal FR, Houwing-Duistermaat JJ, van Houwelingen HC. The family history and inherited thrombophilia. Br J Haematol 1994;87:348-352.
  183. Briët E, Rosendaal FR. Inhibitors in hemophilia A: are some products safer? Semin Hematol 1994;31:11-15.
  184. Cannegieter SC, van der Meer FJ, Briët E, Rosendaal FR. Warfarin and aspirin after heart-valve replacement. N Engl J Med 1994;330:507-508.
  185. Cannegieter SC, Rosendaal FR, Briët E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635-641.
  186. Coebergh JW, Grobbee DE, Vandenbroucke JP. Patients' rights in The Netherlands. BMJ 1994;309:542.
  187. Diamant Z, Timmers MC, van der Veen H, Booms P, Sont JK, Sterk PJ. Effect of an inhaled neutral endopeptidase inhibitor, thiorphan, on airway responsiveness to leukotriene D4 in normal and asthmatic subjects. Eur Respir J 1994;7:459-466.
  188. Ganesh S, Sier CF, Griffioen G, Vloedgraven HJ, de Boer A, Welvaart K, van de Velde CJ, van Krieken JH, Verheijen JH, Lamers CB, . Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994;54:4065-4071.
  189. Janssen M, Dijkmans BA, Lamers CB, Zwinderman AH, Vandenbroucke JP. A gastroscopic study of the predictive value of risk factors for non-steroidal anti-inflammatory drug-associated ulcer disease in rheumatoid arthritis patients. Br J Rheumatol 1994;33:449-454.
  190. Janssen M, Dijkmans BA, Vandenbroucke JP, Biemond I, Lamers CB. Achlorhydria does not protect against benign upper gastrointestinal ulcers during NSAID use. Dig Dis Sci 1994;39:362-365.
  191. Koster T, Rosendaal FR, Reitsma PH, van der Velden PA, Briët E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms--the Leiden Thrombophilia Study (LETS). Thromb Haemost 1994;71:719-722.
  192. Koster T, Rosendaal FR, Briët E, Vandenbroucke JP. John Hageman's factor and deep-vein thrombosis: Leiden thrombophilia Study. Br J Haematol 1994;87:422-424.
  193. Koster T, Rosendaal FR. Activated protein C resistance in venous thrombosis. Lancet 1994;343:541.
  194. Koumbarelis E, Rosendaal FR, Gialeraki A, Karafoulidou A, Noteboom WM, Loizou C, Panayotopoulou C, Markakis C, Mandalaki T. Epidemiology of haemophilia in Greece: an overview. Thromb Haemost 1994;72:808-813.
  195. Mauser-Bunschoten EP, Rosendaal FR, Nieuwenhuis HK, Roosendaal G, Briët E, van den Berg HM. Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A. Thromb Haemost 1994;71:703-706.
  196. Posthuma WF, Westendorp RGJ, Vandenbroucke JP. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ 1994;308:1268-1269.
  197. Rosendaal FR. The emergence of a new species: the professional meta-analyst. J Clin Epidemiol 1994;47:1325-1326.
  198. Rosendaal FR. [Recently discovered frequent cause of venous thrombosis: factor V Leiden, a mutated factor V, resistant against protein C inactivation]. Ned Tijdschr Geneeskd 1994;138:1944-1948.
  199. Rosendaal FR, Algra A. [20,000 kg aspirin and 45 pages British Medical Journal]. Ned Tijdschr Geneeskd 1994;138:996-1000.
  200. Rosendaal FR. Anticoagulation: how low can one go? Lancet 1994;343:867-868.
  201. Rosendaal FR, Sramek R, Sramek A. Is the bleeding time prolonged in oral anticoagulant treatment? Thromb Haemost 1994;71:157-158.
  202. Sijbrands EJ, Westendorp RGJ, Hoffer MJ, Havekes LM, Frants RR, Meinders AE, Frölich M, Smelt AH. Effect of insulin resistance, apoE2 allele, and smoking on combined hyperlipidemia. Arterioscler Thromb 1994;14:1576-1580.
  203. Smit HA, van Rijssen A, Vandenbroucke JP, Coenraads PJ. Susceptibility to and incidence of hand dermatitis in a cohort of apprentice hairdressers and nurses. Scand J Work Environ Health 1994;20:113-121.
  204. Sosef MN, Bosch JG, van Oostayen J, Visser T, Reiber JH, Rosendaal FR. Relation of plasma coagulation factor VII and fibrinogen to carotid artery intima-media thickness. Thromb Haemost 1994;72:250-254.
  205. van Boven HH, Olds RJ, Thein SL, Reitsma PH, Lane DA, Briët E, Vandenbroucke JP, Rosendaal FR. Hereditary antithrombin deficiency: heterogeneity of the molecular basis and mortality in Dutch families. Blood 1994;84:4209-4213.
  206. Van Hees CL, de Boer A, Jager MJ, Bleeker JC, Kakebeeke HM, Crijns MB, Vandenbroucke JP, Bergman W. Are atypical nevi a risk factor for uveal melanoma? A case-control study. J Invest Dermatol 1994;103:202-205.
  207. van Hemert AM, van der Mast RC, Hengeveld MW, Vorstenbosch M. Excess mortality in general hospital patients with delirium: a 5-year follow-up of 519 patients seen in psychiatric consultation. J Psychosom Res 1994;38:339-346.
  208. van Zeben D, Hazes JM, Zwinderman AH, Vandenbroucke JP, Breedveld FC. The severity of rheumatoid arthritis: a 6-year followup study of younger women with symptoms of recent onset. J Rheumatol 1994;21:1620-1625.
  209. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-1457.
  210. Vandenbroucke JP. Increasing the accessibility of data. BMJ 1994;309:879.
  211. Vandenbroucke JP. Can the quality of peer review be measured? J Clin Epidemiol 1994;47:821-822.
  212. Vandenbroucke JP. Should you eat meat, or are you confounded by methodological debate? BMJ 1994;308:1671.
  213. Vandenbroucke JP. New public health and old rhetoric. BMJ 1994;308:994-995.
  214. Vandenbroucke JP. [Health risk due to passive smoking: opposite results or opposite opinions]. Ned Tijdschr Geneeskd 1994;138:507-508.
  215. Vandenbroucke JP, Rosendaal FR. Publication bias. Lancet 1994;343:119.
  216. Vliet Vlieland TP, Buitenhuis NA, van Zeben D, Vandenbroucke JP, Breedveld FC, Hazes JM. Sociodemographic factors and the outcome of rheumatoid arthritis in young women. Ann Rheum Dis 1994;53:803-806.
  217. Westendorp RGJ, Bosch FH, Simons M. [Knowledge of altitude]. Ned Tijdschr Geneeskd 1994;138:1264-1269.
  218. Westendorp RGJ. [Single blood pressure determination in a follow-up visit for hypertension more often leads to management adjustment than multiple measurements]. Ned Tijdschr Geneeskd 1994;138:684-685.
  219. Witteman JC, Grobbee DE, Valkenburg HA, van Hemert AM, Stijnen T, Burger H, Hofman A. J-shaped relation between change in diastolic blood pressure and progression of aortic atherosclerosis. Lancet 1994;343:504-507.
  220. Allaart CF, Rosendaal FR, Noteboom WM, Vandenbroucke JP, Briët E. Survival in families with hereditary protein C deficiency, 1820 to 1993. BMJ 1995;311:910-913.
  221. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995;74:449-453.
  222. Blauw GJ, Westendorp RGJ, Simons M, Chang PC, Frolich M, Meinders AE. beta-Adrenergic receptors contribute to hypoxaemia induced vasodilation in man. Br J Clin Pharmacol 1995;40:453-458.
  223. Blauw GJ, Westendorp RGJ. Asthma deaths in New Zealand: whodunnit? Lancet 1995;345:2-3.
  224. Blauw GJ, Westendorp RGJ, Srivastava N, Burggraaf K, Frolich M, Simons R, Cohen AF, Meinders AE. Hypoxia-induced arterial endothelin does not influence peripheral vascular tone. J Cardiovasc Pharmacol 1995;26 Suppl 3:S242-3.:S242-S243.
  225. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-1596.
  226. Bongers I, Westendorp RGJ, Stolk B, Huysmans HA, Vandenbroucke JP. [Early coronary heart disease together with tyoe II diabetes mellitus in persons of Hindustani origin]. Ned Tijdschr Geneeskd 1995;139:16-18.
  227. Briët E, van der Meer FJ, Rosendaal FR, Houwing-Duistermaat JJ, van Houwelingen HC. Family history and inherited thrombophilia. Br J Haematol 1995;89:691.
  228. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-17.
  229. Crijns MB, Klaver CC, de Boer A, Van Hees CL, Vermeer BJ, Vandenbroucke JP, Bergman W. A comparative study of atypical and melanocytic naevi on the tropical island Curacao and in The Netherlands. Melanoma Res 1995;5:161-167.
  230. de Gouw HW, Westendorp RGJ, Kunst AE, Mackenbach JP, Vandenbroucke JP. Decreased mortality among contemplative monks in The Netherlands. Am J Epidemiol 1995;141:771-775.
  231. den Heijer M, Blom HJ, Gerrits WB, Rosendaal FR, Haak HL, Wijermans PW, Bos GM. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet 1995;345:882-885.
  232. Dijkmans BA, Janssen M, Vandenbroucke JP, Lamers CB. NSAID-associated upper gastrointestinal damage in patients with rheumatoid arthritis. Scand J Gastroenterol Suppl 1995;212:105-8.:105-108.
  233. Florijn KW, Noteboom WM, van Saase JL, Chang PC, Breuning MH, Vandenbroucke JP. A century of mortality in five large families with polycystic kidney disease. Am J Kidney Dis 1995;25:370-374.
  234. George EK, Mearin ML, van der Velde EA, Houwen RH, Bouquet J, Gijsbers CF, Vandenbroucke JP. Low incidence of childhood celiac disease in The Netherlands. Pediatr Res 1995;37:213-218.
  235. Houwing-Duistermaat JJ, Derkx BH, Rosendaal FR, van Houwelingen HC. Testing familial aggregation. Biometrics 1995;51:1292-1301.
  236. Janssen M, Dijkmans BA, Vandenbroucke JP, Biemond I, van Duyn W, Zwinderman AH, Lamers CB. Serum values of pepsinogens and antibodies to Helicobacter pylori in relation to a history of peptic ulcer disease and NSAID use. Scand J Rheumatol 1995;24:204-208.
  237. Koster T, Rosendaal FR, Briët E, van der Meer FJ, Colly LP, Trienekens PH, Poort SR, Reitsma PH, Vandenbroucke JP. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995;85:2756-2761.
  238. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995;345:152-155.
  239. Koster T, Small RA, Rosendaal FR, Helmerhorst FM. Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties. J Intern Med 1995;238:31-37.
  240. Posthuma EF, Westendorp RGJ, van der Sluys V, Kluin-Nelemans JC, Kluin PM, Lamers CB. Fatal infectious mononucleosis: a severe complication in the treatment of Crohn's disease with azathioprine. Gut 1995;36:311-313.
  241. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-625.
  242. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85:1504-1508.
  243. Schlemper RJ, van der Werf SD, Vandenbroucke JP, Biemond I, Lamers CB. Seroepidemiology of gastritis in Japanese and Dutch working populations: evidence for the development of atrophic gastritis that is not related to Helicobacter pylori. Gut 1995;37:199-204.
  244. Schlemper RJ, van der Werf SD, Vandenbroucke JP, Biemond I, Lamers CB. Nonulcer dyspepsia in a Dutch working population and Helicobacter pylori. Ulcer history as an explanation of an apparent association. Arch Intern Med 1995;155:82-87.
  245. Sijbrands EJ, Smelt AH, Westendorp RGJ. Alcohol consumption and mortality among women. N Engl J Med 1995;333:1081-1082.
  246. Sont JK, Booms P, Bel EH, Vandenbroucke JP, Sterk PJ. The severity of breathlessness during challenges with inhaled methacholine and hypertonic saline in atopic asthmatic subjects. The relationship with deep breath-induced bronchodilation. Am J Respir Crit Care Med 1995;152:38-44.
  247. Spek CA, Koster T, Rosendaal FR, Bertina RM, Reitsma PH. Genotypic variation in the promoter region of the protein C gene is associated with plasma protein C levels and thrombotic risk. Arterioscler Thromb Vasc Biol 1995;15:214-218.
  248. Sramek A, Eikenboom JC, Briët E, Vandenbroucke JP, Rosendaal FR. Usefulness of patient interview in bleeding disorders. Arch Intern Med 1995;155:1409-1415.
  249. Stricker BH, Rosendaal FR. [Significance of pharmacoepidemiology for drug monitoring and quality of care: the pill]. Ned Tijdschr Geneeskd 1995;139:2541-2543.
  250. Triemstra M, Rosendaal FR, Smit C, van der Ploeg HM, Briët E. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 1995;123:823-827.
  251. van der Palen J, Doggen CJM, Beaglehole R. Variation in the time and day of onset of myocardial infarction and sudden death. N Z Med J 1995;108:332-334.
  252. Vandenbroucke JP. Re: "Invited commentary: a critical look at some popular meta-analytic methods". Am J Epidemiol 1995;142:1007-1009.
  253. Vandenbroucke JP. [The Cochrane Collaboration and evidence-based medicine]. Ned Tijdschr Geneeskd 1995;139:1476-1477.
  254. Vandenbroucke JP, Briët E, Helmerhorst F, van der Meer FJ. [Oral contraception increases the chance of venous thrombosis in factor V Leiden mutation]. Ned Tijdschr Geneeskd 1995;139:1067-1071.
  255. Vandenbroucke JP. How much of the cardioprotective effect of postmenopausal estrogens is real? Epidemiology 1995;6:207-208.
  256. Vleming LJ, Baelde JJ, Westendorp RGJ, Daha MR, van Es LA, Bruijn JA. Progression of chronic renal disease in humans is associated with the deposition of basement membrane components and decorin in the interstitial extracellular matrix. Clin Nephrol 1995;44:211-219.
  257. Vliet Vlieland TP, Zwinderman AH, Vandenbroucke JP, Breedveld FC, Hazes JM. In-patient treatment for active rheumatoid arthritis: clinical course and predictors of improvement. Br J Rheumatol 1995;34:847-853.
  258. Westendorp RGJ, Langermans JA, de Bel CE, Meinders AE, Vandenbroucke JP, van Furth R, van Dissel JT. Release of tumor necrosis factor: an innate host characteristic that may contribute to the outcome of meningococcal disease. J Infect Dis 1995;171:1057-1060.
  259. Westendorp RGJ, Blauw GJ. End of New Zealand asthma epidemic. Lancet 1995;345:985.
  260. Arend SM, Westendorp RGJ, Kroon FP, van't Wout JW, Vandenbroucke JP, van Es LA, van der Woude FJ. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis 1996;22:920-925.
  261. Azar AJ, Cannegieter SC, Deckers JW, Briët E, van Bergen PF, Jonker JJ, Rosendaal FR. Optimal intensity of oral anticoagulant therapy after myocardial infarction. J Am Coll Cardiol 1996;27:1349-1355.
  262. Bouma PA, Westendorp RGJ, van Dijk JG, Peters AC, Brouwer OF. The outcome of absence epilepsy: a meta-analysis. Neurology 1996;47:802-808.
  263. den Heijer M, Koster T, Blom HJ, Bos GM, Briët E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996;334:759-762.
  264. Krul EJ, Peters LA, Vandenbroucke JP, Vrede A, van Kanten RW, Fleuren GJ. Cervical carcinoma in Surinam. Incidence and staging of cervical carcinoma between 1989 and 1994. Cancer 1996;77:1329-1333.
  265. Lane DA, Mannucci PM, Bauer KA, Bertina RM, Bochkov NP, Boulyjenkov V, Chandy M, Dahlback B, Ginter EK, Miletich JP, Rosendaal FR, Seligsohn U. Inherited thrombophilia: Part 2. Thromb Haemost 1996;76:824-834.
  266. Legnani C, Palareti G, Biagi R, Coccheri S, Bernardi F, Rosendaal FR, Reitsma PH, de Ronde H, Bertina RM. Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation. Br J Haematol 1996;93:694-699.
  267. Lensen RP, Rosendaal FR, Koster T, Allaart CF, de Ronde H, Vandenbroucke JP, Reitsma PH, Bertina RM. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood 1996;88:4205-4208.
  268. Makris M, Preston FE, Rosendaal FR, Underwood JC, Rice KM, Triger DR. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 1996;94:746-752.
  269. Manten A, Westendorp RGJ, van der Meer FJ, Huisman MV. [Thromboembolic complications of central venous catheters]. Ned Tijdschr Geneeskd 1996;140:1797-1800.
  270. Manten B, Westendorp RGJ, Koster T, Reitsma PH, Rosendaal FR. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the factor V Leiden mutation. Thromb Haemost 1996;76:510-513.
  271. Martinelli I, Rosendaal FR, Vandenbroucke JP, Mannucci PM. Oral contraceptives are a risk factor for cerebral vein thrombosis. Thromb Haemost 1996;76:477-478.
  272. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703.
  273. Preston FE, Rosendaal FR, Walker ID, Briët E, Berntorp E, Conard J, Fontcuberta J, Makris M, Mariani G, Noteboom W, Pabinger I, Legnani C, Scharrer I, Schulman S, van der Meer FJ. Increased fetal loss in women with heritable thrombophilia. Lancet 1996;348:913-916.
  274. Psaty BM, Siscovick DS, Weiss NS, Koepsell TD, Rosendaal FR, Lin D, Heckbert SR, Wagner EH, Furberg CD. Hypertension and outcomes research. From clinical trials to clinical epidemiology. Am J Hypertens 1996;9:178-183.
  275. Rosendaal FR. The Scylla and Charybdis of oral anticoagulant treatment. N Engl J Med 1996;335:587-589.
  276. Rosendaal FR, Psaty BM, Furberg CD. [Calcium antagonists: safe or unsafe?]. Ned Tijdschr Geneeskd 1996;140:916-918.
  277. Rosendaal FR. Oral contraceptives and screening for factor V Leiden. Thromb Haemost 1996;75:524-525.
  278. Schlemper RJ, van der Werf SD, Vandenbroucke JP, Biemond I, Lamers CB. Risk factors of peptic ulcer disease: different impact of Helicobacter pylori in Dutch and Japanese populations? J Gastroenterol Hepatol 1996;11:825-831.
  279. Sijbrands EJ, Westendorp RGJ, Hoffer MJ, Frants RR, Meinders AE, Souverijn JH, Gevers Leuven JA, van der Laarse A, Havekes LM, Smelt AH. Effect of apolipoprotein E and insulin resistance on VLDL particles in combined hyperlipidemic patients. Atherosclerosis 1996;126:197-205.
  280. ten Wolde S, Breedveld FC, Hermans J, Vandenbroucke JP, van de Laar MA, Markusse HM, Janssen M, van den Brink HR, Dijkmans BA. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996;347:347-352.
  281. van Boven HH, Reitsma PH, Rosendaal FR, Bayston TA, Chowdhury V, Bauer KA, Scharrer I, Conard J, Lane DA. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996;75:417-421.
  282. van de Wetering J, Westendorp RGJ, van der Hoeven JG, Stolk B, Feuth JD, Chang PC. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996;7:145-150.
  283. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 1996;76:12-16.
  284. Vandenbroucke JP, Vandenbroucke-Grauls CM. In defense of Farr and Nightingale. Ann Intern Med 1996;125:1014.
  285. Vandenbroucke JP. Evidence-based medicine and "medecine d'observation". J Clin Epidemiol 1996;49:1335-1338.
  286. Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996;313:1127-1130.
  287. Vandenbroucke JP, Helmerhorst FM. Risk of venous thrombosis with hormone-replacement therapy. Lancet 1996;348:972.
  288. Vandenbroucke JP, Bloemenkamp KW, Helmerhorst FM, Rosendaal FR. Mortality from venous thromboembolism and myocardial infarction in young women in the Netherlands. Lancet 1996;348:401-402.
  289. Vandenbroucke JP, Westendorp RGJ. Are the effects of cholesterol lowering drugs always equal? Lancet 1996;347:1267-1268.
  290. Vandenbroucke JP. [Screening for familial hypercholesterolemia]. Ned Tijdschr Geneeskd 1996;140:944-948.
  291. Vliet Vlieland TP, Zwinderman AH, Vandenbroucke JP, Breedveld FC, Hazes JM. A randomized clinical trial of in-patient multidisciplinary treatment versus routine out-patient care in active rheumatoid arthritis. Br J Rheumatol 1996;35:475-482.
  292. Voskuyl AE, Zwinderman AH, Westedt ML, Vandenbroucke JP, Breedveld FC, Hazes JM. Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case-control study. Ann Rheum Dis 1996;55:190-192.
  293. Voskuyl AE, Zwinderman AH, Westedt ML, Vandenbroucke JP, Breedveld FC, Hazes JM. The mortality of rheumatoid vasculitis compared with rheumatoid arthritis. Arthritis Rheum 1996;39:266-271.
  294. Westendorp RGJ, Portielje J. Sexual activity and risk of myocardial infarction. JAMA 1996;276:782-783.
  295. Westendorp RGJ, Reitsma PH, Bertina RM. Inherited prethrombotic disorders and infectious purpura. Thromb Haemost 1996;75:899-901.
  296. Westendorp RGJ, Smelt AH. [Cholesterol synthesis inhibitors: lowering of cholesterol for everybody?]. Ned Tijdschr Geneeskd 1996;140:411-414.
  297. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RGJ. Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997;28:946-950.
  298. Bootsma-van der Wiel A, Westendorp RGJ, Knook DL. [Daily functioning and health care utilization among persons 85 years old and older]. Ned Tijdschr Geneeskd 1997;141:2170-2176.
  299. Bornebroek M, Westendorp RGJ, Haan J, Bakker E, Timmers WF, van Broeckhoven C, Roos RAC. Mortality from hereditary cerebral haemorrhage with amyloidosis--Dutch type. The impact of sex, parental transmission and year of birth. Brain 1997;120:2243-2249.
  300. Bouma PA, Bovenkerk AC, Westendorp RGJ, Brouwer OF. The course of benign partial epilepsy of childhood with centrotemporal spikes: a meta-analysis. Neurology 1997;48:430-437.
  301. Cannegieter SC, Rosendaal FR, Bollen EL, Briët E. High intensity of oral anticoagulant therapy in patients with cerebral haemorrhage: cause or consequence of the bleeding? Br J Haematol 1997;96:497-499.
  302. Crijns MB, Klaver C, de Boer A, Van Hees C, Vermeer BJ, Vandenbroucke J, Bergman W. Ultraviolet exposure and the development of banal and atypical naevi--a cross-sectional study on Curacao and in The Netherlands. Melanoma Res 1997;7:407-416.
  303. de Kleijn EM, Vandenbroucke JP, van der Meer JW. Fever of unknown origin (FUO). I A. prospective multicenter study of 167 patients with FUO, using fixed epidemiologic entry criteria. The Netherlands FUO Study Group. Medicine (Baltimore) 1997;76:392-400.
  304. Feinstein AR, Vandenbroucke JP. The state of the Journal. J Clin Epidemiol 1997;50:1-2.
  305. George EK, Mearin ML, Franken HC, Houwen RH, Hirasing RA, Vandenbroucke JP. Twenty years of childhood coeliac disease in The Netherlands: a rapidly increasing incidence? Gut 1997;40:61-66.
  306. Gussekloo J, Westendorp RGJ, Remarque EJ, Lagaay AM, Heeren TJ, Knook DL. Impact of mild cognitive impairment on survival in very elderly people: cohort study. BMJ 1997;315:1053-1054.
  307. Helmerhorst FM, Bloemenkamp KW, Rosendaal FR, Vandenbroucke JP. Oral contraceptives and thrombotic disease: risk of venous thromboembolism. Thromb Haemost 1997;78:327-333.
  308. Hille ET, Westendorp RGJ, Vandenbroucke JP, Rosendaal FR. Mortality and causes of death in families with the factor V Leiden mutation (resistance to activated protein C). Blood 1997;89:1963-1967.
  309. Huizinga TW, Westendorp RGJ, Bollen EL, Keijsers V, Brinkman BM, Langermans JA, Breedveld FC, Verweij CL, van de Gaer L, Dams L, Crusius JB, Garcia-Gonzalez A, van Oosten BW, Polman CH, Pena AS. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 1997;72:149-153.
  310. Hulshof MM, Vandenbroucke JP, Nohlmans LM, Spanjaard L, Bavinck JN, Dijkmans BA. Long-term prognosis in patients treated for erythema chronicum migrans and acrodermatitis chronica atrophicans. Arch Dermatol 1997;133:33-37.
  311. Makris M, Rosendaal FR, Preston FE. Familial thrombophilia: genetic risk factors and management. J Intern Med Suppl 1997;740:9-15.:9-15.
  312. Makris M, Greaves M, Phillips WS, Kitchen S, Rosendaal FR, Preston FE. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997;77:477-480.
  313. Posthuma WF, Ledeboer M, Masclee AA, Dijkmans BA, Westendorp RGJ, Jebbink MC, Breedveld FC, Lamers CB. Do patients with systemic sclerosis have abnormal gallbladder function? Eur J Gastroenterol Hepatol 1997;9:675-677.
  314. Rosendaal FR, van der Meer FJ, Vandenbroucke JP. Management of venous thromboembolism. N Engl J Med 1997;336:1528-1529.
  315. Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. Blood 1997;90:1747-1750.
  316. Rosendaal FR, Algra A. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1997;150:85, 87.
  317. Rosendaal FR. Risk factors for venous thrombosis: prevalence, risk, and interaction. Semin Hematol 1997;34:171-187.
  318. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost 1997;78:1-6.
  319. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT, Jr., Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;89:2817-2821.
  320. Schwartz SM, Siscovick DS, Malinow MR, Rosendaal FR, Beverly RK, Hess DL, Psaty BM, Longstreth WT, Jr., Koepsell TD, Raghunathan TE, Reitsma PH. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997;96:412-417.
  321. Shackleton DP, Westendorp RGJ, Kasteleijn-Nolst Trenite DG, de Boer A, Herings RM. Dispensing epilepsy medication: a method of determining the frequency of symptomatic individuals with seizures. J Clin Epidemiol 1997;50:1061-1068.
  322. Siscovick DS, Schwartz SM, Rosendaal FR, Psaty BM. Thrombosis in the young: effect of atherosclerotic risk factors on the risk of myocardial infarction associated with prothrombotic factors. Thromb Haemost 1997;78:7-12.
  323. Toornvliet AC, Pijl H, Frolich M, Westendorp RGJ, Meinders AE. Insulin and leptin concentrations in obese humans during long-term weight loss. Neth J Med 1997;51:96-102.
  324. Toornvliet AC, Pijl H, Hopman E, Westendorp RGJ, Meinders AE. Predictors of weight loss during treatment with d-fenfluramine. J Intern Med 1997;241:401-406.
  325. van Boven HH, Vandenbroucke JP, Westendorp RGJ, Rosendaal FR. Mortality and causes of death in inherited antithrombin deficiency. Thromb Haemost 1997;77:452-455.
  326. van der Meer FJ, Briët E, Vandenbroucke JP, Sramek DI, Versluijs MH, Rosendaal FR. The role of compliance as a cause of instability in oral anticoagulant therapy. Br J Haematol 1997;98:893-900.
  327. van der Meer FJ, Koster T, Vandenbroucke JP, Briët E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997;78:631-635.
  328. Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KW, Rosendaal FR. Third-generation oral contraceptive and deep venous thrombosis: from epidemiologic controversy to new insight in coagulation. Am J Obstet Gynecol 1997;177:887-891.
  329. Vandenbroucke JP. Homoeopathy trials: going nowhere. Lancet 1997;350:824.
  330. Vandenbroucke JP. Re: "A new perspective on John Snow's communicable disease theory". Am J Epidemiol 1997;146:363-364.
  331. Vandenbroucke JP, Vandenbroucke-Grauls CM. A return to Farr and Nightingale. Ann Intern Med 1997;127:170-171.
  332. Vandenbroucke JP, Rosendaal FR. Pregnancy-related thromboembolism. Ann Intern Med 1997;127:164-165.
  333. Vandenbroucke JP, Rosendaal FR. End of the line for "third-generation-pill" controversy? Lancet 1997;349:1113-1114.
  334. Vandenbroucke JP, Helmerhorst FM, Bloemenkamp KW, Rosendaal FR. Third-generation oral contraceptives and venous thrombosis. Lancet 1997;349:731-733.
  335. Vandenbroucke JP, Bloemenkamp KW, Helmerhorst FM, Rosendaal FR. Risk of oral contraceptives and recency of market introduction. Contraception 1997;55:191-192.
  336. Vandenbroucke JP. [The many faces of epidemiology]. Ned Tijdschr Geneeskd 1997;141:182-184.
  337. Vleming LJ, Baelde JJ, Westendorp RGJ, Daha MR, van Es LA, Bruijn JA. The glomerular deposition of PAS positive material correlates with renal function in human kidney diseases. Clin Nephrol 1997;47:158-167.
  338. Westendorp RGJ, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, Vandenbroucke JP. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997;349:170-173.
  339. Westendorp RGJ, Langermans JA, Huizinga TW, Verweij CL, Sturk A. Genetic influence on cytokine production in meningococcal disease. Lancet 1997;349:1912-1913.
  340. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RGJ. Total cholesterol and risk of mortality in the oldest old. Lancet 1997;350:1119-1123.
  341. Bastiaens MT, Hoefnagel JJ, Bruijn JA, Westendorp RGJ, Vermeer BJ, Bouwes Bavinck JN. Differences in age, site distribution, and sex between nodular and superficial basal cell carcinoma indicate different types of tumors. J Invest Dermatol 1998;110:880-884.
  342. Bertina RM, Rosendaal FR. Venous thrombosis--the interaction of genes and environment. N Engl J Med 1998;338:1840-1841.
  343. Beyer WE, de Bruijn IA, Palache AM, Westendorp RGJ, Osterhaus AD. The plea against annual influenza vaccination? 'The Hoskins' Paradox' revisited. Vaccine 1998;16:1929-1932.
  344. Blauw GJ, Lagaay AM, Westendorp RGJ. Statins for prevention of stroke. Lancet 1998;352:144.
  345. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Koster T, Bertina RM, Vandenbroucke JP. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives. Thromb Haemost 1998;80:382-387.
  346. Cushman M, Rosendaal FR, Psaty BM, Cook EF, Valliere J, Kuller LH, Tracy RP. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. Thromb Haemost 1998;79:912-915.
  347. de Bruijn SF, Stam J, Vandenbroucke JP. Increased risk of cerebral venous sinus thrombosis with third-generation oral contraceptives. Cerebral Venous Sinus Thrombosis Study Group. Lancet 1998;351:1404.
  348. de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users and in [correction of who are] carriers of hereditary prothrombotic conditions. The Cerebral Venous Sinus Thrombosis Study Group. BMJ 1998;316:589-592.
  349. den Heijer M, Rosendaal FR, Blom HJ, Gerrits WB, Bos GM. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998;80:874-877.
  350. den Heijer M, Brouwer IA, Bos GM, Blom HJ, van der Put NM, Spaans AP, Rosendaal FR, Thomas CM, Haak HL, Wijermans PW, Gerrits WB. Vitamin supplementation reduces blood homocysteine levels: a controlled trial in patients with venous thrombosis and healthy volunteers. Arterioscler Thromb Vasc Biol 1998;18:356-361.
  351. Doggen CJM, Manger Cats V, Bertina RM, Reitsma PH, Vandenbroucke JP, Rosendaal FR. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. Thromb Haemost 1998;80:281-285.
  352. Doggen CJM, Kunz G, Rosendaal FR, Lane DA, Vos HL, Stubbs PJ, Manger Cats V, Ireland H. A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction in men. Thromb Haemost 1998;80:743-748.
  353. Doggen CJM, Manger Cats V, Bertina RM, Rosendaal FR. Interaction of coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. Circulation 1998;97:1037-1041.
  354. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RGJ, Huizinga TW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A 1998;95:9465-9470.
  355. George EK, Mearin ML, Kanhai SM, Franken HC, Houwen RH, Hirasing RA, Vandenbroucke JP. [Twenty years of childhood coeliac disease in the Netherlands: more diagnoses and a changed clinical picture]. Ned Tijdschr Geneeskd 1998;142:850-854.
  356. Heijmans BT, Westendorp RGJ, Knook DL, Kluft C, Slagboom PE. The risk of mortality and the factor V Leiden mutation in a population-based cohort. Thromb Haemost 1998;80:607-609.
  357. Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Venous thromboembolism and the pill. The WHO technical report on cardiovascular disease and steroid hormone contraception: state-of-the-art. World Health Organization. Hum Reprod 1998;13:2981-2983.
  358. Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. The pill and venous thromboembolism: a disarray of several layers of debate. Hum Reprod 1998;13:1119-1120.
  359. Hille ET, van Duijn E, Gruis NA, Rosendaal FR, Bergman W, Vandenbroucke JP. Excess cancer mortality in six Dutch pedigrees with the familial atypical multiple mole-melanoma syndrome from 1830 to 1994. J Invest Dermatol 1998;110:788-792.
  360. Kamphuisen PW, Houwing-Duistermaat JJ, van Houwelingen HC, Eikenboom JC, Bertina RM, Rosendaal FR. Familial clustering of factor VIII and von Willebrand factor levels. Thromb Haemost 1998;79:323-327.
  361. Kianmanesh Rad NA, Vandenbussche FP, Le Cessie S, Oepkes D, Westendorp RGJ, Keirse MJ. A risk model approach to the prediction of fetal acidemia. J Perinat Med 1998;26:270-277.
  362. Kluijtmans LA, den Heijer M, Reitsma PH, Heil SG, Blom HJ, Rosendaal FR. Thermolabile methylenetetrahydrofolate reductase and factor V Leiden in the risk of deep-vein thrombosis. Thromb Haemost 1998;79:254-258.
  363. Koopmans SJ, Frolich M, Gribnau EH, Westendorp RGJ, DeFronzo RA. Effect of hyperinsulinemia on plasma leptin concentrations and food intake in rats. Am J Physiol 1998;274:E998-E1001.
  364. Longstreth WT, Jr., Rosendaal FR, Siscovick DS, Vos HL, Schwartz SM, Psaty BM, Raghunathan TE, Koepsell TD, Reitsma PH. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke 1998;29:577-580.
  365. Oosterkamp HM, Brand A, Kluin-Nelemans JC, Vandenbroucke JP. Pregnancy and severe aplastic anaemia: causal relation or coincidence? Br J Haematol 1998;103:315-316.
  366. Rosendaal FR, Bouter LM. [Straying in the methodology. I. Introduction]. Ned Tijdschr Geneeskd 1998;142:1554-1555.
  367. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998;79:706-708.
  368. Rosendaal FR, Vos HL, Poort SL, Bertina RM. Prothrombin 20210A variant and age at thrombosis. Thromb Haemost 1998;79:444.
  369. Sijbrands EJ, Lombardi MP, Westendorp RGJ, Leuven JA, Meinders AE, van der Laarse A, Frants RR, Havekes LM, Smelt AH. Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations. Atherosclerosis 1998;136:247-254.
  370. Simon CH, Vliet Vlieland TP, Dijkmans BA, Bernelot Moens HJ, Janssen M, Hazes JM, Franken HC, Vandenbroucke JP, Breedveld FC. Laboratory screening for side effects of disease modifying antirheumatic drugs in daily rheumatological practice. Scand J Rheumatol 1998;27:170-179.
  371. Triemstra AH, van der Ploeg HM, Smit C, Briët E, Ader HJ, Rosendaal FR. Well-being of haemophilia patients: a model for direct and indirect effects of medical parameters on the physical and psychosocial functioning. Soc Sci Med 1998;47:581-593.
  372. van den Borne BE, Landewe RB, Houkes I, Schild F, van der Heyden PC, Hazes JM, Vandenbroucke JP, Zwinderman AH, Goei The HS, Breedveld FC, Bernelot Moens HJ, Kluin PM, Dijkmans BA. No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1930-1937.
  373. van der Linden MW, Huizinga TW, Stoeken DJ, Sturk A, Westendorp RGJ. Determination of tumour necrosis factor-alpha and interleukin-10 production in a whole blood stimulation system: assessment of laboratory error and individual variation. J Immunol Methods 1998;218:63-71.
  374. van Dissel JT, van Langevelde P, Westendorp RGJ, Kwappenberg K, Frolich M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998;351:950-953.
  375. Vandenbroucke JP. [The administration of a clinical department]. Ned Tijdschr Geneeskd 1998;142:2803-2805.
  376. Vandenbroucke JP. 175th anniversary lecture. Medical journals and the shaping of medical knowledge. Lancet 1998;352:2001-2006.
  377. Vandenbroucke JP, Helmerhorst FM, Rosendaal FR. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med 1998;129:747.
  378. Vandenbroucke JP. Clinical investigation in the 20th century: the ascendancy of numerical reasoning. Lancet 1998;352 Suppl 2:SII12-6.:SII12-SII16.
  379. Vandenbroucke JP, Grobbee DE. [Lessons from a heart valve prosthesis controversy]. Ned Tijdschr Geneeskd 1998;142:1648-1652.
  380. Vandenbroucke JP. Cerebral sinus thrombosis and oral contraceptives. There are limits to predictability. BMJ 1998;317:483-484.
  381. Vandenbroucke JP. Observational research and evidence-based medicine: What should we teach young physicians? J Clin Epidemiol 1998;51:467-472.
  382. Vandenbroucke JP. [How can I keep up with my literature?]. Ned Tijdschr Geneeskd 1998;142:722-724.
  383. Vandenbroucke JP. Maintaining privacy and the health of the public. Should not be seen as in opposition. BMJ 1998;316:1331-1332.
  384. Vandenbroucke JP. Maternal inheritance of longevity. Lancet 1998;351:1064.
  385. Vandenbroucke JP, Bertina RM, Holmes ZR, Spaargaren C, van Krieken JH, Manten B, Reitsma PH. Factor V Leiden and fatal pulmonary embolism. Thromb Haemost 1998;79:511-516.
  386. Vandenbroucke JP. Bias in meta-analysis detected by a simple, graphical test. Experts' views are still needed. BMJ 1998;316:469-470.
  387. Vleming LJ, de Fijter JW, Westendorp RGJ, Daha MR, Bruijn JA, van Es LA. Histomorphometric correlates of renal failure in IgA nephropathy. Clin Nephrol 1998;49:337-344.
  388. Westendorp RGJ, Kirkwood TB. Human longevity at the cost of reproductive success. Nature 1998;396:743-746.
  389. Westendorp RGJ. [Roaming through methodology. VI. Medical perspective on the causes of death]. Ned Tijdschr Geneeskd 1998;142:1950-1953.
  390. Bastiaens MT, Westendorp RGJ, Vermeer BJ, Bavinck JN. Ephelides are more related to pigmentary constitutional host factors than solar lentigines. Pigment Cell Res 1999;12:316-322.
  391. Beyer WE, de Bruijn IA, Palache AM, Westendorp RGJ, Osterhaus AD. Protection against influenza after annually repeated vaccination: a meta-analysis of serologic and field studies. Arch Intern Med 1999;159:182-188.
  392. Bindels AJ, Westendorp RGJ, Frolich M, Seidell JC, Blokstra A, Smelt AH. The prevalence of subclinical hypothyroidism at different total plasma cholesterol levels in middle aged men and women: a need for case-finding? Clin Endocrinol (Oxf) 1999;50:217-220.
  393. Bloemenkamp KW, Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Venous thrombosis, oral contraceptives and high factor VIII levels. Thromb Haemost 1999;82:1024-1027.
  394. Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Venous thromboembolism and oral contraceptives. Lancet 1999;354:1469-1470.
  395. Bloemenkamp KWM, Rosendaal FR, Büller HR, Helmerhorst FM, Colly LP, Vandenbroucke JP. Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med 1999;159:65-70.
  396. Bucciarelli P, Rosendaal FR, Tripodi A, Mannucci PM, de Stefano V, Palareti G, Finazzi G, Baudo F, Quintavalla R. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Thromb Vasc Biol 1999;19:1026-1033.
  397. Cannegieter SC, Torn M, Rosendaal FR. Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications. J Intern Med 1999;245:369-374.
  398. de Bruijn IA, Remarque EJ, Jol-van der Zijde CM, van Tol MJ, Westendorp RGJ, Knook DL. Quality and quantity of the humoral immune response in healthy elderly and young subjects after annually repeated influenza vaccination. J Infect Dis 1999;179:31-36.
  399. de Groot CJ, Bloemenkamp KWM, Duvekot EJ, Helmerhorst FM, Bertina RM, van der Meer FJM, de Ronde H, Oei SG, Kanhai HH, Rosendaal FR. Preeclampsia and genetic risk factors for thrombosis: a case-control study. Am J Obstet Gynecol 1999;181:975-980.
  400. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999;93:1271-1276.
  401. Doggen CJM, Bertina RM, Manger Cats V, Reitsma PH, Rosendaal FR. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with myocardial infarction. Thromb Haemost 1999;82:115-120.
  402. Gussekloo J, Heijmans BT, Slagboom PE, Lagaay AM, Knook DL, Westendorp RGJ. Thermolabile methylenetetrahydrofolate reductase gene and the risk of cognitive impairment in those over 85. J Neurol Neurosurg Psychiatry 1999;67:535-538.
  403. Heijmans BT, Westendorp RGJ, Knook DL, Kluft C, Slagboom PE. Angiotensin I-converting enzyme and plasminogen activator inhibitor-1 gene variants: risk of mortality and fatal cardiovascular disease in an elderly population-based cohort. J Am Coll Cardiol 1999;34:1176-1183.
  404. Heijmans BT, Gussekloo J, Kluft C, Droog S, Lagaay AM, Knook DL, Westendorp RGJ, Slagboom EP. Mortality risk in men is associated with a common mutation in the methylene-tetrahydrofolate reductase gene (MTHFR). Eur J Hum Genet 1999;7:197-204.
  405. Hille ET, Siesling S, Vegter-van der Vlis M, Vandenbroucke JP, Roos RAC, Rosendaal FR. Two centuries of mortality in ten large families with Huntington disease: a rising impact of gene carriership. Epidemiology 1999;10:706-710.
  406. Huisman MV, Rosendaal FR. Thrombophilia. Curr Opin Hematol 1999;6:291-297.
  407. Izaks GJ, Westendorp RGJ, Knook DL. The definition of anemia in older persons. JAMA 1999;281:1714-1717.
  408. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM, Rosendaal FR. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999;81:680-683.
  409. Kuyvenhoven JP, Veenendaal RA, Vandenbroucke JP. Peptic ulcer bleeding: interaction between non-steroidal anti-inflammatory drugs, Helicobacter pylori infection, and the ABO blood group system. Scand J Gastroenterol 1999;34:1082-1086.
  410. Liberti G, Bertina RM, Rosendaal FR. Hormonal state rather than age influences cut-off values of protein S: reevaluation of the thrombotic risk associated with protein S deficiency. Thromb Haemost 1999;82:1093-1096.
  411. Penning-van Beest FJ, Rosendaal FR, Grobbee DE, van Meegen E, Stricker BH. Course of the international Normalized Ratio in response to oral vitamin K1 in patients overanticoagulated with phenprocoumon. Br J Haematol 1999;104:241-245.
  412. Psaty BM, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Rosendaal FR, Smith NL, Heckbert SR, Kaplan RC, Lin D, Fleming TR, Wagner EH. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 1999;282:786-790.
  413. Psaty BM, Koepsell TD, Lin D, Weiss NS, Siscovick DS, Rosendaal FR, Pahor M, Furberg CD. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 1999;47:749-754.
  414. Rosendaal FR. Venous thrombosis: prevalence and interaction of risk factors. Haemostasis 1999;29 Suppl S1:1-9.:1-9.
  415. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999;82:610-619.
  416. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999;353:1167-1173.
  417. Shackleton DP, Westendorp RGJ, Kasteleijn-Nolst Trenite DG, Vandenbroucke JP. Mortality in patients with epilepsy: 40 years of follow up in a Dutch cohort study. J Neurol Neurosurg Psychiatry 1999;66:636-640.
  418. Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM, Ford I, Jukema JW, Hyland M, Gaw A, Lagaay AM, Perry IJ, Macfarlane PW, Meinders AE, Sweeney BJ, Packard CJ, Westendorp RGJ, Twomey C, Stott DJ. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol 1999;84:1192-1197.
  419. Sijpkens YW, Doxiadis II, de Fijter JW, Mallat MJ, van Es LA, de Lange P, Zwinderman AH, Westendorp RGJ, van Kemenade FJ, Bruijn JA, Claas FH, Paul LC. Sharing cross-reactive groups of MHC class I improves long-term graft survival. Kidney Int 1999;56:1920-1927.
  420. Smets YF, Westendorp RGJ, van der Pijl JW, de Charro FT, Ringers J, de Fijter JW, Lemkes HH. Effect of simultaneous pancreas-kidney transplantation on mortality of patients with type-1 diabetes mellitus and end-stage renal failure. Lancet 1999;353:1915-1919.
  421. Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 1999;159:1043-1051.
  422. van Boven HH, Vandenbroucke JP, Briët E, Rosendaal FR. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency. Blood 1999;94:2590-2594.
  423. van der Meer FJ, Vos HL, Rosendaal FR. No indication for APTT screening in patients on oral anticoagulant therapy. Thromb Haemost 1999;81:364-366.
  424. van der Sar-van der Brugge, Arend SM, Bernards AT, Berbee GA, Westendorp RGJ, Feuth JD, van den Broek PJ. Risk factors for acquisition of Serratia marcescens in a surgical intensive care unit. J Hosp Infect 1999;41:291-299.
  425. Vandenbroucke JP. [Evolution of medical statistics and epidemiology in clinical scientific research in the 20th century]. Ned Tijdschr Geneeskd 1999;143:2625-2628.
  426. Vandenbroucke JP. [Risk factors for dying among ibopamine users]. Ned Tijdschr Geneeskd 1999;143:1631-1632.
  427. Vandenbroucke JP. Case reports in an evidence-based world. J R Soc Med 1999;92:159-163.
  428. Vandenbroucke JP. [Roaming through the methodology. XIV. The premature ending of a randomized trial]. Ned Tijdschr Geneeskd 1999;143:1305-1308.
  429. Vandenbroucke JP. Hormone replacement therapy for secondary prevention of coronary heart disease. JAMA 1999;281:796.
  430. Vleming LJ, van der Pijl JW, Lemkes HH, Westendorp RGJ, Maassen JA, Daha MR, van Es LA, van Kooten C. The DD genotype of the ACE gene polymorphism is associated with progression of diabetic nephropathy to end stage renal failure in IDDM. Clin Nephrol 1999;51:133-140.
  431. Westendorp RGJ, Hottenga JJ, Slagboom PE. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet 1999;354:561-563.
  432. Willems HP, den Heijer M, Blom HJ, Gerrits WB, Rosendaal FR, Bos GM. [Hyperhomocysteinemia as a risk factor for venous thrombosis]. Ned Tijdschr Geneeskd 1999;143:552-556.
  433. Blann AD, Noteboom WM, Rosendaal FR. Increased soluble P-selectin levels following deep venous thrombosis: cause or effect? Br J Haematol 2000;108:191-193.
  434. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000;160:49-52.
  435. Bouwes Bavinck JN, Stark S, Petridis AK, Marugg ME, ter Schegget J, Westendorp RGJ, Fuchs PG, Vermeer BJ, Pfister H. The presence of antibodies against virus-like particles of epidermodysplasia verruciformis-associated humanpapillomavirus type 8 in patients with actinic keratoses. Br J Dermatol 2000;142:103-109.
  436. Csizmadia CG, Mearin ML, Oren A, Kromhout A, Crusius JB, von Blomberg BM, Pena AS, Wiggers MN, Vandenbroucke JP. Accuracy and cost-effectiveness of a new strategy to screen for celiac disease in children with Down syndrome. J Pediatr 2000;137:756-761.
  437. de Craen AJ. ['Informed consent' and prerandomization]. Ned Tijdschr Geneeskd 2000;144:1301-1303.
  438. de Craen AJ. [Roaming through methodology. XVII. The placebo effect]. Ned Tijdschr Geneeskd 2000;144:322-324.
  439. de Jong BA, Schrijver HM, Huizinga TW, Bollen EL, Polman CH, Uitdehaag BM, Kersbergen MC, Sturk A, Westendorp RGJ. Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis. Ann Neurol 2000;48:641-646.
  440. de Visser MC, Guasch JF, Kamphuisen PW, Vos HL, Rosendaal FR, Bertina RM. The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost 2000;83:577-582.
  441. Doggen CJM, de Visser MC, Vos HL, Bertina RM, Manger Cats V, Rosendaal FR. The HR2 haplotype of factor V is not associated with the risk of myocardial infarction. Thromb Haemost 2000;84:815-818.
  442. Doggen CJM, Berckmans RJ, Sturk A, Manger Cats V, Rosendaal FR. C-reactive protein, cardiovascular risk factors and the association with myocardial infarction in men. J Intern Med 2000;248:406-414.
  443. Doggen CJM, Bertina RM, Manger Cats V, Rosendaal FR. Fibrinogen polymorphisms are not associated with the risk of myocardial infarction. Br J Haematol 2000;110:935-938.
  444. Eekhoff EM, Rosendaal FR, Vandenbroucke JP. Minor events and the risk of deep venous thrombosis. Thromb Haemost 2000;83:408-411.
  445. Helmerhorst F, Vandenbroucke JP. [Third-generation pill]. Ned Tijdschr Geneeskd 2000;144:818.
  446. Herings RM, Leufkens HG, Vandenbroucke JP. Acute myocardial infarction and prior antibiotic use. JAMA 2000;284:2998-2999.
  447. Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van der Meer FJM, van Hattum J, Chamuleau RA, Adang RP, Vandenbroucke JP, van Hoek B, Rosendaal FR. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000;96:2364-2368.
  448. Jong-Tieben LM, Berkhout RJ, ter Schegget J, Vermeer BJ, de Fijter JW, Bruijn JA, Westendorp RGJ, Bouwes Bavinck JN. The prevalence of human papillomavirus DNA in benign keratotic skin lesions of renal transplant recipients with and without a history of skin cancer is equally high: a clinical study to assess risk factors for keratotic skin lesions and skin cancer. Transplantation 2000;69:44-49.
  449. Kamphuisen PW, Lensen R, Houwing-Duistermaat JJ, Eikenboom JC, Harvey M, Bertina RM, Rosendaal FR. Heritability of elevated factor VIII antigen levels in factor V Leiden families with thrombophilia. Br J Haematol 2000;109:519-522.
  450. Kamphuisen PW, Rosendaal FR, Eikenboom JC, Bos R, Bertina RM. Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V leiden, and relation with factor VIII antigen levels. Arterioscler Thromb Vasc Biol 2000;20:1382-1386.
  451. Kaplan RC, Heckbert SR, Koepsell TD, Rosendaal FR, Psaty BM. Use of calcium channel blockers and risk of hospitalized gastrointestinal tract bleeding. Arch Intern Med 2000;160:1849-1855.
  452. Koster T, Rosendaal FR, Lieuw ALD, Kroes AC, Emmerich JD, van Dissel JT. Chlamydia pneumoniae IgG seropositivity and risk of deep-vein thrombosis. Lancet 2000;355:1694-1695.
  453. Lensen RP, Rosendaal FR, Vandenbroucke J, Bertina R. Factor V Leiden: the venous thrombotic risk in thrombophilic families. Br J Haematol 2000;110:939-945.
  454. Lensen RP, Bertina RM, de Ronde H, Vandenbroucke JP, Rosendaal FR. Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost 2000;83:817-821.
  455. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000;342:696-701.
  456. Nieuwland R, Berckmans RJ, McGregor S, Boing AN, Romijn FP, Westendorp RGJ, Hack CE, Sturk A. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. Blood 2000;95:930-935.
  457. Psaty BM, Doggen C, Vos HL, Vandenbroucke JP, Rosendaal FR. Association of the alpha-adducin polymorphism with blood pressure and risk of myocardial infarction. J Hum Hypertens 2000;14:95-97.
  458. Reiner AP, Kumar PN, Schwartz SM, Longstreth WT, Jr., Pearce RM, Rosendaal FR, Psaty BM, Siscovick DS. Genetic variants of platelet glycoprotein receptors and risk of stroke in young women. Stroke 2000;31:1628-1633.
  459. Rood MJ, van Krugten MV, Zanelli E, van der Linden MW, Keijsers V, Schreuder GM, Verduyn W, Westendorp RGJ, de Vries RR, Breedveld FC, Verweij CL, Huizinga TW. TNF-308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. Arthritis Rheum 2000;43:129-134.
  460. Rosendaal FR. High levels of factor VIII and venous thrombosis. Thromb Haemost 2000;83:1-2.
  461. Sramek A, Bosch JG, Reiber JH, van Oostayen JA, Rosendaal FR. Ultrasound assessment of atherosclerotic vessel wall changes: reproducibility of intima-media thickness measurements in carotid and femoral arteries. Invest Radiol 2000;35:699-706.
  462. Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic drugs and venous thromboembolism. Lancet 2000;356:252.
  463. van der Linden MW, Westendorp RGJ, Sturk A, Bergman W, Huizinga TW. High interleukin-10 production in first-degree relatives of patients with generalized but not cutaneous lupus erythematosus. J Investig Med 2000;48:327-334.
  464. van Driel D, Wesseling J, Rosendaal FR, Odink RJ, van der Veen H, Gerver WJ, Geven-Boere LM, Sauer PJ. Growth until puberty after in utero exposure to coumarins. Am J Med Genet 2000;95:438-443.
  465. van Hylckama Vlieg A, van der Linden I, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000;95:3678-3682.
  466. van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000;95:2855-2859.
  467. Vandenbroucke JP. Snow and the Broad Street pump: a rediscovery. Lancet 2000;356:1688.
  468. Vandenbroucke JP. Invited commentary: the testimony of Dr. Snow. Am J Epidemiol 2000;152:10-12.
  469. Vandenbroucke JP. Scoring the quality of clinical trials. JAMA 2000;283:1422-1423.
  470. Vandenbroucke JP, Bloemenkamp KW, Helmerhorst FM, Rosendaal FR. [Handling small relative risks in science and management: the third-generation pill]. Ned Tijdschr Geneeskd 2000;144:254-258.
  471. Vandenbroucke JP, Helmerhorst FM, Rosendaal FR. Competing interests and controversy about third generation oral contraceptives. BMJ readers should know whose words they read. BMJ 2000;320:381-382.
  472. Vandenbroucke JP, Bloemenkamp KW, Rosendaal FR, Helmerhorst FM. Incidence of venous thromboembolism in users of combined oral contraceptives. Risk is particularly high with first use of oral contraceptives. BMJ 2000;320:57-58.
  473. Weijl NI, Rutten MF, Zwinderman AH, Keizer HJ, Nooy MA, Rosendaal FR, Cleton FJ, Osanto S. Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. J Clin Oncol 2000;18:2169-2178.
  474. Zidane M, Schram MT, Planken EW, Molendijk WH, Rosendaal FR, van der Meer FJ, Huisman MV. Frequency of major hemorrhage in patients treated with unfractionated intravenous heparin for deep venous thrombosis or pulmonary embolism: a study in routine clinical practice. Arch Intern Med 2000;160:2369-2373.
  475. Bootsma-van der Wiel A, Gussekloo J, de Craen AJ, van Exel E, Knook DL, Lagaay AM, Westendorp RGJ. Disability in the oldest old: "can do" or "do do"? J Am Geriatr Soc 2001;49:909-914.
  476. Briet JM, van Wassenaer AG, Dekker FW, de Vijlder JJ, van Baar A, Kok JH. Neonatal thyroxine supplementation in very preterm children: developmental outcome evaluated at early school age. Pediatrics 2001;107:712-718.
  477. Ceelie H, Bertina RM, van Hylckama Vlieg A, Rosendaal FR, Vos HL. Polymorphisms in the prothrombin gene and their association with plasma prothrombin levels. Thromb Haemost 2001;85:1066-1070.
  478. Couture P, Bovill EG, Demers C, Simard J, Delage R, Scott BT, Valliere JE, Callas PW, Jomphe M, Rosendaal FR, Aiach M, Long GL. Evidence of a founder effect for the protein C gene 3363 inserted C mutation in thrombophilic pedigrees of French origin. Thromb Haemost 2001;86:1000-1006.
  479. de Fijter JW, Mallat MJ, Doxiadis II, Ringers J, Rosendaal FR, Claas FH, Paul LC. Increased immunogenicity and cause of graft loss of old donor kidneys. J Am Soc Nephrol 2001;12:1538-1546.
  480. de Visser MC, Poort SR, Vos HL, Rosendaal FR, Bertina RM. Factor X levels, polymorphisms in the promoter region of factor X, and the risk of venous thrombosis. Thromb Haemost 2001;85:1011-1017.
  481. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, de Stefano V, Cumming T, Arruda V, Hillarp A, Reny JL. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001;86:809-816.
  482. Frank MB, Reiner AP, Schwartz SM, Kumar PN, Pearce RM, Arbogast PG, Longstreth WT, Jr., Rosendaal FR, Psaty BM, Siscovick DS. The Kozak sequence polymorphism of platelet glycoprotein Ibalpha and risk of nonfatal myocardial infarction and nonfatal stroke in young women. Blood 2001;97:875-879.
  483. Friedlander Y, Arbogast P, Schwartz SM, Marcovina SM, Austin MA, Rosendaal FR, Reiner AP, Psaty BM, Siscovick DS. Family history as a risk factor for early onset myocardial infarction in young women. Atherosclerosis 2001;156:201-207.
  484. Jager KJ, Merkus MP, Huisman RM, Boeschoten EW, Dekker FW, Korevaar JC, Tijssen JG, Krediet RT. Nutritional status over time in hemodialysis and peritoneal dialysis. J Am Soc Nephrol 2001;12:1272-1279.
  485. Jager KJ, Merkus MP, Boeschoten EW, Dekker FW, Tijssen JG, Krediet RT. What happens to patients starting dialysis in the Netherlands? Neth J Med 2001;58:163-173.
  486. Jansen MA, Korevaar JC, Dekker FW, Jager KJ, Boeschoten EW, Krediet RT. The relationship between Kt/V(urea) and nPNA in anuric peritoneal dialysis patients: a comparison with predialysis patients. Perit Dial Int 2001;21:509-515.
  487. Janssen HL, Wijnhoud A, Haagsma EB, van Uum SH, van Nieuwkerk CM, Adang RP, Chamuleau RA, van Hattum J, Vleggaar FP, Hansen BE, Rosendaal FR, van Hoek B. Extrahepatic portal vein thrombosis: aetiology and determinants of survival. Gut 2001;49:720-724.
  488. Kamper AM, de Craen AJ, Blauw GJ. Forearm blood flow measurements using computerized R-wave triggered strain-gauge venous occlusion plethysmography: unilateral vs. bilateral measurements. Clin Physiol 2001;21:524-527.
  489. Kamphuisen PW, Eikenboom HC, Rosendaal FR, Bertina RM. [High concentration of coagulation factor VIII as a risk factor for thrombosis]. Ned Tijdschr Geneeskd 2001;145:2213-2217.
  490. Kamphuisen PW, Eikenboom JC, Rosendaal FR, Koster T, Blann AD, Vos HL, Bertina RM. High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br J Haematol 2001;115:156-158.
  491. Korevaar JC, Jansen MA, Dekker FW, Jager KJ, Boeschoten EW, Krediet RT, Bossuyt PM. When to initiate dialysis: effect of proposed US guidelines on survival. Lancet 2001;358:1046-1050.
  492. Laine ML, Farre MA, Gonzalez G, van Dijk LJ, Ham AJ, Winkel EG, Crusius JB, Vandenbroucke JP, van Winkelhoff AJ, Pena AS. Polymorphisms of the interleukin-1 gene family, oral microbial pathogens, and smoking in adult periodontitis. J Dent Res 2001;80:1695-1699.
  493. Lensen RP, Bertina RM, Vandenbroucke JP, Rosendaal FR. High factor VIII levels contribute to the thrombotic risk in families with factor V Leiden. Br J Haematol 2001;114:380-386.
  494. Odink AE, van Asperen CJ, Vandenbroucke JP, Cleton-Jansen AM, Hogendoorn PC. An association between cartilaginous tumours and breast cancer in the national pathology registration in The Netherlands points towards a possible genetic trait. J Pathol 2001;193:190-192.
  495. Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH. Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation. Thromb Haemost 2001;86:569-574.
  496. Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH. Drug interactions as a cause of overanticoagulation on phenprocoumon or acenocoumarol predominantly concern antibacterial drugs. Clin Pharmacol Ther 2001;69:451-457.
  497. Portielje JE, Westendorp RGJ, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549-2554.
  498. Psaty BM, Smith NL, Lemaitre RN, Vos HL, Heckbert SR, LaCroix AZ, Rosendaal FR. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA 2001;285:906-913.
  499. Ray JG, Rosendaal FR. The role of dyslipidemia and statins in venous thromboembolism. Curr Control Trials Cardiovasc Med 2001;2:165-170.
  500. Reiner AP, Siscovick DS, Rosendaal FR. Platelet glycoprotein gene polymorphisms and risk of thrombosis: facts and fancies. Rev Clin Exp Hematol 2001;5:262-287.
  501. Reiner AP, Schwartz SM, Frank MB, Longstreth WT, Jr., Hindorff LA, Teramura G, Rosendaal FR, Gaur LK, Psaty BM, Siscovick DS. Polymorphisms of coagulation factor XIII subunit A and risk of nonfatal hemorrhagic stroke in young white women. Stroke 2001;32:2580-2586.
  502. Reiner AP, Siscovick DS, Rosendaal FR. Hemostatic risk factors and arterial thrombotic disease. Thromb Haemost 2001;85:584-595.
  503. Reiner AP, Schwartz SM, Kumar PN, Rosendaal FR, Pearce RM, Aramaki KM, Psaty BM, Siscovick DS. Platelet glycoprotein IIb polymorphism, traditional risk factors and non-fatal myocardial infarction in young women. Br J Haematol 2001;112:632-636.
  504. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Oral contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost 2001;86:112-123.
  505. Rosendaal FR. Bridging case-control studies and randomized trials. Curr Control Trials Cardiovasc Med 2001;2:109-110.
  506. Sijbrands EJ, Westendorp RGJ, Defesche JC, de Meier PH, Smelt AH, Kastelein JJ. Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ 2001;322:1019-1023.
  507. Sramek A, Reiber JH, Gerrits WB, Rosendaal FR. Decreased coagulability has no clinically relevant effect on atherogenesis: observations in individuals with a hereditary bleeding tendency. Circulation 2001;104:762-767.
  508. Tanis BC, van den Bosch MA, Kemmeren JM, Manger Cats V, Helmerhorst FM, Algra A, van der Graaf Y, Rosendaal FR. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001;345:1787-1793.
  509. Terwee CB, Dekker FW, Prummel MF, Wiersinga WM. Graves' ophthalmopathy through the eyes of the patient: A state of the art on health-related quality of life assessment. Orbit 2001;20:281-290.
  510. Thomassen R, Vandenbroucke JP, Rosendaal FR. Antipsychotic medication and venous thrombosis. Br J Psychiatry 2001;179:63-6.:63-66.
  511. Torn M, Algra A, Rosendaal FR. Oral anticoagulation for cerebral ischemia of arterial origin: high initial bleeding risk. Neurology 2001;57:1993-1999.
  512. van der Linden MW, van der Slik AR, Zanelli E, Giphart MJ, Pieterman E, Schreuder GM, Westendorp RGJ, Huizinga TW. Six microsatellite markers on the short arm of chromosome 6 in relation to HLA-DR3 and TNF-308A in systemic lupus erythematosus. Genes Immun 2001;2:373-380.
  513. van der Linden MW, Westendorp RGJ, Zidane M, Meheus L, Huizinga TW. Autoantibodies within families of patients with systemic lupus erythematosus are not directed against the same nuclear antigens. J Rheumatol 2001;28:284-287.
  514. van der Linden MW, van Lopik T, Aarden LA, Westendorp RGJ, Huizinga TW. Soluble CD95 concentrations are increased in patients with severe systemic lupus erythematosus, but not in their first degree relatives. Ann Rheum Dis 2001;60:237-241.
  515. van Dijk PC, Jager KJ, de Charro F, Collart F, Cornet R, Dekker FW, Gronhagen-Riska C, Kramar R, Leivestad T, Simpson K, Briggs JD. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 2001;16:1120-1129.
  516. van Manen JG, Korevaar JC, Dekker FW, Reuselaars MC, Boeschoten EW, Krediet RT. Changes in employment status in end-stage renal disease patients during their first year of dialysis. Perit Dial Int 2001;21:595-601.
  517. van Straaten HL, Tibosch CH, Dorrepaal C, Dekker FW, Kok JH. Efficacy of automated auditory brainstem response hearing screening in very preterm newborns. J Pediatr 2001;138:674-678.
  518. Vandenbroucke JP. Commentary: Treatment of bladder stones and probabilistic reasoning in medicine: an 1835 account and its lessons for the present. Int J Epidemiol 2001;30:1253-1258.
  519. Vandenbroucke JP. Changing images of John Snow in the history of epidemiology. Soz Praventivmed 2001;46:288-293.
  520. Vandenbroucke JP, van der Meer FJM, Helmerhorst FM, Rosendaal FR. Family history and risk of venous thromboembolism with oral contraception. Family history is important tool. BMJ 2001;323:752.
  521. Vandenbroucke JP, de Craen AJ. Alternative medicine: a "mirror image" for scientific reasoning in conventional medicine. Ann Intern Med 2001;135:507-513.
  522. Vandenbroucke JP. [From pill to pill: oral contraception, venous thrombosis and coagulation disorders]. Verh K Acad Geneeskd Belg 2001;63:243-252.
  523. Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN, Rosendaal FR. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001;344:1527-1535.
  524. Vandenbroucke JP, Bloemenkamp KW, Helmerhorst FM, Büller HR, Rosendaal FR. Diagnostic suspicion and referral bias in studies of venous thromboembolism and oral contraceptive use. Eur J Contracept Reprod Health Care 2001;6:56-57.
  525. Vandenbroucke JP. In defense of case reports and case series. Ann Intern Med 2001;134:330-334.
  526. Wesseling J, van Driel D, Heymans HS, Rosendaal FR, Geven-Boere LM, Smrkovsky M, Touwen BC, Sauer PJ, van der Veer E. Coumarins during pregnancy: long-term effects on growth and development of school-age children. Thromb Haemost 2001;85:609-613.
  527. White GC, Rosendaal FR, Aledort LM, Lusher JM, Rothschild C, Ingerslev J. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001;85:560.
  528. Andreescu AC, Cushman M, Rosendaal FR. D-dimer as a risk factor for deep vein thrombosis: the Leiden Thrombophilia Study. Thromb Haemost 2002;87:47-51.
  529. Bauer KA, Rosendaal FR, Heit JA. Hypercoagulability: too many tests, too much conflicting data. Hematology (Am Soc Hematol Educ Program ) 2002;:353-68.:353-368.
  530. Bloemenkamp DG, van den Bosch MA, Mali WP, Tanis BC, Rosendaal FR, Kemmeren JM, Algra A, Visseren FL, van der Graaf Y. Novel risk factors for peripheral arterial disease in young women. Am J Med 2002;113:462-467.
  531. Bloemenkamp DG, Mali WP, Tanis BC, Rosendaal FR, van den Bosch MA, Kemmeren JM, Algra A, Visseren FL, van der Graaf Y. The relation between Helicobacter pylori and atherosclerosis cannot be explained by a high homocysteine concentration. Eur J Clin Invest 2002;32:549-555.
  532. Bloemenkamp DG, Mali WP, Tanis BC, Rosendaal FR, van den Bosch MA, Kemmeren JM, Algra A, Ossewaarde JM, Visseren FL, van Loon AM, van der Graaf Y. Chlamydia pneumoniae, Helicobacter pylori and cytomegalovirus infections and the risk of peripheral arterial disease in young women. Atherosclerosis 2002;163:149-156.
  533. Bucciarelli P, Sramek A, Reiber JH, Rosendaal FR. Arterial intima-media thickness and its relationship with cardiovascular disease and atherosclerosis: a possible contribution of medium-sized arteries. Thromb Haemost 2002;88:961-966.
  534. Chandie Shaw PK, Vandenbroucke JP, Tjandra YI, Rosendaal FR, Rosman JB, Geerlings W, de Charro FT, van Es LA. Increased end-stage diabetic nephropathy in Indo-Asian immigrants living in the Netherlands. Diabetologia 2002;45:337-341.
  535. Curvers J, Christella M, Thomassen LG, de Ronde H, Bertina RM, Rosendaal FR, Tans G, Rosing J. Effects of (pre-)analytical variables on activated protein C resistance determined via a thrombin generation-based assay. Thromb Haemost 2002;87:483-492.
  536. de Jong BA, Huizinga TW, Zanelli E, Giphart MJ, Bollen EL, Uitdehaag BM, Polman CH, Westendorp RGJ. Evidence for additional genetic risk indicators of relapse-onset MS within the HLA region. Neurology 2002;59:549-555.
  537. de Jong BA, Westendorp RGJ, Eskdale J, Uitdehaag BM, Huizinga TW. Frequency of functional interleukin-10 promoter polymorphism is different between relapse-onset and primary progressive multiple sclerosis. Hum Immunol 2002;63:281-285.
  538. de Jong BA, Huizinga TW, Bollen EL, Uitdehaag BM, Bosma GP, van Buchem MA, Remarque EJ, Burgmans AC, Kalkers NF, Polman CH, Westendorp RGJ. Production of IL-1beta and IL-1Ra as risk factors for susceptibility and progression of relapse-onset multiple sclerosis. J Neuroimmunol 2002;126:172-179.
  539. de Jong BA, Westendorp RGJ, Bakker AM, Huizinga TW. Polymorphisms in or near tumour necrosis factor (TNF)-gene do not determine levels of endotoxin-induced TNF production. Genes Immun 2002;3:25-29.
  540. de Visser MC, Souverijn JH, Rosendaal FR, Bertina RM. The effect of plasma caeruloplasmin levels on the sensitivity for activated protein C. Br J Haematol 2002;118:843-846.
  541. Eikenboom JC, Castaman G, Kamphuisen PW, Rosendaal FR, Bertina RM. The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor. Thromb Haemost 2002;87:252-257.
  542. Gadisseur AP, van der Meer FJ, Adriaansen HJ, Fihn SD, Rosendaal FR. Therapeutic quality control of oral anticoagulant therapy comparing the short-acting acenocoumarol and the long-acting phenprocoumon. Br J Haematol 2002;117:940-946.
  543. Goodwin AJ, Rosendaal FR, Kottke-Marchant K, Bovill EG. A review of the technical, diagnostic, and epidemiologic considerations for protein S assays. Arch Pathol Lab Med 2002;126:1349-1366.
  544. Jansen MA, Hart AA, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT. Predictors of the rate of decline of residual renal function in incident dialysis patients. Kidney Int 2002;62:1046-1053.
  545. Kaplan RC, Heckbert SR, Koepsell TD, Rosendaal FR, Furberg CD, Cooper LS, Psaty BM. Calcium channel blocker use and gastrointestinal tract bleeding among older adults. Age Ageing 2002;31:217-218.
  546. Keijzer MB, den Heijer M, Blom HJ, Bos GM, Willems HP, Gerrits WB, Rosendaal FR. Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost 2002;88:723-728.
  547. Kemmeren JM, Tanis BC, van den Bosch MA, Bollen EL, Helmerhorst FM, van der Graaf Y, Rosendaal FR, Algra A. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 2002;33:1202-1208.
  548. Korevaar JC, Merkus MP, Jansen MA, Dekker FW, Boeschoten EW, Krediet RT. Validation of the KDQOL-SF: a dialysis-targeted health measure. Qual Life Res 2002;11:437-447.
  549. Korevaar JC, Jansen MA, Dekker FW, Boeschoten EW, Bossuyt PM, Krediet RT. Evaluation of DOQI guidelines: early start of dialysis treatment is not associated with better health-related quality of life. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 2002;39:108-115.
  550. Laine ML, Farre MA, Garcia-Gonzalez MA, van Dijk LJ, Ham AJ, Winkel EG, Crusius JB, Vandenbroucke JP, van Winkelhoff AJ, Pena AS. [Risk factors in adult periodontitis: polymorphism in the interleukin-1 gene family]. Ned Tijdschr Tandheelkd 2002;109:303-306.
  551. Lemaitre RN, Psaty BM, Heckbert SR, Smith NL, Longstreth WT, Jr., Rosendaal FR. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal ischemic stroke in postmenopausal women. Arterioscler Thromb Vasc Biol 2002;22:1051-1052.
  552. Meijers JC, Marquart JA, Bertina RM, Bouma BN, Rosendaal FR. Protein C inhibitor (plasminogen activator inhibitor-3) and the risk of venous thrombosis. Br J Haematol 2002;118:604-609.
  553. Middeldorp S, Büller HR, Vandenbroucke JP, Helmerhorst FM, Rosendaal FR. [Adverse cardiovascular effects of postmenopausal hormone replacement therapy]. Ned Tijdschr Geneeskd 2002;146:2123-2127.
  554. Penning-van Beest FJ, Gomez Garcia EB, van der Meer FJ, van Meegen E, Rosendaal FR, Stricker BH. Levels of vitamin K-dependent procoagulant and anticoagulant proteins in over-anticoagulated patients. Blood Coagul Fibrinolysis 2002;13:733-739.
  555. Penning-van Beest FJ, Geleijnse JM, van Meegen E, Vermeer C, Rosendaal FR, Stricker BH. Lifestyle and diet as risk factors for overanticoagulation. J Clin Epidemiol 2002;55:411-417.
  556. Poort SR, Vos HL, Rosendaal FR, Bertina RM. The endothelial protein C receptor (EPCR) 23 bp insert mutation and the risk of venous thrombosis. Thromb Haemost 2002;88:160-162.
  557. Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP, Siscovick DS, Bis J, Lumley T, Longstreth WT, Jr., Rosendaal FR. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002;287:1680-1689.
  558. Reiner AP, Rosendaal FR, Reitsma PH, Lemaitre RN, Pearce RM, Friedlander Y, Raghunathan TE, Psaty BM, Siscovick DS. Factor V Leiden, prothrombin G20210A, and risk of sudden coronary death in apparently healthy persons. Am J Cardiol 2002;90:66-68.
  559. Reiner AP, Frank MB, Schwartz SM, Linenberger ML, Longstreth WT, Teramura G, Rosendaal FR, Psaty BM, Siscovick DS. Coagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women. Br J Haematol 2002;116:376-382.
  560. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 2002;22:201-210.
  561. Rosendaal FR. Air travel and thrombosis. Pathophysiol Haemost Thromb 2002;32:341-342.
  562. Rosendaal FR, Vessey M, Rumley A, Daly E, Woodward M, Helmerhorst FM, Lowe GD. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002;116:851-854.
  563. Rosendaal FR, Bovill EG. Heritability of clotting factors and the revival of the prothrombotic state. Lancet 2002;359:638-639.
  564. Rosendaal FR, Bouter LM. [Errors in methodology (conclusion). XXXIX. The ultimate truth]. Ned Tijdschr Geneeskd 2002;146:304-309.
  565. Shackleton DP, Westendorp RGJ, Kasteleijn-Nolst Trenite DG, de Craen AJ, Vandenbroucke JP. Survival of patients with epilepsy: an estimate of the mortality risk. Epilepsia 2002;43:445-450.
  566. Terwee C, Dekker F, Bossuyt P. A taxonomy for responsiveness? J Clin Epidemiol 2002;55:1156.
  567. Terwee C, Wakelkamp I, Tan S, Dekker F, Prummel MF, Wiersinga W. Long-term effects of Graves' ophthalmopathy on health-related quality of life. Eur J Endocrinol 2002;146:751-757.
  568. van Aken BE, Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis: evidence for a role of inflammation in thrombosis. Br J Haematol 2002;116:173-177.
  569. Van Aken MO, de Craen AJ, Gussekloo J, Moghaddam PH, Vandenbroucke JP, Heijmans BT, Slagboom PE, Westendorp RG. No increase in mortality and morbidity among carriers of the C282Y mutation of the hereditary haemochromatosis gene in the oldest old: the Leiden 85-plus study. Eur J Clin Invest 2002;32:750-754.
  570. van den Bosch MA, Mali WP, Bloemenkamp DG, Eikelboom BC, Kemmeren JM, Tanis BC, Algra A, Rosendaal FR, van der Graaf Y. Increased pregnancy loss in young women with aortoiliac disease. Atherosclerosis 2002;164:121-127.
  571. van Hylckama Vlieg A, Komanasin N, Ariens RA, Poort SR, Grant PJ, Bertina RM, Rosendaal FR. Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis. Br J Haematol 2002;119:169-175.
  572. van Manen JG, Korevaar JC, Dekker FW, Boeschoten EW, Bossuyt PM, Krediet RT. How to adjust for comorbidity in survival studies in ESRD patients: a comparison of different indices. Am J Kidney Dis 2002;40:82-89.
  573. van Manen JG, Bindels PJ, Dekker FW, Ijzermans CJ, van der Zee JS, Schade E. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax 2002;57:412-416.
  574. van Roosmalen J, Rosendaal FR. There is still room for disagreement about vaginal delivery of breech infants at term. BJOG 2002;109:967-969.
  575. Vandenbroucke JP. Alvan Feinstein and the art of consulting: how to define a research question. J Clin Epidemiol 2002;55:1176-1177.
  576. Vandenbroucke JP. Do editors live up to the Sept 10, 2001, expectations? Lancet 2002;360:1605-1606.
  577. Vandenbroucke JP. The history of confounding. Soz Praventivmed 2002;47:216-224.
  578. Vandenbroucke JP. Was the LIFE trial independent? Lancet 2002;360:1171.
  579. Vandenbroucke JP. [The importance of case reports as compared to evidence-based medicine and molecular explanation]. Ned Tijdschr Geneeskd 2002;146:1699-1703.
  580. Vandenbroucke JP. Alternative treatments in reproductive medicine. The vexing problem of 'seemingly impeccable trials...'. Hum Reprod 2002;17:2228-2229.
  581. Vandenbroucke JP. [Financing medical research in the Netherlands: start taking care of the future now]. Ned Tijdschr Geneeskd 2002;146:1348-1352.
  582. Vandenbroucke JP. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2002;346:1826-1829.
  583. Vandenbroucke JP. [Medical research and the pharmaceutical industry. Uneasy lovers or premarital agreements?]. Ned Tijdschr Geneeskd 2002;146:337-338.
  584. Zwart-Van Rijkom JE, Plug I, Rosendaal FR, Leufkens HG, Broekmans AW. The uptake of recombinant Factor VIII in the Netherlands. Br J Haematol 2002;119:332-341.
  585. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003;89:493-498.
  586. Bis JC, Smith NL, Psaty BM, Heckbert SR, Edwards KL, Lemaitre RN, Lumley T, Rosendaal FR. Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. Am J Hypertens 2003;16:1011-1017.
  587. Bloemenkamp KWM, Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Thrombophilias and gynaecology. Best Pract Res Clin Obstet Gynaecol 2003;17:509-528.
  588. Chandie Shaw PK, van Es LA, Paul LC, Rosendaal FR, Souverijn JH, Vandenbroucke JP. Renal disease in relatives of Indo-Asian Type 2 diabetic patients with end-stage diabetic nephropathy. Diabetologia 2003;46:618-624.
  589. Coenraad MJ, Meinders AE, Vandenbroucke JP, Frölich M, Taal JC, Bolk JH. Causes of hyponatremia in the Departments of Internal Medicine and Neurosurgery. Eur J Intern Med 2003;14:302-309.
  590. Dahm A, van Hylckama Vlieg A, Bendz B, Rosendaal FR, Bertina RM, Sandset PM. Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood 2003;101:4387-4392.
  591. de Bock GH, Tollenaar RA, Papelard H, Vliet Vlieland TP, Devilee P, Cornelisse CJ, Vandenbroucke JP. Re: Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2003;95:1011-1012.
  592. de Visser MC, Sandkuijl LA, Lensen RP, Vos HL, Rosendaal FR, Bertina RM. Linkage analysis of factor VIII and von Willebrand factor loci as quantitative trait loci. J Thromb Haemost 2003;1:1771-1776.
  593. Doggen CJM, Reiner AP, Vos HL, Rosendaal FR. Two factor XIII gene polymorphisms associated with a structural and functional defect and the risk of myocardial infarction in men. J Thromb Haemost 2003;1:2056-2058.
  594. Fihn SD, Gadisseur AA, Pasterkamp E, van der Meer FJ, Breukink-Engbers WG, Geven-Boere LM, van Meegen E, Vries-Goldschmeding H, Antheunissen-Anneveld I, van't Hoff AR, Harderman D, Smink M, Rosendaal FR. Comparison of control and stability of oral anticoagulant therapy using acenocoumarol versus phenprocoumon. Thromb Haemost 2003;90:260-266.
  595. Fredriks AM, van Buuren S, Jeurissen SE, Dekker FW, Verloove-Vanhorick SP, Wit JM. Height, weight, body mass index and pubertal development reference values for children of Turkish origin in the Netherlands. Eur J Pediatr 2003;162:788-793.
  596. Gadisseur AP, Breukink-Engbers WG, van der Meer FJ, van den Besselaar AM, Sturk A, Rosendaal FR. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial. Arch Intern Med 2003;163:2639-2646.
  597. Gadisseur AP, van der Meer FJ, Rosendaal FR. Sustained intake of paracetamol (acetaminophen) during oral anticoagulant therapy with coumarins does not cause clinically important INR changes: a randomized double-blind clinical trial. J Thromb Haemost 2003;1:714-717.
  598. Groothoff JW, Offringa M, Eck-Smit BL, Gruppen MP, van de Kar NJ, Wolff ED, Lilien MR, Davin JC, Heymans HS, Dekker FW. Severe bone disease and low bone mineral density after juvenile renal failure. Kidney Int 2003;63:266-275.
  599. Hauben EI, Arends J, Vandenbroucke JP, van Asperen CJ, van Marck E, Hogendoorn PC. Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. Eur J Hum Genet 2003;11:611-618.
  600. Jager KJ, van Dijk PC, Dekker FW, Stengel B, Simpson K, Briggs JD. The epidemic of aging in renal replacement therapy: an update on elderly patients and their outcomes. Clin Nephrol 2003;60:352-360.
  601. Kenis H, Doggen CJ, Vos HL, Reutelingsperger CP, van Heerde WL. The C-1T mutation in the annexin A5 Kozak sequence slightly increases the risk of myocardial infarction in men. J Thromb Haemost 2003;1:2688-2689.
  602. Korevaar J, van Manen JG, Boeschoten EW, Dekker FW, Krediet RT. Evaluation of guidelines for peritoneal dialysis patients: a review from the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD). Contrib Nephrol 2003;142-150.
  603. Korevaar JC, Feith GW, Dekker FW, van Manen JG, Boeschoten EW, Bossuyt PM, Krediet RT. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. Kidney Int 2003;64:2222-2228.
  604. Korevaar JC, Dekker FW, Krediet RT. Initiation of dialysis: is the problem solved by NECOSAD? Nephrol Dial Transplant 2003;18:1228-1229.
  605. Linthorst GE, Hollak CE, Korevaar JC, van Manen JG, Aerts JM, Boeschoten EW. alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease. Nephrol Dial Transplant 2003;18:1581-1584.
  606. Lowe GD, Sandercock PA, Rosendaal FR. Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance? Lancet 2003;362:504-505.
  607. Reiner AP, Heckbert SR, Vos HL, Ariens RA, Lemaitre RN, Smith NL, Lumley T, Rea TD, Hindorff LA, Schellenbaum GD, Rosendaal FR, Siscovick DS, Psaty BM. Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction. Blood 2003;102:25-30.
  608. Ricci MA, Emmerich J, Callas PW, Rosendaal FR, Stanley AC, Naud S, Vossen C, Bovill EG. Evaluating chronic venous disease with a new venous severity scoring system. J Vasc Surg 2003;38:909-915.
  609. Riyazi N, Spee J, Huizinga TW, Schreuder GM, de Vries RR, Dekker FW, Kloppenburg M. HLA class II is associated with distal interphalangeal osteoarthritis. Ann Rheum Dis 2003;62:227-230.
  610. Rosendaal FR. Genetic studies in complex disease: the case pro association studies. J Thromb Haemost 2003;1:1679-1680.
  611. Rosendaal FR. Clotting and myocardial infarction: a cycle of insights. J Thromb Haemost 2003;1:640-642.
  612. Rosendaal FR, van Hylckama Vlieg A, Tanis BC, Helmerhorst FM. Estrogens, progestogens and thrombosis. J Thromb Haemost 2003;1:1371-1380.
  613. Rosendaal FR, Büller HR, Kesteven P, Toff WD. Long haul flights and deep vein thrombosis: who is at risk? Br J Haematol 2003;120:367.
  614. Schreijer AJ, Cannegieter SC, Rosendaal FR. Effect of prolonged sitting on thrombin generation: not evidenced yet: rebuttal. J Thromb Haemost 2003;1:2700.
  615. Shackleton DP, Kasteleijn-Nolst Trenite DG, de Craen AJ, Vandenbroucke JP, Westendorp RGJ. Living with epilepsy: long-term prognosis and psychosocial outcomes. Neurology 2003;61:64-70.
  616. Sramek A, Kriek M, Rosendaal FR. Decreased mortality of ischaemic heart disease among carriers of haemophilia. Lancet 2003;362:351-354.
  617. Sramek A, Reiber JH, Baak-Pablo R, Sturk A, Rosendaal FR. Lipoprotein(a) and ultrasonographically determined early atherosclerotic changes in the carotid and femoral artery. J Thromb Haemost 2003;1:374-379.
  618. Stengel B, Billon S, van Dijk PC, Jager KJ, Dekker FW, Simpson K, Briggs JD. Trends in the incidence of renal replacement therapy for end-stage renal disease in Europe, 1990-1999. Nephrol Dial Transplant 2003;18:1824-1833.
  619. Tanis BC, Rosendaal FR. Venous and arterial thrombosis during oral contraceptive use: risks and risk factors. Semin Vasc Med 2003;3:69-84.
  620. Tanis BC, Bloemenkamp DG, van den Bosch MA, Kemmeren JM, Algra A, van der Graaf Y, Rosendaal FR. Prothrombotic coagulation defects and cardiovascular risk factors in young women with acute myocardial infarction. Br J Haematol 2003;122:471-478.
  621. Tans G, van Hylckama Vlieg A, Thomassen MC, Curvers J, Bertina RM, Rosing J, Rosendaal FR. Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol 2003;122:465-470.
  622. Termorshuizen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW, Krediet RT. Hemodialysis and peritoneal dialysis: comparison of adjusted mortality rates according to the duration of dialysis: analysis of The Netherlands Cooperative Study on the Adequacy of Dialysis 2. J Am Soc Nephrol 2003;14:2851-2860.
  623. Termorshuizen F, Korevaar JC, Dekker FW, van Manen JG, Boeschoten EW, Krediet RT. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD )-2. Am J Kidney Dis 2003;41:1293-1302.
  624. Termorshuizen F, Korevaar JC, Dekker FW, Jager KJ, van Manen JG, Boeschoten EW, Krediet RT. Time trends in initiation and dose of dialysis in end-stage renal disease patients in The Netherlands. Nephrol Dial Transplant 2003;18:552-558.
  625. Terwee CB, Dekker FW, Wiersinga WM, Prummel MF, Bossuyt PM. On assessing responsiveness of health-related quality of life instruments: guidelines for instrument evaluation. Qual Life Res 2003;12:349-362.
  626. Terwee CB, Dekker FW, Bonsel GJ, Heisterkamp SH, Prummel MF, Baldeschi L, Wiersinga WM. Facial disfigurement: is it in the eye of the beholder? A study in patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2003;58:192-198.
  627. Torn M, Rosendaal FR. Oral anticoagulation in surgical procedures: risks and recommendations. Br J Haematol 2003;123:676-682.
  628. van den Bosch MA, Bloemenkamp DG, Mali WP, Kemmeren JM, Tanis BC, Algra A, Rosendaal FR, van der Graaf Y. Hyperhomocysteinemia and risk for peripheral arterial occlusive disease in young women. J Vasc Surg 2003;38:772-778.
  629. van den Bosch MA, Kemmeren JM, Tanis BC, Mali WP, Helmerhorst FM, Rosendaal FR, Algra A, van der Graaf Y. The RATIO study: oral contraceptives and the risk of peripheral arterial disease in young women. J Thromb Haemost 2003;1:439-444.
  630. van der Horst I, Zijlstra F, van't Hof AW, Doggen CJ, de Boer MJ, Suryapranata H, Hoorntje JC, Dambrink JH, Gans RO, Bilo HJ. Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction: the glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol 2003;42:784-791.
  631. van Hylckama Vlieg A, Rosendaal FR. High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly. J Thromb Haemost 2003;1:2677-2678.
  632. van Hylckama Vlieg A, Rosendaal FR. Interaction between oral contraceptive use and coagulation factor levels in deep venous thrombosis. J Thromb Haemost 2003;1:2186-2190.
  633. van Hylckama Vlieg A, Callas PW, Cushman M, Bertina RM, Rosendaal FR. Inter-relation of coagulation factors and d-dimer levels in healthy individuals. J Thromb Haemost 2003;1:516-522.
  634. van Korlaar I, Vossen C, Rosendaal FR, Cameron L, Bovill E, Kaptein A. Quality of life in venous disease. Thromb Haemost 2003;90:27-35.
  635. van Manen JG, Bindels PJ, Dekker FW, Bottema BJ, van der Zee JS, Ijzermans CJ, Schade E. The influence of COPD on health-related quality of life independent of the influence of comorbidity. J Clin Epidemiol 2003;56:1177-1184.
  636. van Manen JG, Korevaar JC, Dekker FW, Boeschoten EW, Bossuyt PM, Krediet RT. Adjustment for comorbidity in studies on health status in ESRD patients: which comorbidity index to use? J Am Soc Nephrol 2003;14:478-485.
  637. van Rooden CJ, Rosendaal FR, Barge RM, van Oostayen JA, van der Meer FJ, Meinders AE, Huisman MV. Central venous catheter related thrombosis in haematology patients and prediction of risk by screening with Doppler-ultrasound. Br J Haematol 2003;123:507-512.
  638. van Rooden CJ, Monraats PS, Kettenis IM, Rosendaal FR, Huisman MV. Low physician compliance of prescribing anticoagulant prophylaxis in patients with solid tumor or hematological malignancies and central vein catheters. J Thromb Haemost 2003;1:1842-1843.
  639. Vandenbroucke JP, van Leeuwen FE, Helmerhorst FM. [Breast cancer and the use of the hormones around the menopause]. Ned Tijdschr Geneeskd 2003;147:1829-1834.
  640. Vandenbroucke JP. Balancing benefits and harms in health care: observational data on harm should complement systematic reviews of benefit. BMJ 2003;327:750.
  641. Vandenbroucke JP. Continuing controversies over "risks and rates"--more than a century after William Farr's "On prognosis". Soz Praventivmed 2003;48:216-218.
  642. Vandenbroucke JP. The 1855 cholera epidemic in Ferrara: lessons from old data reanalysed with modern means. Eur J Epidemiol 2003;18:599-602.
  643. Vandenbroucke JP. More on the LIFE study. Lancet 2003;361:532-533.
  644. Biermasz NR, Dekker FW, Pereira AM, van Thiel SW, Schutte PJ, van Dulken H, Romijn JA, Roelfsema F. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab 2004;89:2789-2796.
  645. Blom JW, Osanto S, Rosendaal FR. The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma. J Thromb Haemost 2004;2:1760-1765.
  646. Ceelie H, Spaargaren-Van Riel CC, Bertina RM, Vos HL. G20210A is a functional mutation in the prothrombin gene; effect on protein levels and 3'-end formation. J Thromb Haemost 2004;2:119-127.
  647. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-1580.
  648. de Groot CJ, Jansen MW, Bertina RM, Schonkeren JJ, Helmerhorst FM, Huizinga TW. Interleukin 10-2849AA genotype protects against pre-eclampsia. Genes Immun 2004;5:313-314.
  649. de Maat MP, Jansen MW, Hille ET, Vos HL, Bloemenkamp KW, Buitendijk S, Helmerhorst FM, Wladimiroff JW, Bertina RM, de Groot CJ. Preeclampsia and its interaction with common variants in thrombophilia genes. J Thromb Haemost 2004;2:1588-1593.
  650. Doggen CJ, Smith NL, Lemaitre RN, Heckbert SR, Rosendaal FR, Psaty BM. Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 2004;24:1970-1975.
  651. Doggen CJM, Lemaitre RN, Smith NL, Heckbert SR, Psaty BM. HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost 2004;2:700-701.
  652. Ehrenforth S, Nemes L, Mannhalter C, Rosendaal FR, Koder S, Zoghlami-Rintelen C, Scharrer I, Pabinger I. Impact of environmental and hereditary risk factors on the clinical manifestation of thrombophilia in homozygous carriers of factor V:G1691A. J Thromb Haemost 2004;2:430-436.
  653. Fredriks AM, van Buuren S, Jeurissen SE, Dekker FW, Verloove-Vanhorick SP, Wit JM. Height, weight, body mass index and pubertal development references for children of Moroccan origin in The Netherlands. Acta Paediatr 2004;93:817-824.
  654. Gadisseur AP, Kaptein AA, Breukink-Engbers WG, van der Meer FJ, Rosendaal FR. Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life. J Thromb Haemost 2004;2:584-591.
  655. Glasziou P, Vandenbroucke JP, Chalmers I. Assessing the quality of research. BMJ 2004;328:39-41.
  656. Guimaraes AH, van Tilburg NH, Vos HL, Bertina RM, Rijken DC. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br J Haematol 2004;124:659-665.
  657. Hasstedt SJ, Scott BT, Callas PW, Vossen CY, Rosendaal FR, Long GL, Bovill EG. Genome scan of venous thrombosis in a pedigree with protein C deficiency. J Thromb Haemost 2004;2:868-873.
  658. Houdijk WP, van den Besselaar AM. International multicenter international sensitivity index (ISI) calibration of a new human tissue factor thromboplastin reagent derived from cultured human cells. J Thromb Haemost 2004;2:266-270.
  659. Hovens MM, Cannegieter SC. [Acetylsalicylic acid in patients with diabetes for the primary prevention of cardiovascular disease]. Ned Tijdschr Geneeskd 2004;148:2097-2098.
  660. Jager KJ, Korevaar JC, Dekker FW, Krediet RT, Boeschoten EW. The effect of contraindications and patient preference on dialysis modality selection in ESRD patients in The Netherlands. Am J Kidney Dis 2004;43:891-899.
  661. Jansen MW, Bertina RM, Vos HL, Bloemenkamp KW, Helmerhorst FM, Wladimiroff JW, de Groot CJ. C825T polymorphism in the human G protein beta 3 subunit gene and preeclampsia; a case control study. Hypertens Pregnancy 2004;23:211-218.
  662. Kamphuisen PW, Rosendaal FR. Thrombophilia screening: a matter of debate. Neth J Med 2004;62:180-187.
  663. Kerkhoffs JL, Atsma DE, Oemrawsingh PV, Eikenboom J, van der Meer FJ. Acute myocardial infarction during substitution with recombinant factor VIII concentrate in a patient with mild haemophilia A. Thromb Haemost 2004;92:425-426.
  664. Kharagjitsingh AV, Dekker FW, Vandenbroucke JP. [Epoetin-induced pure red-cell aplasia]. Ned Tijdschr Geneeskd 2004;148:2550-2553.
  665. Korevaar JC, van Manen JG, Dekker FW, de Waart DR, Boeschoten EW, Krediet RT. Effect of an increase in C-reactive protein level during a hemodialysis session on mortality. J Am Soc Nephrol 2004;15:2916-2922.
  666. Kroft LJ, Reijnierse M, Kloppenburg M, Verbist BM, Bloem JL, van Buchem MA. Rheumatoid arthritis: epidural enhancement as an underestimated cause of subaxial cervical spinal stenosis. Radiology 2004;231:57-63.
  667. Medina P, Navarro S, Estelles A, Vaya A, Woodhams B, Mira Y, Villa P, Migaud-Fressart M, Ferrando F, Aznar J, Bertina RM, Espana F. Contribution of polymorphisms in the endothelial protein C receptor gene to soluble endothelial protein C receptor and circulating activated protein C levels, and thrombotic risk. Thromb Haemost 2004;91:905-911.
  668. Murad SD, Valla DC, de Groen PC, Zeitoun G, Hopmans JA, Haagsma EB, van Hoek B, Hansen BE, Rosendaal FR, Janssen HL. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004;39:500-508.
  669. Nielen MM, van Schaardenburg D, Reesink HW, Twisk JW, van de Stadt RJ, van der Horst-Bruinsma IE, de Gast T, Habibuw MR, Vandenbroucke JP, Dijkmans BA. Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum 2004;50:2423-2427.
  670. Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-386.
  671. Paffen E, Vos HL, Bertina RM. C-reactive protein does not directly induce tissue factor in human monocytes. Arterioscler Thromb Vasc Biol 2004;24:975-981.
  672. Plug I, van der Bom JG, Peters M, Mauser-Bunschoten EP, Goede-Bolder A, Heijnen L, Smit C, Zwart-Van Rijkom JE, Willemse J, Rosendaal FR. Thirty years of hemophilia treatment in the Netherlands, 1972-2001. Blood 2004;..
  673. Poller L, Keown M, Chauhan N, van den Besselaar AM, Tripodi A, Shiach C, Jespersen J. European concerted action on anticoagulation. Quality assessment of the CoaguChek Mini and TAS PT-NC point-of-care whole-blood prothrombin time monitors. Clin Chem 2004;50:537-544.
  674. Posthouwer D, Voorbij HA, Grobbee DE, Numans ME, van der Bom JG. Influenza and pneumococcal vaccination as a model to assess C-reactive protein response to mild inflammation. Vaccine 2004;23:362-365.
  675. Prummel MF, Terwee CB, Gerding MN, Baldeschi L, Mourits MP, Blank L, Dekker FW, Wiersinga WM. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab 2004;89:15-20.
  676. Reitsma PH, Rosendaal FR. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study. J Thromb Haemost 2004;2:619-622.
  677. Rosendaal FR. We have all been elected! J Thromb Haemost 2004;2:1479.
  678. Rosendaal FR. Risk of myocardial infarction associated with the use of oral contraception. Contraception 2004;70:85-86.
  679. Rosendaal FR. [Starting January 1, 2004, editors of the Dutch Journal of Medicine; gender identity in front of authors' names in the Journal]. Ned Tijdschr Geneeskd 2004;148:398-399.
  680. Rosendaal FR, Reitsma PH. Genetic studies in complex disease. J Thromb Haemost 2004;2:342.
  681. Schaar CG, Snijder S, Oostindier MJ, Rosendaal FR, Willemze R, Kluin-Nelemans JC. Monoclonal proteinaemia and solid tumours. Eur J Cancer 2004;40:1539-1544.
  682. Schalekamp T, Oosterhof M, van Meegen E, van der Meer FJ, Conemans J, Hermans M, Meijerman I, de Boer A. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther 2004;76:409-417.
  683. Senden IP, de Groot CJ, Steegers EA, Bertina RM, Swinkels DW. Preeclampsia and the C282Y mutation in the hemochromatosis (HFE) gene. Clin Chem 2004;50:973-974.
  684. Sijpkens YW, Joosten SA, Wong MC, Dekker FW, Benediktsson H, Bajema IM, Bruijn JA, Paul LC. Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 2004;65:2409-2418.
  685. Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss NS, Larson EB, Rosendaal FR, Psaty BM. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 2004;292:1581-1587.
  686. Sramek A, Bucciarelli P, Federici AB, Mannucci PM, de Rosa V, Castaman G, Morfini M, Mazzucconi MG, Rocino A, Schiavoni M, Scaraggi FA, Reiber JH, Rosendaal FR. Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation 2004;109:740-744.
  687. Tanis BC, Blom HJ, Bloemenkamp DG, van den Bosch MA, Algra A, van der Graaf Y, Rosendaal FR. Folate, homocysteine levels, methylenetetrahydrofolate reductase (MTHFR) 677C --> T variant, and the risk of myocardial infarction in young women: effect of female hormones on homocysteine levels. J Thromb Haemost 2004;2:35-41.
  688. Termorshuizen F, Dekker FW, van Manen JG, Korevaar JC, Boeschoten EW, Krediet RT. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004;15:1061-1070.
  689. Tesselaar ME, Ouwerkerk J, Nooy MA, Rosendaal FR, Osanto S. Risk factors for catheter-related thrombosis in cancer patients. Eur J Cancer 2004;40:2253-2259.
  690. Tjernberg P, Vos HL, Castaman G, Bertina RM, Eikenboom JC. Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues. J Thromb Haemost 2004;2:257-265.
  691. Torn M, van der Meer FJ, Rosendaal FR. Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism. Arch Intern Med 2004;164:668-673.
  692. Uitte de Willige S, van Marion V, Rosendaal FR, Vos HL, de Visser MC, Bertina RM. Haplotypes of the EPCR gene, plasma sEPCR levels and the risk of deep venous thrombosis. J Thromb Haemost 2004;2:1305-1310.
  693. van den Besselaar AM, Barrowcliffe TW, Houbouyan-Reveillard LL, Jespersen J, Johnston M, Poller L, Tripodi A. Guidelines on preparation, certification, and use of certified plasmas for ISI calibration and INR determination. J Thromb Haemost 2004;2:1946-1953.
  694. van den Besselaar AM, Poller L, Tripodi A. Definition of the International Normalized Ratio (INR) and its consequences for the calibration procedure of thromboplastin preparations: a rebuttal. J Thromb Haemost 2004;2:1490-1491.
  695. van der Heijden JF, Rekke B, Hutten BA, van der Meer FJ, Remkes MG, Vermeulen M, Büller HR, Reitsma PH. Non-fatal major bleeding during treatment with vitamin K antagonists: influence of soluble thrombomodulin and mutations in the propeptide of coagulation factor IX. J Thromb Haemost 2004;2:1104-1109.
  696. van der Neut Kolfschoten M, Dirven RJ, Poort SR, van Wijk R, Vos HL, Rosendaal FR, Bertina RM. Characterization of an immunologic polymorphism (D79H) in the heavy chain of factor V. J Thromb Haemost 2004;2:910-917.
  697. van der Neut Kolfschoten M, Dirven RJ, Poort SR, van Wijk R, Vos HL, Rosendaal FR, Bertina RM. Characterization of an immunologic polymorphism (D79H) in the heavy chain of factor V. J Thromb Haemost 2004;2:910-917.
  698. van der Neut Kolfschoten M, Dirven RJ, Vos HL, Tans G, Rosing J, Bertina RM. Factor Va is inactivated by activated protein C in the absence of cleavage sites at Arg-306, Arg-506, and Arg-679. J Biol Chem 2004;279:6567-6575.
  699. van Dijk K, van der Bom JG, Fischer K, Grobbee DE, van den Berg HM. Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature. Thromb Haemost 2004;92:305-310.
  700. van Dijk K, van der Bom JG, Bax KN, van der Zee DC, van den Berg HM. Use of implantable venous access devices in children with severe hemophilia: benefits and burden. Haematologica 2004;89:189-194.
  701. van Driel D, Wesseling J, ter Huurne K, Geven-Boere LM, Rosendaal FR, van der Veen H, de Jong-van den Berg LT. Adherence to a guideline for coumarins in pregnancy. Pharm World Sci 2004;26:297-300.
  702. van Hylckama Vlieg A, Sandkuijl LA, Rosendaal FR, Bertina RM, Vos HL. Candidate gene approach in association studies: would the factor V Leiden mutation have been found by this approach? Eur J Hum Genet 2004;12:478-482.
  703. van Hylckama Vlieg A, Sandkuijl LA, Rosendaal FR, Bertina RM, Vos HL. Candidate gene approach in association studies: would the factor V Leiden mutation have been found by this approach? Eur J Hum Genet 2004;12:478-482.
  704. van Korlaar IM, Vossen CY, Rosendaal FR, Bovill EG, Cushman M, Naud S, Kaptein AA. The impact of venous thrombosis on quality of life. Thromb Res 2004;114:11-18.
  705. van Rooden CJ, Rosendaal FR, Meinders AE, van Oostayen JA, van der Meer FJ, Huisman MV. The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis. Haematologica 2004;89:201-206.
  706. van Rooden CJ, Molhoek SG, Rosendaal FR, Schalij MJ, Meinders AE, Huisman MV. Incidence and risk factors of early venous thrombosis associated with permanent pacemaker leads. J Cardiovasc Electrophysiol 2004;15:1258-1262.
  707. van Vliet HA, Winkel TA, Noort I, Rosing J, Rosendaal FR. Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost 2004;2:2060-2062.
  708. Vandenbroucke JP, Rosendaal FR. Factor V Leiden and venous thromboembolism. Ann Intern Med 2004;141:484.
  709. Vandenbroucke JP. Benefits and harms of drug treatments. BMJ 2004;329:2-3.
  710. Vandenbroucke JP. Commentary: the HRT story: vindication of old epidemiological theory. Int J Epidemiol 2004;33:456-457.
  711. Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet 2004;363:1728-1731.
  712. Vossen CY, Strandberg K, Stenflo J, Rosendaal FR, Callas PW, Long GL, Bovill EG. No effect of the prothrombin G20210A mutation on protein C activation in a large kindred with type I protein C deficiency. Blood Coagul Fibrinolysis 2004;15:573-576.
  713. Vossen CY, van Korlaar IM, Cushman M, Rosendaal FR, Bovill EG. Sensitivity of a questionnaire for data collection on venous thrombosis. Thromb Res 2004;114:259-263.
  714. Vossen CY, Conard J, Fontcuberta J, Makris M, van der Meer FJ, Pabinger I, Palareti G, Preston FE, Scharrer I, Souto JC, Svensson P, Walker ID, Rosendaal FR. Familial thrombophilia and lifetime risk of venous thrombosis. J Thromb Haemost 2004;2:1526-1532.
  715. Vossen CY, Preston FE, Conard J, Fontcuberta J, Makris M, van der Meer FJ, Pabinger I, Palareti G, Scharrer I, Souto JC, Svensson P, Walker ID, Rosendaal FR. Hereditary thrombophilia and fetal loss: a prospective follow-up study. J Thromb Haemost 2004;2:592-596.
  716. Vossen CY, Hasstedt SJ, Rosendaal FR, Callas PW, Bauer KA, Broze GJ, Hoogendoorn H, Long GL, Scott BT, Bovill EG. Heritability of plasma concentrations of clotting factors and measures of a prethrombotic state in a protein C-deficient family. J Thromb Haemost 2004;2:242-247.
  717. Al Shanqeeti A, van Hylckama Vlieg A, Berntorp E, Rosendaal FR, Broze GJ, Jr. Protein Z and protein Z-dependent protease inhibitor. Determinants of levels and risk of venous thrombosis. Thromb Haemost 2005;93:411-413.
  718. Bertina RM, Poort SR, Vos HL, Rosendaal FR. The 46C-->T polymorphism in the factor XII gene (F12) and the risk of venous thrombosis. J Thromb Haemost 2005;3:597-599.
  719. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715-722.
  720. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Old and new risk factors for upper extremity deep venous thrombosis. J Thromb Haemost 2005;3:2471-2478.
  721. Brummel-Ziedins K, Vossen CY, Rosendaal FR, Umezaki K, Mann KG. The plasma hemostatic proteome: thrombin generation in healthy individuals. J Thromb Haemost 2005;3:1472-1481.
  722. Brummel-Ziedins KE, Vossen CY, Butenas S, Mann KG, Rosendaal FR. Thrombin generation profiles in deep venous thrombosis. J Thromb Haemost 2005;3:2497-2505.
  723. Buddingh EP, van Hylckama Vlieg A, Rosendaal FR. The angiotensin-converting enzyme gene insertion/deletion polymorphism: insufficient evidence for a role in deep venous thrombosis. J Thromb Haemost 2005;3:403-404.
  724. Ceelie H, Spaargaren-Van Riel CC, Lyon E, Bertina RM, Vos HL. Functional analysis of two polymorphisms in the 3'-UTR of the human prothrombin gene. J Thromb Haemost 2005;3:806-808.
  725. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005;293:2352-2361.
  726. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005;293:2352-2361.
  727. Dahm AE, Andersen TO, Rosendaal F, Sandset PM. A novel anticoagulant activity assay of tissue factor pathway inhibitor I (TFPI). J Thromb Haemost 2005;3:651-658.
  728. de Craen AJ, van Vliet HA, Helmerhorst FM. An analysis of systematic reviews indicated low incorpororation of results from clinical trial quality assessment. J Clin Epidemiol 2005;58:311-313.
  729. de Galan-Roosen AE, Kuijpers JC, Rosendaal FR, Steegers EA, van Beers WA, Ponjee GA, Merkus HM. Maternal and paternal thrombophilia: risk factors for perinatal mortality. BJOG 2005;112:306-311.
  730. de Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 2005;3:1993-1997.
  731. de Visser MC, van Hylckama Vlieg A, Tans G, Rosing J, Dahm AE, Sandset PM, Rosendaal FR, Bertina RM. Determinants of the APTT- and ETP-based APC sensitivity tests. J Thromb Haemost 2005;3:1488-1494.
  732. de Wolf CJ, Cupers RM, Bertina RM, Vos HL. Initiation of Protein S mRNA synthesis in human liver and various cell lines. J Thromb Haemost 2005;3:410-412.
  733. Dijkmans BA, van Schaardenbrug D, van der Horst-Bruinsma IE, Reesink HW, Vandenbroucke JP, Boers M. [The predictive value of autoantibodies in disseminating lupus erythematosus and rheumatoid arthritis]. Ned Tijdschr Geneeskd 2005;149:688-693.
  734. Eikenboom JC, van Wordragen R, Brand A. Compliance with prophylactic platelet transfusion trigger in haematological patients. Transfus Med 2005;15:45-48.
  735. Emmerich J, Vossen CY, Callas PW, Demers C, Naud S, Long GL, Couture P, Rosendaal FR, Bovill EG. Chronic venous abnormalities in symptomatic and asymptomatic protein C deficiency. J Thromb Haemost 2005;3:1428-1431.
  736. Euser AM, Finken MJ, Keijzer-Veen MG, Hille ET, Wit JM, Dekker FW. Associations between prenatal and infancy weight gain and BMI, fat mass, and fat distribution in young adulthood: a prospective cohort study in males and females born very preterm. Am J Clin Nutr 2005;81:480-487.
  737. Galan-Roosen AE, Kuijpers JC, Rosendaal FR, Steegers EA, van Beers WA, Ponjee GA, Merkus HM. Maternal and paternal thrombophilia: risk factors for perinatal mortality. BJOG 2005;112:306-311.
  738. Geest-Daalderop JH, Mulder AB, Boonman-de Winter LJ, Hoekstra MM, van den Besselaar AM. Preanalytical variables and off-site blood collection: influences on the results of the prothrombin time/international normalized ratio test and implications for monitoring of oral anticoagulant therapy. Clin Chem 2005;51:561-568.
  739. Glazer NL, Smith NL, Heckbert SR, Doggen CJ, Lemaitre RN, Psaty BM. Risk of myocardial infarction attributable to elevated levels of total cholesterol among hypertensives. Am J Hypertens 2005;18:759-766.
  740. Glazer NL, Smith NL, Heckbert SR, Doggen CJ, Lemaitre RN, Psaty BM. Risk of myocardial infarction attributable to elevated levels of total cholesterol among hypertensives. Am J Hypertens 2005;18:759-766.
  741. Grote FK, Oostdijk W, de Muinck Keizer-Schrama SM, Dekker FW, Verkerk PH, Wit JM. Growth monitoring and diagnostic work-up of short stature: an international inventorization. J Pediatr Endocrinol Metab 2005;18:1031-1038.
  742. Guimaraes AH, Bertina RM, Rijken DC. A new functional assay of thrombin activatable fibrinolysis inhibitor. J Thromb Haemost 2005;3:1284-1292.
  743. Jansen IM, Fischer K, van der Bom JG, van den Berg HM. No protective effect of breastfeeding on inhibitor formation in severe hemophilia. Pediatr Hematol Oncol 2005;22:575-580.
  744. Jansen MA, Termorshuizen F, Korevaar JC, Dekker FW, Boeschoten E, Krediet RT. Predictors of survival in anuric peritoneal dialysis patients. Kidney Int 2005;68:1199-1205.
  745. Keijzer-Veen MG, Finken MJ, Nauta J, Dekker FW, Hille ET, Frolich M, Wit JM, van der Heijden AJ. Is blood pressure increased 19 years after intrauterine growth restriction and preterm birth? A prospective follow-up study in The Netherlands. Pediatrics 2005;116:725-731.
  746. Keijzer-Veen MG, Schrevel M, Finken MJ, Dekker FW, Nauta J, Hille ET, Frolich M, van der Heijden BJ. Microalbuminuria and lower glomerular filtration rate at young adult age in subjects born very premature and after intrauterine growth retardation. J Am Soc Nephrol 2005;16:2762-2768.
  747. Keijzer-Veen MG, Euser AM, van Montfoort N, Dekker FW, Vandenbroucke JP, van Houwelingen HC. A regression model with unexplained residuals was preferred in the analysis of the fetal origins of adult diseases hypothesis. J Clin Epidemiol 2005;58:1320-1324.
  748. Kellen E, Zeegers MP, Vandenbroucke JP, Buntinx F. [The investigation of gene-environment interaction using case-control comparisons]. Ned Tijdschr Geneeskd 2005;149:977-982.
  749. Kellen E, Zeegers MP, Vandenbroucke JP, Buntinx F. [The investigation of gene-environment interaction using case-control comparisons]. Ned Tijdschr Geneeskd 2005;149:977-982.
  750. Kharagjitsingh AV, Korevaar JC, Vandenbroucke JP, Boeschoten EW, Krediet RT, Daha MR, Dekker FW. Incidence of recombinant erythropoietin (EPO) hyporesponse, EPO-associated antibodies, and pure red cell aplasia in dialysis patients. Kidney Int 2005;68:1215-1222.
  751. Komanasin N, Catto AJ, Futers TS, van Hylckama Vlieg A, Rosendaal FR, Ariens RA. A novel polymorphism in the factor XIII B-subunit (His95Arg): relationship to subunit dissociation and venous thrombosis. J Thromb Haemost 2005;3:2487-2496.
  752. Korevaar JC, van Manen JG, Boeschoten EW, Dekker FW, Krediet RT. When to start dialysis treatment: where do we stand? Perit Dial Int 2005;25 Suppl 3:S69-72.:S69-S72.
  753. Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005;105:1102-1105.
  754. Lisman T, de Groot PG, Meijers JC, Rosendaal FR. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005;105:1102-1105.
  755. Martini CH, Doggen CJ, Cavallini C, Rosendaal FR, Mannucci PM. No effect of polymorphisms in prothrombotic genes on the risk of myocardial infarction in young adults without cardiovascular risk factors. J Thromb Haemost 2005;3:177-179.
  756. Medina P, Navarro S, Estelles A, Vaya A, Bertina RM, Espana F. Influence of the 4600A/G and 4678G/C polymorphisms in the endothelial protein C receptor (EPCR) gene on the risk of venous thromboembolism in carriers of factor V Leiden. Thromb Haemost 2005;94:389-394.
  757. Morelli VM, de Visser MC, Vos HL, Bertina RM, Rosendaal FR. ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden. J Thromb Haemost 2005;3:183-185.
  758. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Am J Kidney Dis 2005;46:925-932.
  759. Nossent AY, Dai L, Rosendaal FR, Vos HL, Eikenboom JC. Beta 2 adrenergic receptor polymorphisms: association with factor VIII and von Willebrand factor levels and the risk of venous thrombosis. J Thromb Haemost 2005;3:405-407.
  760. Pasterkamp E, Kruithof CJ, van der Meer FJ, Rosendaal FR, Vanderschoot JP. A model-based algorithm for the monitoring of long-term anticoagulation therapy. J Thromb Haemost 2005;3:915-921.
  761. Poller L, Keown M, Chauhan N, van den Besselaar AM, Tripodi A, Shiach C, Jespersen J. European Concerted Action on Anticoagulation. A multicentre calibration study of WHO international reference preparations for thromboplastin, rabbit (RBT/90) and human (rTF/95). J Clin Pathol 2005;58:667-669.
  762. Posthouwer D, Plug I, van der Bom JG, Fischer K, Rosendaal FR, Mauser-Bunschoten EP. Hepatitis C and health-related quality of life among patients with hemophilia. Haematologica 2005;90:846-850.
  763. Posthouwer D, Plug I, van der Bom JG, Fischer K, Rosendaal FR, Mauser-Bunschoten EP. Hepatitis C infection among Dutch haemophilia patients: a nationwide cross-sectional study of prevalence and antiviral treatment. Haemophilia 2005;11:270-275.
  764. Reitsma PH, van der Heijden JF, Groot AP, Rosendaal FR, Büller HR. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2005;2:e312.
  765. Riyazi N, Kurreeman FA, Huizinga TW, Dekker FW, Stoeken-Rijsbergen G, Kloppenburg M. The role of interleukin 10 promoter polymorphisms in the susceptibility of distal interphalangeal osteoarthritis. J Rheumatol 2005;32:1571-1575.
  766. Riyazi N, Meulenbelt I, Kroon HM, Ronday KH, Hellio le Graverand MP, Rosendaal FR, Breedveld FC, Slagboom PE, Kloppenburg M. Evidence for familial aggregation of hand, hip, and spine but not knee osteoarthritis in siblings with multiple joint involvement: the GARP study. Ann Rheum Dis 2005;64:438-443.
  767. Riyazi N, Slagboom E, de Craen AJ, Meulenbelt I, Houwing-Duistermaat JJ, Kroon HM, van Schaardenbrug D, Rosendaal FR, Breedveld FC, Huizinga TW, Kloppenburg M. Association of the risk of osteoarthritis with high innate production of interleukin-1beta and low innate production of interleukin-10 ex vivo, upon lipopolysaccharide stimulation. Arthritis Rheum 2005;52:1443-1450.
  768. Rosendaal FR. Venous thrombosis: the role of genes, environment, and behavior. Hematology Am Soc Hematol Educ Program 2005;1-12.
  769. Rutjes AW, Reitsma JB, Vandenbroucke JP, Glas AS, Bossuyt PM. Case-control and two-gate designs in diagnostic accuracy studies. Clin Chem 2005;51:1335-1341.
  770. Schooten CJ, Tjernberg P, Westein E, Terraube V, Castaman G, Mourik JA, Hollestelle MJ, Vos HL, Bertina RM, Berg HM, Eikenboom JC, Lenting PJ, Denis CV. Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost 2005;3:2228-2237.
  771. Schreijer AJ, Cannegieter SC, Rosendaal FR, Helmerhorst FM. A case of thrombosis at high altitude. Thromb Haemost 2005;94:1104-1105.
  772. Slooter AJ, Rosendaal FR, Tanis BC, Kemmeren JM, van der Graaf Y, Algra A. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. J Thromb Haemost 2005;3:1213-1217.
  773. Stel VS, van Dijk PC, van Manen JG, Dekker FW, Ansell D, Conte F, Kramar R, Leivestad T, Vela E, Briggs JD, Jager KJ. Prevalence of co-morbidity in different European RRT populations and its effect on access to renal transplantation. Nephrol Dial Transplant 2005;..
  774. Tanis BC, Kapiteijn K, Hage RM, Rosendaal FR, Helmerhorst FM. Dutch women with a low birth weight have an increased risk of myocardial infarction later in life: a case control study. Reprod Health 2005;2:1.
  775. Terwee CB, Prummel MF, Gerding MN, Kahaly GJ, Dekker FW, Wiersinga WM. Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2005;62:145-155.
  776. Tjernberg P, van der Heijden JF, Eikenboom JC, Reitsma PH. Evaluation of the von Willebrand factor Y1584C polymorphism as a potential risk factor for bleeding in patients receiving anticoagulant treatment with vitamin K antagonists. J Thromb Haemost 2005;3:797-798.
  777. Torn M, Bollen WL, van der Meer FJ, van der Wall EE, Rosendaal FR. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med 2005;165:1527-1532.
  778. Uitte de Willige S, de Visser MC, Houwing-Duistermaat JJ, Rosendaal FR, Vos HL, Bertina RM. Genetic variation in the fibrinogen gamma gene increases the risk of deep venous thrombosis by reducing plasma fibrinogen {gamma}' levels. Blood 2005;..
  779. Valkenburg-van den Berg AW, Sprij AJ, Oostvogel PM, Mutsaers JA, Renes WB, Rosendaal FR, Dorr JP. Prevalence of colonisation with group B Streptococci in pregnant women of a multi-ethnic population in The Netherlands. Eur J Obstet Gynecol Reprod Biol 2005;..
  780. van Baar AL, van Wassenaer AG, Briet JM, Dekker FW, Kok JH. Very preterm birth is associated with disabilities in multiple developmental domains. J Pediatr Psychol 2005;30:247-255.
  781. van Bemmel T, Vandenbroucke JP, Westendorp RG, Gussekloo J. In an observational study elderly patients had an increased risk of falling due to home hazards. J Clin Epidemiol 2005;58:63-67.
  782. van den Besselaar AM, Hoekstra MM. Long-term stability and reproducibility of CoaguChek test strips. Thromb Haemost 2005;93:1189-1192.
  783. van den Besselaar AM, Rutten WP, Witteveen E. Effect of magnesium contamination in evacuated blood collection tubes on the prothrombin time test and ISI calibration using recombinant human thromboplastin and different types of coagulometer. Thromb Res 2005;115:239-244.
  784. van der Putten HH, Bertina RM, Vos HL. Is the prothrombin 19911A>G polymorphism a functional noncoding variant? Blood 2005;105:2995-2996.
  785. van der Sman-de Beer F, Verhagen C, Rombach SM, Boorsma P, van Manen JG, Korevaar JC, van den Bogaard R, Boeschoten EW, Krediet RT, Navis GJ, Vandenbroucke JP, Dekker FW. ACE I/D polymorphism is associated with mortality in a cohort study of patients starting with dialysis. Kidney Int 2005;68:2237-2243.
  786. van Dijk K, Fischer K, van der Bom JG, Grobbee DE, van den Berg HM. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia 2005;11:438-443.
  787. van Dijk K, Fischer K, van der Bom JG, Scheibel E, Ingerslev J, van den Berg HM. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005;130:107-112.
  788. van Dijk K, van der Bom JG, Lenting PJ, de Groot PG, Mauser-Bunschoten EP, Roosendaal G, Grobbee DE, van den Berg HM. Factor VIII half-life and clinical phenotype of severe hemophilia A. Haematologica 2005;90:494-498.
  789. van Dunne FM, Doggen CJ, Heemskerk M, Rosendaal FR, Helmerhorst FM. Factor V Leiden mutation in relation to fecundity and miscarriage in women with venous thrombosis. Hum Reprod 2005;20:802-806.
  790. van Korlaar I, Vossen CY, Rosendaal FR, Bovill EG, Naud S, Cameron LD, Kaptein AA. Attitudes toward genetic testing for thrombophilia in asymptomatic members of a large family with heritable protein C deficiency. J Thromb Haemost 2005;3:2437-2444.
  791. van Minkelen R, de Visser MC, Vos HL, Bertina RM, Rosendaal FR. The Marburg I polymorphism of factor VII-activating protease is not associated with venous thrombosis. Blood 2005;105:4898.
  792. van Montfoort N, Finken MJ, Le Cessie S, Dekker FW, Wit JM. Could cortisol explain the association between birth weight and cardiovascular disease in later life? A meta-analysis. Eur J Endocrinol 2005;153:811-817.
  793. van Rooden CJ, Tesselaar ME, Osanto S, Rosendaal FR, Huisman MV. Deep vein thrombosis associated with central venous catheters - a review. J Thromb Haemost 2005;..
  794. van Rooden CJ, Schippers EF, Barge RM, Rosendaal FR, Guiot HF, van der Meer FJ, Meinders AE, Huisman MV. Infectious complications of central venous catheters increase the risk of catheter-related thrombosis in hematology patients: a prospective study. J Clin Oncol 2005;23:2655-2660.
  795. van Stralen KJ, Blom JW, Doggen CJ, Rosendaal FR. Strenuous sport activities involving the upper extremities increase the risk of venous thrombosis of the arm. J Thromb Haemost 2005;3:2110-2111.
  796. van Vliet HA, Frolich M, Christella M, Thomassen LG, Doggen CJ, Rosendaal FR, Rosing J, Helmerhorst FM. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens. Hum Reprod 2005;20:563-568.
  797. Vandenbroucke JP. Homoeopathy and "the growth of truth". Lancet 2005;366:691-692.
  798. Vandenbroucke JP, Kroep JR. Bortezomib in multiple myeloma. N Engl J Med 2005;353:1297-1298.
  799. Verschuur M, Jellema A, Bladbjerg EM, EJ MF, Mensink RP, Moller L, Vos HL, de Maat MP. The plasminogen activator inhibitor-1 (PAI-1) promoter haplotype is related to PAI-1 plasma concentrations in lean individuals. Atherosclerosis 2005;181:275-284.
  800. Verschuur M, de Jong M, Felida L, de Maat MP, Vos HL. A hepatocyte nuclear factor-3 site in the fibrinogen beta promoter is important for interleukin 6-induced expression, and its activity is influenced by the adjacent -148C/T polymorphism. J Biol Chem 2005;280:16763-16771.
  801. von Elm E., Altman DG, Pocock S, Vandenbroucke JP, Egger M. Re: "quality of reporting of observational longitudinal research". Am J Epidemiol 2005;162:1032-1033.
  802. von Elm E, Altman DG, Pocock S, Vandenbroucke JP, Egger M. Quality of reporting of observational longitudinal research. Am J Epidemiol 2005;..
  803. Vossen CY, Walker ID, Svensson P, Souto JC, Scharrer I, Preston FE, Palareti G, Pabinger I, van der Meer FJ, Makris M, Fontcuberta J, Conard J, Rosendaal FR. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol 2005;25:1992-1997.
  804. Vossen CY, Rosendaal FR. The protective effect of the factor XIII Val34Leu mutation on the risk of deep venous thrombosis is dependent on the fibrinogen level. J Thromb Haemost 2005;3:1102-1103.
  805. Vossen CY, Conard J, Fontcuberta J, Makris M, van der Meer FJ, Pabinger I, Palareti G, Preston FE, Scharrer I, Souto JC, Svensson P, Walker ID, Rosendaal FR. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost 2005;3:459-464.
  806. Vossen CY, Naud S, Bovill EG, Weissgold DJ. Normal retinal vasculature despite familial protein C deficiency. Am J Ophthalmol 2005;139:944-945.
  807. Wettinger SB, Doggen CJ, Spek CA, Rosendaal FR, Reitsma PH. High throughput mRNA profiling highlights associations between myocardial infarction and aberrant expression of inflammatory molecules in blood cells. Blood 2005;105:2000-2006.
  808. Witsenburg CP, Rosendaal FR, Middeldorp JM, van der Meer FJ, Scherjon SA. Factor VIII levels and the risk of pre-eclampsia, HELLP syndrome, pregnancy related hypertension and severe intrauterine growth retardation. Thromb Res 2005;115:387-392.
  809. Appels CW, Vandenbroucke JP. Overweight, obesity, and mortality. N Engl J Med 2006;355:2699-1.
  810. Blom JW, Vanderschoot JP, Oostindier MJ, Osanto S, van der Meer FJ, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 2006;4:529-535.
  811. Blom JW, Osanto S, Rosendaal FR. High risk of venous thrombosis in patients with pancreatic cancer: a cohort study of 202 patients. Eur J Cancer 2006;42:410-414.
  812. Botha-Scheepers S, Riyazi N, Kroon HM, Scharloo M, Houwing-Duistermaat JJ, Slagboom E, Rosendaal FR, Breedveld FC, Kloppenburg M. Activity limitations in the lower extremities in patients with osteoarthritis: the modifying effects of illness perceptions and mental health. Osteoarthritis Cartilage 2006;14:1104-1110.
  813. Brenchley PE, Lindholm B, Dekker FW, Navis G. Translating knowledge of the human genome into clinical practice in nephrology dialysis and transplantation: the renal genome network (ReGeNet). Nephrol Dial Transplant 2006;21:2681-2683.
  814. Cannegieter SC, Doggen CJ, van Houwelingen HC, Rosendaal FR. Travel-related venous thrombosis: results from a large population-based case control study (MEGA study). PLoS Med 2006;3:e307.
  815. Chinthammitr Y, Vos HL, Rosendaal FR, Doggen CJ. The association of prothrombin A19911G polymorphism with plasma prothrombin activity and venous thrombosis: results of the MEGA study, a large population-based case-control study. J Thromb Haemost 2006;4:2587-2592.
  816. Christiansen SC, Naess IA, Cannegieter SC, Hammerstrom J, Rosendaal FR, Reitsma PH. Inflammatory cytokines as risk factors for a first venous thrombosis: a prospective population-based study. PLoS Med 2006;3:e334.
  817. Coebergh JW, van Veen EB, Vandenbroucke JP, van Diest P, Oosterhuis W. One-time general consent for research on biological samples: opt out system for patients is optimal and endorsed in many countries. BMJ 2006;332:665.
  818. Coppens M, van Doormaal FF, Schreijer AJ, Rosendaal FR, Büller HR. Intermittent mechanical compression for prevention of travellers' thrombosis. J Thromb Haemost 2006;4:1836-1838.
  819. Curb JD, Prentice RL, Bray PF, Langer RD, van Horn L, Barnabei VM, Bloch MJ, Cyr MG, Gass M, Lepine L, Rodabough RJ, Sidney S, Uwaifo GI, Rosendaal FR. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166:772-780.
  820. Dahm A, Rosendaal FR, Andersen TO, Sandset PM. Tissue factor pathway inhibitor anticoagulant activity: risk for venous thrombosis and effect of hormonal state. Br J Haematol 2006;132:333-338.
  821. de Buck PD, de Bock GH, van Dijk F, van den Hout WB, Vandenbroucke JP, Vliet Vlieland TP. Sick leave as a predictor of job loss in patients with chronic arthritis. Int Arch Occup Environ Health 2006;80:160-170.
  822. de Miranda E, van der Bom JG, Bonsel GJ, Bleker OP, Rosendaal FR. Membrane sweeping and prevention of post-term pregnancy in low-risk pregnancies: a randomised controlled trial. BJOG 2006;113:402-408.
  823. de Mutsert R, Krediet RT. [Malnutrition, inflammation and atherosclerosis (MIA-syndrome) in dialysis patients]. Ned Tijdschr Geneeskd 2006;150:2023-2027.
  824. den Elzen WP, van Manen JG, Boeschoten EW, Krediet RT, Dekker FW. The effect of single and repeatedly high concentrations of C-reactive protein on cardiovascular and non-cardiovascular mortality in patients starting with dialysis. Nephrol Dial Transplant 2006;21:1588-1595.
  825. Doggen CJ, Rosendaal FR, Meijers JC. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: Opposite and synergistic effects of factors XI and XII. Blood 2006;108:4045-4051.
  826. Finken MJ, Dekker FW, de Zegher F, Wit JM. Long-term height gain of prematurely born children with neonatal growth restraint: parallellism with the growth pattern of short children born small for gestational age. Pediatrics 2006;118:640-643.
  827. Finken MJ, Inderson A, van Montfoort N, Keijzer-Veen MG, van Weert AW, Carfil N, Frolich M, Hille ET, Romijn JA, Dekker FW, Wit JM. Lipid profile and carotid intima-media thickness in a prospective cohort of very preterm subjects at age 19 years: effects of early growth and current body composition. Pediatr Res 2006;59:604-609.
  828. Finken MJ, Keijzer-Veen MG, Dekker FW, Frolich M, Hille ET, Romijn JA, Wit JM. Preterm birth and later insulin resistance: effects of birth weight and postnatal growth in a population based longitudinal study from birth into adult life. Diabetologia 2006;49:478-485.
  829. Garcia AA, van der Heijden JF, Meijers JC, Rosendaal FR, Reitsma PH. The relationship between ABO blood group and the risk of bleeding during vitamin K antagonist treatment. J Thromb Haemost 2006;4:1418-1420.
  830. Hallan S, de Mutsert R, Carlsen S, Dekker FW, Aasarod K, Holmen J. Obesity, smoking, and physical inactivity as risk factors for CKD: are men more vulnerable? Am J Kidney Dis 2006;47:396-405.
  831. Hallan SI, Dahl K, Oien CM, Grootendorst DC, Aasberg A, Holmen J, Dekker FW. Screening strategies for chronic kidney disease in the general population: follow-up of cross sectional health survey. BMJ 2006;333:1047.
  832. Havekes B, van Manen JG, Krediet RT, Boeschoten EW, Vandenbroucke JP, Dekker FW. Serum troponin T concentration as a predictor of mortality in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 2006;47:823-829.
  833. Helmerhorst FM, Belfield T, Kulier R, Maitra N, O'Brien P, Grimes DA. The Cochrane Fertility Regulation Group: synthesizing the best evidence about family planning. Contraception 2006;74:280-286.
  834. Kapiteijn K, de Bruijn CS, de Boer E, de Craen AJ, Burger CW, van Leeuwen FE, Helmerhorst FM. Does subfertility explain the risk of poor perinatal outcome after IVF and ovarian hyperstimulation? Hum Reprod 2006;21:3228-3234.
  835. Kornaat PR, Bloem JL, Ceulemans RY, Riyazi N, Rosendaal FR, Nelissen RG, Carter WO, Hellio le Graverand MP, Kloppenburg M. Osteoarthritis of the knee: association between clinical features and MR imaging findings. Radiology 2006;239:811-817.
  836. Kuipers S, Cannegieter SC, Middeldorp S, Rosendaal FR, Büller HR. Use of preventive measures for air travel-related venous thrombosis in professionals who attend medical conferences. J Thromb Haemost 2006;4:2373-2376.
  837. Kulier R, Helmerhorst FM, O'Brien P, Usher-Patel M, d'Arcangues C. Copper containing, framed intra-uterine devices for contraception. Cochrane Database Syst Rev 2006;3:CD005347.
  838. Lamberts SW, Langeveld CH, Vandenbroucke JP. Population screening for single genes that codetermine common diseases in adulthood had limited effects. J Clin Epidemiol 2006;59:358-364.
  839. Levi M, Rosendaal FR, Büller HR. [Deep-vein thrombosis and pulmonary embolism due to air travel]. Ned Tijdschr Geneeskd 2006;150:2474-2478.
  840. Martini CH, Brandts A, de Bruijne EL, van Hylckama Vlieg A, Leebeek FW, Lisman T, Rosendaal FR. The effect of genetic variants in the thrombin activatable fibrinolysis inhibitor (TAFI) gene on TAFI-antigen levels, clot lysis time and the risk of venous thrombosis. Br J Haematol 2006;134:92-94.
  841. Naess IA, Christiansen SC, Cannegieter SC, Rosendaal FR, Hammerstroem J. A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost 2006;4:44-49.
  842. Noordzij M, Korevaar JC, Bos WJ, Boeschoten EW, Dekker FW, Bossuyt PM, Krediet RT. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients. Nephrol Dial Transplant 2006;21:2513-2520.
  843. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT. Hyperphosphataemia and related mortality. Nephrol Dial Transplant 2006;21:2676-2677.
  844. Nossent AY, van Marion V, van Tilburg NH, Rosendaal FR, Bertina RM, van Mourik JA, Eikenboom HC. von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. J Thromb Haemost 2006;4:2556-2562.
  845. Nossent AY, Eikenboom JC, Vos HL, Bakker E, Tanis BC, Doggen CJ, Bertina RM, Rosendaal FR. Haplotypes encoding the factor VIII 1241 Glu variation, factor VIII levels and the risk of venous thrombosis. Thromb Haemost 2006;95:942-948.
  846. Oren E, Smith NL, Doggen CJ, Heckbert SR, Lemaitre RN. Body mass index and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost 2006;4:2273-2275.
  847. Perquin DA, de Craen AJ, Helmerhorst FM. Difficulties in recruitment for a randomized controlled trial involving hysterosalpingography. Reprod Health 2006;3:5.
  848. Plug I, Mauser-Bunschoten EP, Brocker-Vriends AH, van Amstel HK, van der Bom JG, van Diemen-Homan JE, Willemse J, Rosendaal FR. Bleeding in carriers of hemophilia. Blood 2006;108:52-56.
  849. Plug I, van der Bom JG, Peters M, Mauser-Bunschoten EP, de Goede-Bolder A, Heijnen L, Smit C, Willemse J, Rosendaal FR. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J Thromb Haemost 2006;4:510-516.
  850. Pruijm MT, de Fijter HJ, Doxiadis II, Vandenbroucke JP. Preemptive versus Non-preemptive simultaneous pancreas-kidney transplantation: a single-center, long-term, follow-up study. Transplantation 2006;81:1119-1124.
  851. Rombouts EK, Rosendaal FR, van der Meer FJ. The effect of vitamin K supplementation on anticoagulant treatment. J Thromb Haemost 2006;4:691-692.
  852. Rosendaal FR. Interventions to prevent venous thrombosis after air travel: are they necessary? No. J Thromb Haemost 2006;4:2306-2307.
  853. Rutten JH, Korevaar JC, Boeschoten EW, Dekker FW, Krediet RT, Boomsma F, van den Meiracker AH. B-type natriuretic peptide and amino-terminal atrial natriuretic peptide predict survival in peritoneal dialysis. Perit Dial Int 2006;26:598-602.
  854. Schreijer AJ, Cannegieter SC, Meijers JC, Middeldorp S, Büller HR, Rosendaal FR. Activation of coagulation system during air travel: a crossover study. Lancet 2006;367:832-838.
  855. Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Rosendaal FR, Psaty BM. Conjugated equine estrogen, esterified estrogen, prothrombotic variants, and the risk of venous thrombosis in postmenopausal women. Arterioscler Thromb Vasc Biol 2006;26:2807-2812.
  856. Smith NL, Heckbert SR, Doggen CJ, Lemaitre RN, Reiner AP, Lumley T, Meijers JC, Psaty BM, Rosendaal FR. The differential association of conjugated equine estrogen and esterified estrogen with activated protein C resistance in postmenopausal women. J Thromb Haemost 2006;4:1701-1706.
  857. Stukart MJ, Strijbosch MP, Hooiveld MH, van Rees-Wortelboer MM, Vandenbroucke JP, Klasen EC. [Physicians and scientific research: slight decline of the numbers of physicians with a doctoral degree]. Ned Tijdschr Geneeskd 2006;150:1509-1512.
  858. Tanis B, Algra A, van der Graaf Y, Helmerhorst F, Rosendaal F. Procoagulant factors and the risk of myocardial infarction in young women. Eur J Haematol 2006;77:67-73.
  859. Uitte de Willige S, Doggen CJ, de Visser MC, Bertina RM, Rosendaal FR. Haplotypes of the fibrinogen gamma gene do not affect the risk of myocardial infarction. J Thromb Haemost 2006;4:474-476.
  860. Valkenburg-van den Berg AW, Sprij AJ, Oostvogel PM, Mutsaers JA, Renes WB, Rosendaal FR, Joep DP. Prevalence of colonisation with group B Streptococci in pregnant women of a multi-ethnic population in The Netherlands. Eur J Obstet Gynecol Reprod Biol 2006;124:178-183.
  861. van Bemmel T, Woittiez K, Blauw GJ, van der Sman-de Beer F, Dekker FW, Westendorp RG, Gussekloo J. Prospective study of the effect of blood pressure on renal function in old age: the Leiden 85-Plus Study. J Am Soc Nephrol 2006;17:2561-2566.
  862. van der Hagen PB, Folsom AR, Jenny NS, Heckbert SR, O'Meara ES, Reich LM, Rosendaal FR, Cushman M. Subclinical atherosclerosis and the risk of future venous thrombosis in the Cardiovascular Health Study. J Thromb Haemost 2006;4:1903-1908.
  863. van Dunne FM, de Craen AJ, Heijmans BT, Helmerhorst FM, Westendorp RG. Gender-specific association of the factor V Leiden mutation with fertility and fecundity in a historic cohort. The Leiden 85-Plus Study. Hum Reprod 2006;21:967-971.
  864. van Vliet HA, Grimes DA, Lopez LM, Schulz KF, Helmerhorst FM. Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev 2006;3:CD003553.
  865. van Winkelen P, van Denderen JS, Vossen CY, Huizinga TW, Dekker FW. How evidence-based are advertisements in journals regarding the subspecialty of rheumatology? Rheumatology (Oxford) 2006;45:1154-1157.
  866. Vandenbroucke JP. [The N-of-1 trial: the ideal study design that is underused]. Ned Tijdschr Geneeskd 2006;150:2794-2795.
  867. Vandenbroucke JP. [Levels of evidence are insufficient]. Ned Tijdschr Geneeskd 2006;150:2485.
  868. Vandenbroucke JP. [No prior informed consent required for 'no-risk' scientific research]. Ned Tijdschr Geneeskd 2006;150:616.
  869. Vandenbroucke JP. What is the best evidence for determining harms of medical treatment? CMAJ 2006;174:645-646.
  870. Vandenbroucke JP. Case reports of suspected adverse drug reactions: case reports were dismissed too quickly. BMJ 2006;332:488.
  871. Vermeulen CF, Grunberg A, Peters LA, van der Linden-Narain IB, Vrede MA, Krul EJ, Dekker FW, Fleuren GJ. Ethnic patterns of cytologic abnormalities in cervical smears in suriname, a high-risk area for cervical cancer. Acta Cytol 2006;50:621-626.
  872. Vossen CY, Rosendaal FR. Risk of arterial thrombosis in carriers of familial thrombophilia. J Thromb Haemost 2006;4:916-918.
  873. Vossen CY, Hasstedt SJ, Scott BT, Rosendaal FR, Bovill EG. A genome search for genetic determinants of markers of protein C activation. J Thromb Haemost 2006;4:706-708.
  874. Vriesendorp TM, DeVries JH, van Santen S, Moeniralam HS, de Jonge E, Roos YB, Schultz MJ, Rosendaal FR, Hoekstra JB. Evaluation of short-term consequences of hypoglycemia in an intensive care unit. Crit Care Med 2006;34:2714-2718.
  875. Vriesendorp TM, van Santen S, DeVries JH, de Jonge E, Rosendaal FR, Schultz MJ, Hoekstra JB. Predisposing factors for hypoglycemia in the intensive care unit. Crit Care Med 2006;34:96-101.
  876. Wiendels NJ, Knuistingh Neven A, Rosendaal FR, Spinhoven P, Zitman FG, Assendelft WJ, Ferrari MD. Chronic frequent headache in the general population: prevalence and associated factors. Cephalalgia 2006;26:1434-1442.
  877. Bauer MP, Wiersum-Osselton J, Schipperus M, Vandenbroucke JP, Briët E. Clinical predictors of alloimmunization after red blood cell transfusion. Transfusion 2007;47:2066-2071.
  878. Berger SP, Roos A, Mallat MJ, Schaapherder AF, Doxiadis II, van Kooten C, Dekker FW, Daha MR, de Fijter JW. Low pretransplantation mannose-binding lectin levels predict superior patient and graft survival after simultaneous pancreas-kidney transplantation. J Am Soc Nephrol 2007;18:2416-2422.
  879. Bergheanu SC, van Tol A, linga-Thie GM, Liem A, Dunselman PH, van der Bom JG, Jukema JW. Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterol. Curr Med Res Opin 2007;23:2235-2240.
  880. Bernstein CN, Sargent M, Vos HL, Rosendaal FR. Mutations in clotting factors and inflammatory bowel disease. Am J Gastroenterol 2007;102:338-343.
  881. Bezemer ID, Rosendaal FR. Predictive genetic variants for venous thrombosis: what's new? Semin Hematol 2007;44:85-92.
  882. Bezemer ID, Doggen CJ, Vos HL, Rosendaal FR. No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study. Arch Intern Med 2007;167:497-501.
  883. Botha-Scheepers SA, Watt I, Slagboom E, Meulenbelt I, Rosendaal FR, Breedveld FC, Kloppenburg M. Influence of familial factors on radiologic disease progression over two years in siblings with osteoarthritis at multiple sites: a prospective longitudinal cohort study. Arthritis Rheum 2007;57:626-632.
  884. Boukes FS, Wiersma TJ, de Leest K, Helmerhorst FM, Picavet C, van der Wijden CL. [New recommendations as regards forgetting to take the contraceptive pill]. Ned Tijdschr Geneeskd 2007;151:1923-1926.
  885. Brandts A, van Hylckama Vlieg A, Rosing J, Baglin TP, Rosendaal FR. The risk of venous thrombosis associated with a high endogenous thrombin potential in the absence and presence of activated protein C. J Thromb Haemost 2007;5:416-418.
  886. Burkart J, Piraino B, Kaldas H, Lee JY, Bender FH, Krediet RT, Boeschoten EW, Dekker FW, Vonesh E, Mujais S. Why is the evidence favoring hemodialysis over peritoneal dialysis misleading? Semin Dial 2007;20:200-202.
  887. Chandie Shaw PK, Berger SP, Mallat M, Frolich M, Dekker FW, Rabelink TJ. Central obesity is an independent risk factor for albuminuria in nondiabetic South Asian subjects. Diabetes Care 2007;30:1840-1844.
  888. Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR. ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men. Blood 2007;109:1998-2000.
  889. Cohn DM, Roshani S, Middeldorp S. Thrombophilia and venous thromboembolism: implications for testing. Semin Thromb Hemost 2007;33:573-581.
  890. Coppens M, Schreijer AJ, Berger FH, Cannegieter SC, Rosendaal FR, Büller HR. Mechanical prophylaxis for travellers' thrombosis: a comparison of three interventions that promote venous outflow. J Thromb Haemost 2007;5:1556-1567.
  891. de Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A, Berger SP, Gelinck LB, van Houwelingen HC, van den Broek PJ, Kuijper EJ, Kroon FP, Vandenbroucke JP. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source? Clin Infect Dis 2007;44:1143-1149.
  892. de Bruijne EL, Murad SD, de Maat MP, Tanck MW, Haagsma EB, van Hoek B, Rosendaal FR, Janssen HL, Leebeek FW. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis. Thromb Haemost 2007;97:181-185.
  893. de Mutsert R, Snijder MB, van der Sman-de Beer F, Seidell JC, Boeschoten EW, Krediet RT, Dekker JM, Vandenbroucke JP, Dekker FW. Association between body mass index and mortality is similar in the hemodialysis population and the general population at high age and equal duration of follow-up. J Am Soc Nephrol 2007;18:967-974.
  894. Dekkers OM, Vandenbroucke JP. [Generalizability of therapeutic trials]. Ned Tijdschr Geneeskd 2007;151:2203-2206.
  895. den Heijer M, Willems HP, Blom HJ, Gerrits WB, Cattaneo M, Eichinger S, Rosendaal FR, Bos GM. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. Blood 2007;109:139-144.
  896. Egger M, Altman DG, Vandenbroucke JP. Commentary: strengthening the reporting of observational epidemiology the STROBE statement. Int J Epidemiol 2007;36:948-950.
  897. Euser AM, Le Cessie S, Finken MJ, Wit JM, Dekker FW. Reliability studies can be designed more efficiently by using variance components estimates from different sources. J Clin Epidemiol 2007;60:1010-1014.
  898. Finken MJ, Meulenbelt I, Dekker FW, Frolich M, Romijn JA, Slagboom PE, Wit JM. The 23K variant of the R23K polymorphism in the glucocorticoid receptor gene protects against postnatal growth failure and insulin resistance after preterm birth. J Clin Endocrinol Metab 2007;92:4777-4782.
  899. Gadisseur AP, Christiansen SC, van der Meer FJ, Rosendaal FR. The quality of oral anticoagulant therapy and recurrent venous thrombotic events in the Leiden Thrombophilia Study. J Thromb Haemost 2007;5:931-936.
  900. Goorhuis A, van der Kooi T, Vaessen N, Dekker FW, van den Berg R, Harmanus C, van den Hof S, Notermans DW, Kuijper EJ. Spread and epidemiology of Clostridium difficile polymerase chain reaction ribotype 027/toxinotype III in The Netherlands. Clin Infect Dis 2007;45:695-703.
  901. Gouw SC, van den Berg HM, Le Cessie S, van der Bom JG. Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost 2007;5:1383-1390.
  902. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007;109:4648-4654.
  903. Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgard U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007;109:4693-4697.
  904. Grootendorst DC, de Jager DJ, Brandenburg VM, Boeschoten EW, Krediet RT, Dekker FW. Excellent agreement between C-reactive protein measurement methods in end-stage renal disease patients--no additional power for mortality prediction with high-sensitivity CRP. Nephrol Dial Transplant 2007;22:3277-3284.
  905. Grote FK, Oostdijk W, de Muinck Keizer-Schrama SM, Dekker FW, van Dommelen P, van Buuren S, lodder-van der Kooij AM, Verkerk PH, Wit JM. Referral patterns of children with poor growth in primary health care. BMC Public Health 2007;7:77.
  906. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol 2007;6:115-124.
  907. Hasstedt SJ, Scott BT, Rosendaal FR, Callas PW, Vossen CY, Long GL, Bovill EG. Exclusion of the alpha2 subunit of platelet-activating factor acetylhydrolase 1b (PAFAH1B2) as a prothrombotic gene in a protein C-deficient kindred and population-based case-control sample. Thromb Haemost 2007;98:587-592.
  908. Helmerhorst, F. M. Epidemiology of hormonal therapy related thrombosis. Thromb Res. 119, S62-S63. 2007.
    Ref Type: Journal (Full)
  909. Hermans MM, Brandenburg V, Ketteler M, Kooman JP, van der Sande FM, Boeschoten EW, Leunissen KM, Krediet RT, Dekker FW. Association of serum fetuin-A levels with mortality in dialysis patients. Kidney Int 2007;72:202-207.
  910. Hoek FJ, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT. Reply-Cystatin C for Estimation of Residual GFR. Nephrol Dial Transplant 2007.
  911. Hoek FJ, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT. Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystatin C level. Nephrol Dial Transplant 2007;22:1633-1638.
  912. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007;153:175-181.
  913. Jager KJ, Stel VS, Wanner C, Zoccali C, Dekker FW. The valuable contribution of observational studies to nephrology. Kidney Int 2007;72:671-675.
  914. Jager KJ, Zoccali C, Kramar R, Dekker FW. Measuring disease occurrence. Kidney Int 2007;72:412-415.
  915. Jazet IM, de Groot GH, Tuijnebreyer WE, Fogteloo AJ, Vandenbroucke JP, Meinders AE. Cardiovascular risk factors after bariatric surgery: Do patients gain more than expected from their substantial weight loss? Eur J Intern Med 2007;18:39-43.
  916. Kaptein AA, van Korlaar I, Cameron LD, Vossen CY, van der Meer FJ, Rosendaal FR. Using the common-sense model to predict risk perception and disease-related worry in individuals at increased risk for venous thrombosis. Health Psychol 2007;26:807-812.
  917. Keijzer-Veen MG, Kleinveld HA, Lequin MH, Dekker FW, Nauta J, de Rijke YB, van der Heijden BJ. Renal function and size at young adult age after intrauterine growth restriction and very premature birth. Am J Kidney Dis 2007;50:542-551.
  918. Keijzer MB, Borm GF, Blom HJ, Bos GM, Rosendaal FR, den Heijer M. No interaction between factor V Leiden and hyperhomocysteinemia or MTHFR 677TT genotype in venous thrombosis. Results of a meta-analysis of published studies and a large case-only study. Thromb Haemost 2007;97:32-37.
  919. Knoester M, Vandenbroucke JP, Helmerhorst FM, van der Westerlaken LA, Walther FJ, Veen S. Matched follow-up study of 5-8 year old ICSI-singletons: comparison of their neuromotor development to IVF and naturally conceived singletons. Hum Reprod 2007;22:1638-1646.
  920. Knoester M, Helmerhorst FM, van der Westerlaken LA, Walther FJ, Veen S. Matched follow-up study of 5 8-year-old ICSI singletons: child behaviour, parenting stress and child (health-related) quality of life. Hum Reprod 2007;22:3098-3107.
  921. Kolesnyk I, Dekker FW, Noordzij M, Le Cessie S, Struijk DG, Krediet RT. Impact of ACE inhibitors and AII receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients. Perit Dial Int 2007;27:446-453.
  922. Korevaar JC, Boeschoten EW, Dekker FW, Krediet RT. What have we learned from NECOSAD? Practical implications for peritoneal dialysis patients. Perit Dial Int 2007;27:11-15.
  923. Kuipers S, Schreijer AJ, Cannegieter SC, Büller HR, Rosendaal FR, Middeldorp S. Travel and venous thrombosis: a systematic review. J Intern Med 2007;262:615-634.
  924. Kuipers S, Cannegieter SC, Middeldorp S, Robyn L, Büller HR, Rosendaal FR. The absolute risk of venous thrombosis after air travel: a cohort study of 8,755 employees of international organisations. PLoS Med 2007;4:e290.
  925. Kulier R, O'Brien PA, Helmerhorst FM, Usher-Patel M, d'Arcangues C. Copper containing, framed intra-uterine devices for contraception. Cochrane Database Syst Rev 2007;CD005347.
  926. Liem SS, van der Hoeven BL, Oemrawsingh PV, Bax JJ, van der Bom JG, Bosch J, Viergever EP, van Rees C, Padmos I, Sedney MI, van Exel HJ, Verwey HF, Atsma DE, van der Veen H, Jukema JW, van der Wall EE, Schalij MJ. MISSION!: optimization of acute and chronic care for patients with acute myocardial infarction. Am Heart J 2007;153:14-11.
  927. Meltzer ME, Doggen CJ, de Groot PG, Rosendaal FR, Lisman T. Fibrinolysis and the risk of venous and arterial thrombosis. Curr Opin Hematol 2007;14:242-248.
  928. Middeldorp S, Levi M. Thrombophilia: an update. Semin Thromb Hemost 2007;33:563-572.
  929. Middeldorp S. Thrombophilia and pregnancy complications: cause or association? J Thromb Haemost 2007;5 Suppl 1:276-282.
  930. Middeldorp S. Pregnancy failure and heritable thrombophilia. Semin Hematol 2007;44:93-97.
  931. Morelli VM, de Visser MC, van Tilburg NH, Vos HL, Eikenboom JC, Rosendaal FR, Bertina RM. ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. Thromb Haemost 2007;97:534-541.
  932. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007;5:692-699.
  933. Nagai N, Lijnen HR, Cleuren AC, Rosendaal FR, van Hoef B, Hoylaerts MF, van Vlijmen BJ. Factor V Leiden mutation is associated with enhanced arterial thrombotic tendency in lean but not in obese mice. Thromb Haemost 2007;98:858-863.
  934. Noordzij M, Boeschoten EW, Bos WJ, Dekker FW, Bossuyt PM, Krediet RT, Korevaar JC. Disturbed mineral metabolism is associated with muscle and skin complaints in a prospective cohort of dialysis patients. Nephrol Dial Transplant 2007;22:2944-2949.
  935. Nossent AY, Eikenboom JC, Tanis BC, Doggen CJ, Rosendaal FR. Haplotypes encoding the factor VIII 1241Glu variation and the risk of myocardial infarction. J Thromb Haemost 2007;5:619-621.
  936. Oien CM, Reisaeter AV, Leivestad T, Dekker FW, Line PD, Os I. Living donor kidney transplantation: the effects of donor age and gender on short- and long-term outcomes. Transplantation 2007;83:600-606.
  937. Pomp ER, Le Cessie S, Rosendaal FR, Doggen CJ. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007;139:289-296.
  938. Pons D, Monraats PS, de Maat MP, Pires NM, Quax PH, van Vlijmen BJ, Rosendaal FR, Zwinderman AH, Doevendans PA, Waltenberger J, de Winter RJ, Tio RA, Frants RR, van der Laarse A, van der Wall EE, Jukema JW. The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions. Thromb Haemost 2007;98:1323-1328.
  939. Pruissen DM, Rosendaal FR, Gorter JW, Garcia AA, Kappelle LJ, Algra A. Haemostatic genetic variants, ABO blood group and bleeding risk during oral anticoagulant treatment after cerebral ischaemia of arterial origin. J Neurol 2007;254:1660-1665.
  940. Reitsma PH, Rosendaal FR. Past and future of genetic research in thrombosis. J Thromb Haemost 2007;5 Suppl 1:264-269.
  941. Rombouts EK, Rosendaal FR, van der Meer FJ. Daily vitamin K supplementation improves anticoagulant stability. J Thromb Haemost 2007;5:2043-2048.
  942. Rosendaal FR, van Hylckama Vlieg A, Doggen CJ. Venous thrombosis in the elderly. J Thromb Haemost 2007;5 Suppl 1:310-317.
  943. Smith NL, Hindorff LA, Heckbert SR, Lemaitre RN, Marciante KD, Rice K, Lumley T, Bis JC, Wiggins KL, Rosendaal FR, Psaty BM. Association of genetic variations with nonfatal venous thrombosis in postmenopausal women. JAMA 2007;297:489-498.
  944. Snoep JD, Dekkers OM, Vandenbroucke JP. A possible overestimation of the effect of aspirin. Arch Intern Med 2007;167:2372-2373.
  945. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007;167:1593-1599.
  946. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J 2007;154:221-231.
  947. Stel VS, Jager KJ, Zoccali C, Wanner C, Dekker FW. The randomized clinical trial: an unbeatable standard in clinical research? Kidney Int 2007;72:539-542.
  948. Suetens C, Niclaes L, Jans B, Verhaegen J, Schuermans A, van Eldere J, Vandenbroucke JP, Buntinx F. Determinants of methicillin-resistant Staphylococcus aureus carriage in nursing homes. Age Ageing 2007;36:327-330.
  949. Tchaikovski SN, van Vliet HA, Thomassen MC, Bertina RM, Rosendaal FR, Sandset PM, Helmerhorst FM, Tans G, Rosing J. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost 2007;98:1350-1356.
  950. Thong MS, Kaptein AA, Krediet RT, Boeschoten EW, Dekker FW. Social support predicts survival in dialysis patients. Nephrol Dial Transplant 2007;22:845-850.
  951. Tripepi G, Jager KJ, Dekker FW, Wanner C, Zoccali C. Measures of effect: relative risks, odds ratios, risk difference, and 'number needed to treat'. Kidney Int 2007;72:789-791.
  952. van der Eijk EA, van de Vosse E, Vandenbroucke JP, van Dissel JT. Heredity versus environment in tuberculosis in twins: the 1950s United Kingdom Prophit Survey Simonds and Comstock revisited. Am J Respir Crit Care Med 2007;176:1281-1288.
  953. van Dijk JM, TerBrugge KG, van der Meer FJ, Wallace MC, Rosendaal FR. Thrombophilic factors and the formation of dural arteriovenous fistulas. J Neurosurg 2007;107:56-59.
  954. van Dijk K, van der Bom JG, Fischer K, de Groot PG, van den Berg HM. Phenotype of severe hemophilia A and plasma levels of risk factors for thrombosis. J Thromb Haemost 2007;5:1062-1064.
  955. van Dijk PC, Zwinderman AH, Dekker FW, Schon S, Stel VS, Finne P, Jager KJ. Effect of general population mortality on the north-south mortality gradient in patients on replacement therapy in Europe. Kidney Int 2007;71:53-59.
  956. van Hylckama Vlieg A, Christiansen SC, Luddington R, Cannegieter SC, Rosendaal FR, Baglin TP. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol 2007;138:769-774.
  957. van Hylckama Vlieg A, Montes R, Rosendaal FR, Hermida J. Autoantibodies against endothelial protein C receptor and the risk of a first deep vein thrombosis. J Thromb Haemost 2007;5:1449-1454.
  958. van Leeuwen Y, Rombouts EK, Kruithof CJ, van der Meer FJ, Rosendaal FR. Improved control of oral anticoagulant dosing: a randomized controlled trial comparing two computer algorithms. J Thromb Haemost 2007;5:1644-1649.
  959. van Manen JG, van Dijk PC, Stel VS, Dekker FW, Cleries M, Conte F, Feest T, Kramar R, Leivestad T, Briggs JD, Stengel B, Jager KJ. Confounding effect of comorbidity in survival studies in patients on renal replacement therapy. Nephrol Dial Transplant 2007;22:187-195.
  960. van Minkelen R, de Visser MC, Houwing-Duistermaat JJ, Vos HL, Bertina RM, Rosendaal FR. Haplotypes of IL1B, IL1RN, IL1R1, and IL1R2 and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol 2007;27:1486-1491.
  961. van Stralen KJ, Le Cessie S, Rosendaal FR, Doggen CJ. Regular sports activities decrease the risk of venous thrombosis. J Thromb Haemost 2007;5:2186-2192.
  962. van Stralen KJ, Terveer EM, Doggen CJ, Helmerhorst FM, Vandenbroucke JP. The tortuous history of the implementation of early ambulation after delivery. J R Soc Med 2007;100:90-96.
  963. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 2007;18:805-835.
  964. Vandenbroucke JP. The making of STROBE. Epidemiology 2007;18:797-799.
  965. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007;4:e297.
  966. Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007;147:W163-W194.
  967. Vandenbroucke JP. [The N-of-1 trial: the ideal study design that is underused]. Ned Tijdschr Tandheelkd 2007;114:260-262.
  968. Vandenbroucke JP. Analytic approaches to observational studies with treatment selection bias. JAMA 2007;297:2077-2078.
  969. Vermeulen CF, Boon ME, Grunberg A, van der Linden-Narain IB, Vrede MA, Dekker FW, Peters AA, Fleuren GJ. Decreased prevalence of dysplasia in high-risk population immigrants in a low-risk area for cervical cancer. Int J Gynecol Cancer 2007;17:646-650.
  970. Verschuur M, Spinhoven P, van Emmerik A, Rosendaal F. Making a bad thing worse: effects of communication of results of an epidemiological study after an aviation disaster. Soc Sci Med 2007;65:1430-1441.
  971. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007;370:1453-1457.
  972. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology 2007;18:800-804.
  973. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ 2007;85:867-872.
  974. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med 2007;45:247-251.
  975. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335:806-808.
  976. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007;4:e296.
  977. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007;147:573-577.
  978. Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, Boeschoten EW, Huisman RM, Krediet RT, Dekker FW. High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant 2007;22:2909-2916.
  979. Vossen CY, Callas PW, Hasstedt SJ, Long GL, Rosendaal FR, Bovill EG. A genetic basis for the interrelation of coagulation factors. J Thromb Haemost 2007;5:1930-1935.
  980. Vossen CY, Hasstedt SJ, Demers C, Rosendaal FR, Bovill EG. Linkage analysis for three coagulation factors clustering on chromosome 13q34: factor VII, factor X and protein Z. J Thromb Haemost 2007;5:1325-1327.
  981. Weijenborg PT, Greeven A, Dekker FW, Peters AA, Ter Kuile MM. Clinical course of chronic pelvic pain in women. Pain 2007;132 Suppl 1:S117-S123.
  982. Arends JJ, Vandenbroucke JP. What conclusions should be drawn between critical care physician management and patient mortality in the intensive care unit? Ann Intern Med 2008;149:768-769.
  983. Bartholomeeusen S, Vandenbroucke JP, Truyers C, Buntinx F. Trends in total cholesterol screening and in prescribing lipid-lowering drugs in general practice in the period 1994-2003. BMC Fam Pract 2008;9:39.
  984. Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost 2008;6:1720-1725.
  985. Bezemer ID, Bare LA, Doggen CJ, Arellano AR, Tong C, Rowland CM, Catanese J, Young BA, Reitsma PH, Devlin JJ, Rosendaal FR. Gene variants associated with deep vein thrombosis. JAMA 2008;299:1306-1314.
  986. Botha-Scheepers S, Watt I, Slagboom E, de Craen AJ, Meulenbelt I, Rosendaal FR, Breedveld FC, Huizinga TW, Kloppenburg M. Innate production of tumour necrosis factor alpha and interleukin 10 is associated with radiological progression of knee osteoarthritis. Ann Rheum Dis 2008;67:1165-1169.
  987. Botha-Scheepers S, Watt I, Rosendaal FR, Breedveld FC, Hellio le Graverand MP, Kloppenburg M. Changes in outcome measures for impairment, activity limitation, and participation restriction over two years in osteoarthritis of the lower extremities. Arthritis Rheum 2008;59:1750-1755.
  988. Bresters D, van Gils I, Dekker FW, Lankester AC, Bredius RG, Schweizer JJ. Abnormal liver enzymes two years after haematopoietic stem cell transplantation in children: prevalence and risk factors. Bone Marrow Transplant 2008;41:27-31.
  989. Coppens M, Reijnders JH, Middeldorp S, Doggen CJ, Rosendaal FR. Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis. J Thromb Haemost 2008;6:1474-1477.
  990. Dahm AE, Sandset PM, Rosendaal FR. The association between protein S levels and anticoagulant activity of tissue factor pathway inhibitor type 1. J Thromb Haemost 2008;6:393-395.
  991. de Mutsert R, Grootendorst DC, Axelsson J, Boeschoten EW, Krediet RT, Dekker FW. Excess mortality due to interaction between protein-energy wasting, inflammation and cardiovascular disease in chronic dialysis patients. Nephrol Dial Transplant 2008;23:2957-2964.
  992. Dekker FW, de Mutsert R, van Dijk PC, Zoccali C, Jager KJ. Survival analysis: time-dependent effects and time-varying risk factors. Kidney Int 2008;74:994-997.
  993. Dekker FW, de Mutsert R, van Dijk PC, Zoccali C, Jager KJ. Survival analysis: time-dependent effects and time-varying risk factors. Kidney Int 2008;74:994-997.
  994. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008;93:61-67.
  995. Doggen CJ. Thromboprophylaxis in cancer outpatients. Blood 2008;111:4833.
  996. Dorhout Mees SM. Magnesium in aneurysmal subarachnoid hemorrhage (MASH II) phase III clinical trial MASH-II study group. Int J Stroke 2008;3:63-65.
  997. Euser AM, Dekker FW, Le Cessie S. A practical approach to Bland-Altman plots and variation coefficients for log transformed variables. J Clin Epidemiol 2008;61:978-982.
  998. Finken MJ, Keijzer-Veen MG, Dekker FW, Frolich M, Walther FJ, Romijn JA, van der Heijden BJ, Wit JM. Antenatal glucocorticoid treatment is not associated with long-term metabolic risks in individuals born before 32 weeks of gestation. Arch Dis Child Fetal Neonatal Ed 2008;93:F442-F447.
  999. Fleischer K, van Vliet HA, Rosendaal FR, Rosing J, Tchaikovski S, Helmerhorst FM. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: A cross-over study. Thromb Res 2008.
  1000. Flinterman LE, van Hylckama Vlieg A, Rosendaal FR, Doggen CJ. Recurrent thrombosis and survival after a first venous thrombosis of the upper extremity. Circulation 2008;118:1366-1372.
  1001. Flinterman LE, van der Meer FJ, Rosendaal FR, Doggen CJ. Current perspective of venous thrombosis in the upper extremity. J Thromb Haemost 2008;6:1262-1266.
  1002. Fouque D, McKenzie J, de Mutsert R, Azar R, Teta D, Plauth M, Cano N. Use of a renal-specific oral supplement by haemodialysis patients with low protein intake does not increase the need for phosphate binders and may prevent a decline in nutritional status and quality of life. Nephrol Dial Transplant 2008;23:2902-2910.
  1003. Goorhuis A, Bakker D, Corver J, Debast SB, Harmanus C, Notermans DW, Bergwerff AA, Dekker FW, Kuijper EJ. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008;47:1162-1170.
  1004. Grote FK, Oostdijk W, de Muinck Keizer-Schrama SM, van Dommelen P, van Buuren S, Dekker FW, Ketel AG, Moll HA, Wit JM. The diagnostic work up of growth failure in secondary health care; an evaluation of consensus guidelines. BMC Pediatr 2008;8:21.
  1005. Hallan S, Euser AM, Irgens LM, Finken MJ, Holmen J, Dekker FW. Effect of intrauterine growth restriction on kidney function at young adult age: the Nord Trondelag Health (HUNT 2) Study. Am J Kidney Dis 2008;51:10-20.
  1006. Helmerhorst FM. [Hirsutism]. Ned Tijdschr Geneeskd 2008;152:231-232.
  1007. Helmerhorst FM, Lopez LM, Kaptein AA. Premenstrual syndrome. Lancet 2008;372:446.
  1008. Hille ET, Dorrepaal C, Perenboom R, Gravenhorst JB, Brand R, Verloove-Vanhorick SP. Social lifestyle, risk-taking behavior, and psychopathology in young adults born very preterm or with a very low birthweight. J Pediatr 2008;152:793-800, 800.
  1009. Hofstede FG, Fijnvandraat K, Plug I, Kamphuisen PW, Rosendaal FR, Peters M. Obesity: a new disaster for haemophilic patients? A nationwide survey. Haemophilia 2008;14:1035-1038.
  1010. Hopman EG, von Blomberg ME, Batstra MR, Morreau H, Dekker FW, Koning F, Lamers CB, Mearin ML. Gluten tolerance in adult patients with celiac disease 20 years after diagnosis? Eur J Gastroenterol Hepatol 2008;20:423-429.
  1011. Jager KJ, van Dijk PC, Zoccali C, Dekker FW. The analysis of survival data: the Kaplan-Meier method. Kidney Int 2008;74:560-565.
  1012. Jager KJ, Zoccali C, Macleod A, Dekker FW. Confounding: what it is and how to deal with it. Kidney Int 2008;73:256-260.
  1013. Jager KJ, van Dijk PC, Zoccali C, Dekker FW. The analysis of survival data: the Kaplan-Meier method. Kidney Int 2008;74:560-565.
  1014. Knoester M, Helmerhorst FM, Vandenbroucke JP, van der Westerlaken LA, Walther FJ, Veen S. Perinatal outcome, health, growth, and medical care utilization of 5- to 8-year-old intracytoplasmic sperm injection singletons. Fertil Steril 2008;89:1133-1146.
  1015. Knoester M, Helmerhorst FM, Vandenbroucke JP, van der Westerlaken LA, Walther FJ, Veen S. Cognitive development of singletons born after intracytoplasmic sperm injection compared with in vitro fertilization and natural conception. Fertil Steril 2008;90:289-296.
  1016. Knol MJ, Vandenbroucke JP, Scott P, Egger M. What Do Case-Control Studies Estimate? Survey of Methods and Assumptions in Published Case-Control Research. Am J Epidemiol 2008;168:1073-1081.
  1017. Kreutz R, Bolbrinker J, van der Sman-de Beer F, Boeschoten EW, Dekker FW, Kain S, Martus P, Sietmann A, Friedrichs F, Stoll M, Offermann G, Beige J. CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine. Pharmacogenomics J 2008;8:416-422.
  1018. Le Cessie S, Nagelkerke N, Rosendaal FR, van Stralen KJ, Pomp ER, van Houwelingen HC. Combining Matched and Unmatched Control Groups in Case-Control Studies. Am J Epidemiol 2008;168:1204-1210.
  1019. Levi M, Hovingh GK, Cannegieter SC, Vermeulen M, Büller HR, Rosendaal FR. Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood 2008;111:4471-4476.
  1020. Lopez LM, Kaptein A, Helmerhorst FM. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev 2008;CD006586.
  1021. Meltzer ME, Lisman T, Doggen CJ, de Groot PG, Rosendaal FR. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PLoS Med 2008;5:e97.
  1022. Middelburg RA, van Stein D, Briët E, van der Bom JG. The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: a systematic review. Transfusion 2008;48:2167-2176.
  1023. Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? Br J Haematol 2008;143:321-335.
  1024. Middeldorp S. Heparin: From animal organ extract to designer drug. Thromb Res 2008;122:753-762.
  1025. Naess IA, Christiansen SC, Romundstad PR, Cannegieter SC, Blom HJ, Rosendaal FR, Hammerstrom J. Prospective study of homocysteine and MTHFR 677TT genotype and risk for venous thrombosis in a general population--results from the HUNT 2 study. Br J Haematol 2008;141:529-535.
  1026. Niks EH, van Leeuwen Y, Leite MI, Dekker FW, Wintzen AR, Wirtz PW, Vincent A, van Tol MJ, Jol-van der Zijde CM, Verschuuren JJ. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J Neuroimmunol 2008;195:151-156.
  1027. Noordzij M, Korevaar JC, Dekker FW, Boeschoten EW, Bos WJ, Krediet RT, Bossuyt PM, Geskus RB. Mineral metabolism and mortality in dialysis patients: a reassessment of the K/DOQI guideline. Blood Purif 2008;26:231-237.
  1028. Nossent AY, Vos HL, Rosendaal FR, Bertina RM, Eikenboom JC. Aquaporin 2 gene variations, risk of venous thrombosis and plasma levels of von Willebrand factor and factor VIII. Haematologica 2008;93:959-960.
  1029. Nout RA, Fiets WE, Struikmans H, Rosendaal FR, Putter H, Nortier JW. The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer. Breast Cancer Res Treat 2008;109:567-572.
  1030. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost 2008;6:622-631.
  1031. Paffen E, Medina P, de Visser MC, van Wijngaarden A, Zorio E, Estelles A, Rosendaal FR, Espana F, Bertina RM, Doggen CJ. The -589C>T polymorphism in the interleukin-4 gene (IL-4) is associated with a reduced risk of myocardial infarction in young individuals. J Thromb Haemost 2008;6:1633-1638.
  1032. Plug I, Peters M, Mauser-Bunschoten EP, de Goede-Bolder A, Heijnen L, Smit C, Willemse J, Rosendaal FR, van der Bom JG. Social participation of patients with hemophilia in the Netherlands. Blood 2008;111:1811-1815.
  1033. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008;6:632-637.
  1034. Pomp ER, Rosendaal FR, Doggen CJ. Alcohol consumption is associated with a decreased risk of venous thrombosis. Thromb Haemost 2008;99:59-63.
  1035. Pomp ER, Rosendaal FR, Doggen CJ. Smoking increases the risk of venous thrombosis and acts synergistically with oral contraceptive use. Am J Hematol 2008;83:97-102.
  1036. Pruissen DM, Rosendaal FR, Frijns CJ, Kappelle LJ, Vos HL, Algra A. Prothrombotic gene variation and new vascular events after cerebral ischemia of arterial origin. J Thromb Haemost 2008;6:1639-1644.
  1037. Pruissen DM, Kappelle LJ, Rosendaal FR, Algra A. Prothrombotic gene variation in patients with large and small vessel disease. Neuroepidemiology 2008;31:89-92.
  1038. Pruissen DM, Slooter AJ, Rosendaal FR, van der Graaf Y, Algra A. Coagulation factor XIII gene variation, oral contraceptives, and risk of ischemic stroke. Blood 2008;111:1282-1286.
  1039. Psaty BM, Vandenbroucke JP. Opportunities for enhancing the FDA guidance on pharmacovigilance. JAMA 2008;300:952-954.
  1040. Riyazi N, Rosendaal FR, Slagboom E, Kroon HM, Breedveld FC, Kloppenburg M. Risk factors in familial osteoarthritis: the GARP sibling study. Osteoarthritis Cartilage 2008;16:654-659.
  1041. Rodger MA, Paidas M, Claire M, Middeldorp S, Kahn S, Martinelli I, Hague W, Rosene MK, Greer I. Inherited thrombophilia and pregnancy complications revisited. Obstet Gynecol 2008;112:320-324.
  1042. Rosendaal FR. Hormone replacement therapy and thrombotic risk: beauty is only skin deep. Nat Clin Pract Cardiovasc Med 2008;5:684-685.
  1043. Schlieper G, Kruger T, Djuric Z, Damjanovic T, Markovic N, Schurgers LJ, Brandenburg VM, Westenfeld R, Dimkovic S, Ketteler M, Grootendorst DC, Dekker FW, Floege J, Dimkovic N. Vascular access calcification predicts mortality in hemodialysis patients. Kidney Int 2008;74:1582-1587.
  1044. Schreijer AJ, Cannegieter SC, Caramella M, Meijers JC, Krediet RT, Simons RM, Rosendaal FR. Fluid loss does not explain coagulation activation during air travel. Thromb Haemost 2008;99:1053-1059.
  1045. Spreafico M, Lodigiani C, van Leeuwen Y, Pizzotti D, Rota LL, Rosendaal F, Mannucci PM, Peyvandi F. Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy. Pharmacogenomics 2008;9:1237-1250.
  1046. Thong MS, Kaptein AA, Benyamini Y, Krediet RT, Boeschoten EW, Dekker FW. Association between a self-rated health question and mortality in young and old dialysis patients: a cohort study. Am J Kidney Dis 2008;52:111-117.
  1047. Tick LW, Kramer MH, Rosendaal FR, Faber WR, Doggen CJ. Risk factors for post-thrombotic syndrome in patients with a first deep venous thrombosis. J Thromb Haemost 2008;6:2075-2081.
  1048. Tripepi G, Jager KJ, Dekker FW, Zoccali C. Linear and logistic regression analysis. Kidney Int 2008;73:806-810.
  1049. Tripepi G, Jager KJ, Dekker FW, Wanner C, Zoccali C. Bias in clinical research. Kidney Int 2008;73:148-153.
  1050. Uitte de Willige S, de Visser MC, Vos HL, Houwing-Duistermaat JJ, Rosendaal FR, Bertina RM. Selectin haplotypes and the risk of venous thrombosis: influence of linkage disequilibrium with the factor V Leiden mutation. J Thromb Haemost 2008;6:478-485.
  1051. van den Beukel TO, Dekker FW, Siegert CE. Increased survival of immigrant compared to native dialysis patients in an urban setting in the Netherlands. Nephrol Dial Transplant 2008;23:3571-3577.
  1052. van den Beukel TO, Dekker FW, Siegert CE. Increased survival of immigrant compared to native dialysis patients in an urban setting in the Netherlands. Nephrol Dial Transplant 2008;23:3571-3577.
  1053. van der Krabben MD, Rosendaal FR, van der Bom JG, Doggen CJ. Polymorphisms in coagulation factors and the risk of recurrent cardiovascular events in men after a first myocardial infarction. J Thromb Haemost 2008;6:720-725.
  1054. van Dijk PC, Jager KJ, Zwinderman AH, Zoccali C, Dekker FW. The analysis of survival data in nephrology: basic concepts and methods of Cox regression. Kidney Int 2008;74:705-709.
  1055. van Hylckama Vlieg A, Baglin CA, Bare LA, Rosendaal FR, Baglin TP. Proof of principle of potential clinical utility of multiple SNP analysis for prediction of recurrent venous thrombosis. J Thromb Haemost 2008;6:751-754.
  1056. van Leeuwen Y, Rosendaal FR, van der Meer FJ. The relationship between maintenance dosages of three vitamin K antagonists: Acenocoumarol, warfarin and phenprocoumon. Thromb Res 2008;123:225-230.
  1057. van Leeuwen Y, Rosendaal FR, Cannegieter SC. Prediction of hemorrhagic and thrombotic events in patients with mechanical heart valve prostheses treated with oral anticoagulants. J Thromb Haemost 2008;6:451-456.
  1058. van Minkelen R, de Visser MC, van Hylckama Vlieg A, Vos HL, Bertina RM. Sequence variants and haplotypes of the factor IX gene and the risk of venous thrombosis. J Thromb Haemost 2008;6:1610-1613.
  1059. van Rooden CJ, Schippers EF, Guiot HF, Barge RM, Hovens MM, van der Meer FJ, Rosendaal FR, Huisman MV. Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies. J Clin Oncol 2008;26:428-433.
  1060. van Stralen KJ, Doggen CJ, Bezemer ID, Pomp ER, Lisman T, Rosendaal FR. Mechanisms of the factor V Leiden paradox. Arterioscler Thromb Vasc Biol 2008;28:1872-1877.
  1061. van Stralen KJ, Jager KJ, Zoccali C, Dekker FW. Agreement between methods. Kidney Int 2008;74:1116-1120.
  1062. van Stralen KJ, Rosendaal FR, Doggen CJ. Minor injuries as a risk factor for venous thrombosis. Arch Intern Med 2008;168:21-26.
  1063. van Stralen KJ, Doggen CJ, Lumley T, Cushman M, Folsom AR, Psaty BM, Siscovick D, Rosendaal FR, Heckbert SR. The relationship between exercise and risk of venous thrombosis in elderly people. J Am Geriatr Soc 2008;56:517-522.
  1064. van Stralen KJ, Jager KJ, Zoccali C, Dekker FW. Agreement between methods. Kidney Int 2008;74:1116-1120.
  1065. van Vliet HA, Bertina RM, Dahm AE, Rosendaal FR, Rosing J, Sandset PM, Helmerhorst FM. Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost 2008;6:346-351.
  1066. van Vliet HA, Rodrigues SP, Snieders MN, van der Meer FJ, Frolich M, Rosendaal FR, Rosing J, Helmerhorst FM. Sensitivity to activated protein C during the menstrual cycle in women with and without factor VLeiden. Thromb Res 2008;121:757-761.
  1067. Vandenbroucke JP. Observational research, randomised trials, and two views of medical science. PLoS Med 2008;5:e67.
  1068. Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. JAMA 2008;300:2417-2419.
  1069. Verschuur MJ, Spinhoven P, Rosendaal FR. Offering a medical examination following disaster exposure does not result in long-lasting reassurance about health complaints. Gen Hosp Psychiatry 2008;30:200-207.
  1070. Verschuur MJ, Spinhoven P, van Emmerik AA, Rosendaal FR. Participation in a trauma-focused epidemiological investigation may result in sensitization for current health problems. Soc Psychiatry Psychiatr Epidemiol 2008;43:132-139.
  1071. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies]. Rev Esp Salud Publica 2008;82:251-259.
  1072. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting of observational studies]. Internist (Berl) 2008;49:688-693.
  1073. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. [The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies]. Gac Sanit 2008;22:144-150.
  1074. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61:344-349.
  1075. Vriesendorp TM, DeVries JH, Rosendaal F, Hoekstra JB. Severe hypoglycemia in critically ill: risk and outcomes. Crit Care Med 2008;36:1390-1391.